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CHAPTER	  I	  	  	  INTRODUCTION	  
	  
Introduction	  to	  Dopamine	  and	  Dopaminergic	  Circuitry	  	   The	   neurotransmitter	   dopamine	   (3,4-­‐dihydroxyphenethylamine;	   DA)	   plays	  an	  important	  role	  in	  brain	  function	  through	  its	  modulatory	  role	  on	  several	  functions	  including	  movement,	  motivation	  and	  reward,	  and	  attention	  (Giros	  and	  Caron,	  1993;	  Bannon,	  2005;	  Pamiter,	  2008).	  	  DA	  is	  synthesized	  in	  a	  two-­‐step	  process	  in	  which	  the	  amino	   acid	   tyrosine	   is	   first	   hydroxylated	  by	   tyrosine	  hydroxylase	   (TH)	   to	   form	  L-­‐DOPA	   (L-­‐dihydroxyphenylalanine)	   (Nagatsu	   et	   al.,	   1964).	   	   L-­‐DOPA	   is	   then	  decarboxylated	   by	   aromatic	   acid	   decarboxylase	   (AADC)	   to	   produce	  DA	   (Blaschko,	  1942)	  (Fig.	  1A).	  TH	  is	  the	  rate-­‐limiting	  enzyme	  in	  DA	  synthesis	  (Spector	  et	  al.,	  1967).	  	   Once	   synthesized,	   DA	   is	   packaged	   into	   synaptic	   vesicles	   by	   vesicular	  monoamine	  transporter	  2	  (VMAT-­‐2).	   	  VMAT-­‐2	  utilizes	  the	  proton	  gradient	  present	  across	  the	  vesicular	  membrane	  to	  pump	  DA	  into	  vesicles	  (Njus	  et	  al.,	  1986;	  Kanner	  and	  Schuldiner,	  1987;	  Johnson,	  1988).	  The	  other	  VMAT	  isoform,	  VMAT-­‐1,	  is	  typically	  associated	   with	   large	   secretory	   granule	   vesicles	   utilized	   by	   endocrine/paracrine	  cells	   and	   in	   the	   sympathetic	   nervous	   system,	   whereas	   VMAT-­‐2	   is	   predominantly	  found	  on	  small	  synaptic	  vesicles	  in	  the	  central	  nervous	  system	  (Henry	  et	  al.,	  1994;	  Weihe	  et	  al.,	  1994).	  In	  most	  brain	  regions,	  including	  the	  striatum,	  free	  intracellular	  DA	   is	   degraded	   by	   monoamine	   oxidase	   into	   3,4-­‐dihydroxyphenylacetic	   acid	  (DOPAC)	   (Rutledge	   and	   Jonason,	   1968).	   	   However,	   at	   some	   sites,	   such	   as	   the	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  Figure	   1.	   Synthesis	   and	   degradation	   of	   dopamine.	   (A)	   Tyrosine	   is	   converted	   to	   L-­‐DOPA	   by	   TH,	   and	   L-­‐DOPA	   to	   DA	   by	   AADC.	   (B)	   DA	   is	  metabolized	   by	  monoamine	  oxidase	  (MAO)	  and	  catechol-­‐O-­‐methyl	  transferase	  (COMT).	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prefrontal	  cortex,	  DA	  is	  degraded	  by	  catechol-­‐O-­‐methyl	  transferase	  (COMT)	  into	  3-­‐methoxytyramine	  (3-­‐MT)	  (Yavich	  et	  al.,	  2007)	  (Fig.	  1B).	  Furthermore,	  in	  some	  sites,	  especially	  the	  peripheral	  nervous	  system,	  DA	  is	  used	  as	  a	  precursor	  for	  the	  synthesis	  of	  norepinephrine	  (NE)	  and	  epinephrine.	  	   DA	   is	   utilized	   as	   a	   neurotransmitter	   in	   four	   major	   brain	   circuits:	   the	  tuberoinfundibular,	   nigrostriatal,	  mesocortical,	   and	  mesolimbic	   pathways	   (Fig.	   2).	  The	  tuberoinfundibular	  pathway	  originates	  in	  the	  arcuate	  and	  periventricular	  nuclei	  of	  the	  hypothalamus	  and	  projects	  to	  the	  median	  eminence	  (Gudelsky,	  1981).	  	  There,	  DA	  provides	  tonic	  inhibition	  of	  prolactin	  secretion	  from	  the	  pituitary	  gland	  (Birge	  et	  al.,	   1970;	   Shaar	   and	   Clemens,	   1974;	   Ben-­‐Jonathan	   and	   Hnasko,	   2001).	   	   The	  nigrostriatal	  pathway	  originates	  in	  the	  substantia	  nigra	  (SN),	  a	  brain	  region	  named	  for	  the	  distinct	  pigmentation	  of	  its	  neurons	  (Foley	  and	  Baxter,	  1958),	  and	  projects	  to	  the	   striatum	   (in	   primates,	   the	   striatum	   is	   typically	   subdivided	   into	   the	   caudate	  nucleus	   and	   putamen)	   (Bédard	   et	   al.,	   1969;	   reviewed	   in	   Björklund	   and	   Dunnett,	  2007).	   	   The	  mesocortical	   and	  mesolimbic	   pathways	   both	   originate	   in	   the	   ventral	  tegmental	  area	  (VTA),	  a	  midbrain	  nucleus,	  and	  project	  to	  the	  prefrontal	  cortex	  and	  nucleus	  accumbens	  (NAc),	  respectively	  (reviewed	  in	  Le	  Moal	  and	  Simon,	  1991).	  	  The	  mesocortical	   pathway	   is	   associated	   with	   emotion,	   executive	   function,	   and	  modulation	  of	  emotions	  (reviewed	  in	  Floresco	  and	  Magyar,	  2006;	  and	  Cools,	  2008),	  while	   the	   mesolimbic	   pathway	   is	   typically	   implicated	   in	   pleasure	   and	   reward	  (reviewed	   in	   Salamone	   and	   Correa,	   2012).	   	   Despite	   separate	   functions,	   the	  mesocortical	   and	   mesolimbic	   circuits	   are	   often	   collectively	   termed	   the	  mesocorticolimbic	  pathway,	   as	   they	   share	   a	   common	  origin.	  DA	  also	  has	   a	   role	   in	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  Figure	   2.	   Schematic	   diagram	   of	   dopaminergic	   pathways	   in	   the	   human	   brain.	   	   DA	  neurons	  in	  	  SN	  project	  to	  the	  striatum	  via	  the	  nigrostriatal	  pathway.	  DA	  neurons	  in	  the	  VTA	  project	  to	  the	  nucleus	  accumbens	  and	  frontal	  cortex	  via	  the	  mesolimbic	  and	  mesocortical	   pathways,	   respectively.	   	   The	   tuberoinfundibular	   pathway	   is	   not	  pictured.	  Adapted	  from	  Neuroanatomy,	  An	  Atlas	  of	  Structures,	  Sections,	  and	  Systems	  (Haines,	  2011).	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several	  peripheral	  processes	  including	  olfactory	  (Dacks	  et	  al.,	  2012;	  Liu	  et	  al.,	  2012)	  retinal	  (Nir	  et	  al.	  2000;	  Ruan	  et	  al.,	  2008),	  cardiovascular	  and	  renal	  (Jose	  et	  al.,	  1992;	  Zeng	   et	   al.,	   2007;	   Hussain	   and	   Likhandwala,	   2008;	   Asico	   et	   al.,	   2011;	   Harris	   and	  Zhang,	  2012),	  and	  immune	  system	  (Basu	  and	  Dasgupta,	  2000;	  Kavelaars	  et	  al.,	  2005)	  function,	   as	   well	   as	   regulation	   of	   some	   hormone	   signaling	   (Ben-­‐Jonathan	   and	  Hnasko,	   2001)	   and	   the	   sympathetic	   nervous	   system	   (Hadjiconstantinou	   and	   Neff,	  1987;	  Hollon	  et	  al.,	  2002).	  
DA	  Receptor	  Signaling	  	   Dopamine	  typically	  acts	  in	  a	  relatively	  slow,	  modulatory	  fashion	  to	  fine-­‐tune	  fast	   synaptic	   transmission	  mediated	  by	   the	   excitatory	  neurotransmitter	   glutamate	  and	   inhibitory	   neurotransmitter	   gamma-­‐aminobutyric	   acid	   (GABA).	   In	   order	   to	  exert	  its	  modulatory	  effects,	  DA	  activates	  members	  of	  a	  family	  of	  G	  protein-­‐coupled	  receptors.	  	  Initially,	  two	  populations	  of	  DA	  receptors	  were	  identified	  based	  on	  their	  ability	   to	  modulate	   adenylate	   cyclase	   activity	   (Kebabian	   and	   Calne,	   1979).	   	   Later	  characterization	  identified	  multiple	  receptor	  subtypes	  (Bunzow	  et	  al.,	  1988;	  Dearry	  et	  al.,	  1990;	  Monsma	  et	  al.,	  1990;	  Sokoloff	  et	  al.,	  1990;	  Zhou	  et	  al.,	  1990;	  Sunahara	  et	  al.,	  1991;	  Tiberi	  et	  al.,	  1991;	  Van	  Tol	  et	  al.,	  1991)	   that	  are	  subdivided	   into	  D1-­‐like	  (D1	  and	  D5)	  and	  D2-­‐like	  (D2,	  D3,	  and	  D4)	  receptors	  based	  on	  their	  pharmacological	  and	   biochemical	   properties	   (Andersen	   et	   al.,	   1990;	   Tiberi	   et	   al.,	   1991;	  Niznik	   and	  Van	  Tol,	  1992;	  Sibley	  and	  Monsma,	  1992;	  Sokoloff	  et	  al.,	  1992;	  Van	  Tol	  et	  al.,	  1992;	  Civelli	   et	   al.,	   1993;	   Vallone	   et	   al.,	   2000).	   	   It	   is	   generally	   accepted	   that	   D1-­‐like	  receptors	  activate	  Gαs/olf	  G	  proteins	  and	  stimulate	  cAMP	  production,	  while	  D2-­‐like	  receptors	   are	   coupled	   to	   Gαi/o	   G	   proteins	   and	   act	   to	   inhibit	   adenylate	   cyclase.	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Furthermore,	  D1	  and	  D5	  receptors	  are	  exclusively	  expressed	  postsynaptically,	  while	  D2	  and	  D3	  receptors	  are	  expressed	  both	  postsynaptically	  on	  target	  cells	  as	  well	  as	  presynaptically	   on	   dopaminergic	   neurons	   (Sokoloff	   et	   al.,	   2006;	   Rondou	   et	   al.,	  2010).	  	   DA	  receptors	  have	  broad	  expression	  profiles	  in	  the	  brain	  and	  the	  periphery.	  In	   the	   brain,	   D1	   receptors	   are	   highly	   expressed	   in	   nigrostriatal	   and	  mesocorticolimbic	   projection	   areas	   such	   as	   the	   striatum	   (caudate	   and	   putamen),	  NAc,	  SN,	  and	  frontal	  cortex,	  and	  appear	  at	  lower	  levels	  in	  hippocampus,	  cerebellum,	  thalamus,	  and	  hypothalamus	  (Missale	  et	  al.,	  1998;	  Gerfen,	  2000).	  D2	  receptors	  are	  also	   highly	   expressed	   in	   the	   SN,	   VTA,	   hypothalamus,	   cortex,	   and	   hippocampus	  (Missale	   et	   al.,	   1998;	   Gerfen,	   2000;	   Vallone	   et	   al.,	   2000;	   Seeman,	   2006).	   	   D3	  receptors	  have	  a	  more	  limited	  distribution,	  with	  the	  highest	  expression	  in	  the	  NAc	  and	  olfactory	  tubercle	  and	  lower	  expression	  in	  the	  striatum,	  SN,	  VTA,	  hippocampus,	  and	  cortical	  areas	  (Missale	  et	  al.,	  1998;	  Sokoloff	  et	  al.,	  2006).	   	  The	  D4	  receptor	  has	  the	   lowest	   expression	   in	   the	   brain,	   with	   expression	   in	   the	   frontal	   cortex,	  hippocampus,	   SN,	   and	   thalamus	   (Missale	   et	   al.,	   1998;	   Rondou	   et	   al.,	   2010).	   D5	  receptors	   are	   also	   expressed	   at	   low	   levels	   in	   several	   brain	   regions	   including	  prefrontal	   cortex	   pyramidal	   neurons,	   cingulate	   cortex,	   substantia	   nigra,	   and	  hippocampus	  (Missale	  et	  al.,	  1998;	  Gerfen,	  2000).	  	   The	   functional	   roles	   of	   DA	   receptors	   vary	   widely,	   as	   DA	   is	   involved	   in	  numerous	  physiological	  processes.	   	  Several	   lines	  of	  evidence	  demonstrate	   that	  D1,	  D2,	  and	  D3	  receptors	  control	  locomotor	  activity	  (Missale	  et	  al.,	  1998;	  Sibley,	  1999).	  D1	   receptor	   activation	   has	   a	   stimulatory	   effect	   on	   locomotion,	   while	   D2	   and	   D3	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receptors	   have	   more	   complex	   functions	   as	   they	   are	   expressed	   both	   pre-­‐	   and	  postsynaptically.	  	  Presynaptic	  D2	  autoreceptors	  form	  a	  negative	  feedback	  loop	  that	  attenuates	  neuron	  firing	  rate	  (Lacey	  et	  al.,	  1987;	  Beckstead	  et	  al.,	  2007;	  Jang	  et	  al.,	  2011)	   as	   well	   as	   DA	   synthesis	   (Lindgren	   et	   al.,	   2001;	   Anzalone	   et	   al.,	   2012)	   and	  release	  (Anzalone	  et	  al.,	  2012;	  Zhang	  and	  Sulzer,	  2012)	  in	  response	  to	  extracellular	  DA	   levels.	   	   Activation	   of	   presynaptic	   D2	   receptors	   leads	   to	   less	   DA	   release	   and	   a	  decrease	   in	   locomotor	   behavior,	   whereas	   activation	   of	   postsynaptic	   D2	   receptors	  stimulates	  locomotion.	  	   Interestingly,	   the	   D2	   receptor	   is	   the	   only	   DA	   receptor	   with	   multiple	  functional	  splice	  isoforms	  (Giros	  et	  al.,	  1989).	  	  The	  long	  isoform,	  D2L,	  has	  a	  29	  amino	  acid	  insertion	  in	  the	  third	  intracellular	  loop	  that	  the	  short	  isoform,	  D2S,	  lacks.	  	  D2L	  is	   predominantly	  postsynaptic	  while	  D2S	   is	   predominantly	  presynaptic	   (Usiello	   et	  al.,	  2000;	  De	  Mei	  et	  al.,	  2009).	  In	  addition,	  D2L	  and	  D2S	  differ	  in	  their	  sensitivity	  to	  D2	  receptor	  agonists,	  including	  DA;	  D2S	  is	  activated	  by	  lower	  agonist	  concentrations	  than	  needed	  to	  activate	  D2L	  (Drukarch	  and	  Stoof,	  1992).	  	  This	  can	  result	  in	  biphasic	  locomotor	  responses,	  as	  low	  agonist	  concentration	  favors	  D2S	  and	  therefore	  inhibits	  locomotion,	   while	   higher	   agonist	   concentration	   favors	   D2L	   and	   thus	   stimulates	  locomotor	  activity.	  	   Along	  with	   locomotor	   activity,	   D1	   and	   D2	   receptors	   also	   play	   key	   roles	   in	  response	   to	   rewards	   and	   addictive	   drugs	   (Hyman	   et	   al.,	   2006;	   Di	   Chiara	   and	  Bassareo,	   2007;	   De	   Mei	   et	   al.,	   2009)	   and	   working	   memory	   mediated	   by	   the	  prefrontal	  cortex	  (Goldman-­‐Rakic	  et	  al.,	  2004;	  Xu	  et	  al.,	  2009).	  	  Similarly,	  D3,	  D4,	  and	  D5	   receptors	   contribute	   a	   minor	   modulatory	   influence	   on	   cognitive	   functions	  
	   8	  
mediated	   by	   the	   hippocampus	   (Sibley,	   1999;	   Sokoloff	   et	   al.,	   2006;	   Rondou	   et	   al.,	  2010).	   	  Other	  specific	  roles	  for	  D3,	  D4,	  and	  D5	  receptors	  are	  unclear;	  D3	  receptors	  have	  been	  shown	  to	  have	  a	  minor	  influence	  on	  several	  functions	  typically	  attributed	  to	  D2	  receptors	  (Sibley,	  1999;	  Joseph	  et	  al.,	  2002;	  Sokoloff	  et	  al.,	  2006;	  Beaulieu	  et	  al.,	   2007;	   De	   Mei	   et	   al.,	   2009).	   	   	   DA	   receptors	   also	   have	   modulatory	   roles	   in	  regulating	  attention,	  impulse	  control,	  motor	  learning,	  sleep,	  reproductive	  behavior,	  and	   regulation	   of	   food	   intake	   (Missale	   et	   al.,	   1998;	  Di	   Chiara	   and	  Bassareo,	   2007;	  Koob	  and	  Volkow,	  2010;	  Rondou	  et	  al.,	  2010).	  	   The	   signaling	   pathways	   downstream	   of	   DA	   receptors	   vary	   greatly	   and	   are	  highly	  complex.	  	  For	  example,	  D1	  and	  D2	  receptors	  both	  modulate	  protein	  kinase	  A	  (PKA)	   activity,	   and	   therefore	   impact	   a	   vast	   array	   of	   PKA	   target	   molecules	   (DA	  receptor	   regulation	   and	   downstream	   signaling	   reviewed	   in	   Beaulieu	   and	  Gainetdinov,	   2011).	   	   A	  pair	   of	   interesting	   and	   important	  pathways	   through	  which	  dopamine	  signals	  include	  dopamine	  and	  cAMP-­‐regulated	  phospho-­‐protein	  (DARPP-­‐32)	   and	   glycogen	   synthase	   kinase	   3	   (GSK3).	   DARPP-­‐32	   plays	   a	   key	   role	   in	  integrating	  dopaminergic	  and	  glutamatergic	  signaling,	  as	  it	  is	  regulated	  by	  both	  PKA	  (downstream	   of	   D1	   and	   D2	   receptor	   activation)	   and	   cyclin	   dependent	   kinase	   5	  (CDK5;	   downstream	   of	   NMDA	   receptor	   activation).	   	   DARPP-­‐32	   also	   regulates	  protein	   phosphatase	   1	   (PP1)	   activity	   and	   can	   therefore	   affect	   other	   proteins	   by	  regulating	   phosphorylation	   state	   (Hemmings	   et	   al.,	   1984;	   Desdouits	   et	   al.,	   1995;	  Bibb	   et	   al.,	   1999;	   reviewed	   in	   Greengard	   et	   al.,	   1998;	   Greengard,	   	   2001;	  Svenningsson	  et	  al.,	  2004;	  Le	  Novère	  et	  al.,	  2008).	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Since	   DA	   receptors	   are	   all	   G	   protein-­‐coupled	   receptors	   (GPCRs),	   they	   are	  inactivated	   by	   desensitization,	   internalization,	   and	   signal	   termination.	   Upon	  GPCR	  activation,	   receptors	   are	   quickly	   phosphorylated	   by	   GPCR	   kinases	   (GRKs),	   which	  leads	  to	  recruitment	  of	  scaffolding	  proteins	  known	  as	  arrestins	  (Lohse	  et	  al.,	  1990;	  Benovic	  et	  al.,	  1991;	  Arriza	  et	  al.,	  1992;	  Shenoy	  and	  Lefkowitz,	  2003;	  Gainetdnov	  et	  al.,	   2004;)	   and	   subsequent	   uncoupling	   of	   the	   receptor	   from	   the	   G	   proteins.	  	  Association	  with	  an	  arrestin	  protein	  leads	  to	  clathrin-­‐mediated	  internalization	  of	  a	  GPCR	   (Lohse	   et	   al.,	   1990;	   Ferguson	   et	   al.,	   1996;	   Laporte	   et	   al.,	   2002;	   Shenoy	   and	  Lefkowitz,	   2003).	   	   However,	   β-­‐arrestin	   2	   can	   associate	   with	   D2	   receptors	   and	  regulate	  Akt	  and	  GSK3	  independent	  of	  PKA	  activation	  (Beaulieu	  et	  al.,	  2004,	  2005,	  2006).	  	  D2	  receptor	  activation	  leads	  to	  formation	  of	  a	  protein	  complex	  containing	  β-­‐arrestin,	   Akt,	   and	   protein	   phosphatase	   A	   (PP2A)	   (Beaulieu	   et	   al.,	   2005).	   	   PP2A	  deactivates	  Akt,	  thus	  disinhibiting	  GSK3	  (Beaulieu	  et	  al.,	  2004,	  2005).	  	  GSK3β,	  once	  activated,	  facilitates	  DA-­‐associated	  locomotor	  behaviors	  (Beaulieu	  et	  al.,	  2004).	  
The	  Dopamine	  Transporter	  
Discovery	  and	  Cloning	  	   Although	  MAO	  and	  COMT	  metabolize	  some	  DA	  as	  addressed	  above,	  most	  DA	  (and	   other	   catecholamine	   transmitters)	   is	   cleared	   from	   synapses	   by	   transporter	  proteins.	   	   Early	   studies	   actually	   focused	   on	   NE	   reuptake;	   Hertting	   and	   Axelrod	  demonstrated	   that	   [3H]-­‐NE	   could	   be	   selectively	   taken	   up	   and	   sequestered	   in	  sympathetic	   nerve	   terminals	   (Hertting	   and	   Axelrod,	   1961),	   and	   went	   on	   to	  demonstrate	   that	   antidepressants	   (i.e.	   imipramine)	   and	   psychostimulants	   (i.e.	  AMPH)	  block	  NE	  accumulation	  (Axelrod	  et	  al.,	  1961;	  Hertting	  et	  al.,	  1961).	  	  Several	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studies	  later	  demonstrated	  that	  both	  NE	  and	  DA	  accumulate	  in	  brain	  slices	  and	  that	  psychostimulants	   blocked	   this	   process	   (Glowinski	   and	   Axelrod,	   1966;	   Ross	   and	  Renyi,	   1967).	   	   Ross	   and	   Renyi	   also	   differentiated	   DA	   uptake	   from	   NE	   uptake,	  showing	  that	  cocaine	  and	  AMPH	  inhibit	  both	  DA	  and	  NE	  uptake	  in	  the	  striatum,	  but	  desipramine	   (a	   norepinephrine	   transporter	   (NET)	   inhibitor)	   only	   weakly	   inhibits	  DA	  uptake	  in	  striatum	  while	  potently	  blocking	  cortical	  NE	  uptake	  (Ross	  and	  Renyi,	  1967).	   Coyle	   and	   Snyder	   went	   on	   to	   show	   that	   AMPH	   isomers	   were	   differential	  inhibitors	   of	   DA	   (equally	   inhibited	   by	   L-­‐	   and	   D-­‐AMPH)	   and	   NE	   (preferentially	  inhibited	  by	  D-­‐AMPH)	  (Coyle	  and	  Snyder,	  1969),	  further	  supporting	  the	  idea	  that	  DA	  and	   NE	   transport	   are	   separate	   processes.	   	   Nearly	   two	   decades	   later,	   Ritz	   and	  colleagues	   showed	   that	   cocaine’s	   potency	   to	   block	   DA	   clearance	  was	   significantly	  higher	  than	  it’s	  ability	  to	  block	  NE	  clearance	  (Ritz	  et	  al.,	  1987).	  	   Since	  DA	   and	  NE	   uptake	  were	   pharmacologically	   distinct,	   efforts	   turned	   to	  identification	   of	   the	   dopamine	   transporter.	   	   The	   first	   approach	   was	   to	   identify	  cocaine	   binding	   sites	   in	   the	   brain.	   	   Reith	   and	   colleagues	   used	   plasma	  membranes	  from	   mouse	   brain	   to	   identify	   and	   define	   the	   kinetic	   parameters	   of	   the	   cocaine	  binding	   site	   using	   [3H]-­‐cocaine	   (Reith	   et	   al.,	   1980,	   1981).	   	   Subsequent	  work	  drew	  correlations	   between	   occupancy	   of	   the	   cocaine	   binding	   site	   and	   the	   effects	  (locomotor	   activity,	   self-­‐administration,	   local	   anesthetic	   properties)	   of	   cocaine	  (Sershen	   et	   al.,	   1983).	   Further	   autoradiographic	   studies	   using	   a	   tritiated	   cocaine	  analog,	   [3H]	   2	   beta-­‐carbomethoxy-­‐3	   beta-­‐(4-­‐fluorophenyl)tropane	   ([3H]-­‐CFT),	  localized	  cocaine	  binding	  to	  the	  striatum	  of	  squirrel	  monkeys	  (Canfield	  et	  al.,	  1990).	  Today	  we	  understand	  that	  the	  cocaine	  binding	  sites	  reflect	  the	  presence	  of	  DAT.	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   In	  an	  effort	  to	  identify	  and	  characterize	  neurotransmitter	  transporter	  genes,	  Blakely	   and	   colleagues	   expressed	   mRNAs	   from	   several	   brain	   regions	   in	   Xenopus	  
laevis	   oocytes	   and	   demonstrated	   the	   transport	   of	   radiolabeled	   neurotransmitters	  (glutamate,	  GABA,	  glycine,	  DA,	  serotonin	  (5-­‐HT),	  and	  choline)	  (Blakely	  et	  al.,	  1988).	  The	   expression	   patterns	   of	   the	   mRNAs	   that	   expressed	   proteins	   competent	   for	  neurotransmitter	   transport	  were	  consistent	  with	  the	  neuroanatomical	  distribution	  of	   the	   cell	   bodies	   for	   particular	   neurotransmitter	   systems	   and	   paved	   the	  way	   for	  expression	  cloning	  of	  the	  neurotransmitter	  transporters	  (Blakely	  et	  al.,	  1991b).	  	   Shortly	   thereafter,	   genes	   for	   the	   human	   norepinephrine	   transporter	   (NET)	  (Pacholczyk	   et	   al.,	   1991),	   rat	   serotonin	   transporter	   (Blakely	   et	   al.,	   1991a)	   and	   rat	  and	  bovine	  dopamine	  transporter	  (Giros	  et	  al.,	  1991;	  Kilty	  et	  al.,	  1991;	  Shimada	  et	  al.,	  1991;	  Usdin	  et	  al.,	  1991)	  were	  successfully	  cloned.	  	  Furthermore,	  DAT	  expression	  in	   dopamine	   neuron	   cell	   bodies	   in	   the	   SN	   and	   VTA	   was	   confirmed	   by	   in	   situ	  hybridization	   (Giros	   et	   al.,	   1991;	  Kilty	   et	   al.,	   1991;	   Shimada	  et	   al.,	   1991).	   	   Further	  evidence	  that	  the	  cloned	  gene	  was,	  in	  fact,	  DAT	  was	  that	  in	  vivo	  application	  of	  DAT	  inhibitors	   blocked	   DA	   transport	   with	   similar	   potencies	   as	   previously	   reported	   in	  synaptosomes	  (Ritz	  et	  al.,	  1987).	  	   Based	  on	   the	   rat	  DAT	   sequence,	   oligonucleotide	  probes	  were	  designed	  and	  used	  to	  screen	  a	  cDNA	  library	  derived	  from	  substantia	  nigra,	  resulting	  in	  the	  cloning	  of	  human	  DAT	  (hDAT)	  (Giros	  et	  al.,	  1992;	  Vandenbergh	  et	  al.,	  1992).	  	  Human	  DAT	  is	  a	  620	  amino	  acid	  protein	  that	  is	  92%	  homologous	  with	  the	  previously	  identified	  rat	  DAT	   as	   well	   as	   66%	   homologous	   to	   hNET	   and	   50%	   homologous	   to	   hSERT.	  	  Hydropathicity	   analysis	   of	   DAT	   predicts	   12	   transmembrane	   domains	   (TMD)	   and	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both	  N-­‐	  and	  C-­‐termini	  oriented	  intracellularly	  (Fig.	  3).	  A	  novel	  splice	  variant	  of	  DAT	  exists	  in	  human	  blood	  cells	  (Sogawa	  et	  al.,	  2010).	  	  This	  splice	  isoform	  lacks	  exon	  6,	  which	   results	   in	   deletion	   of	   TMD5	   and	   re-­‐orientation	   of	   the	   C-­‐terminus	   to	   the	  extracellular	  side	  of	  the	  cell	  membrane.	  When	  expressed	  in	  a	  heterologous	  system,	  the	  splice	  isoform	  lacks	  DA	  transport	  activity	  and,	  when	  co-­‐expressed	  with	  WT	  DAT,	  acts	  in	  a	  dominant	  negative	  fashion.	  	  In	  addition,	  Talkowski	  and	  colleagues	  reported	  a	  cassette	  exon	  located	  within	  intron	  3	  in	  a	  schizophrenic	  population	  (Talkowski	  et	  al.,	   2010).	   	   This	   alternate	   exon	   introduces	   multiple	   stop	   codons,	   resulting	   in	   a	  truncated	  protein	  product	  that	  is	  likely	  subject	  to	  nonsense-­‐mediated	  decay.	  	  Other	  factors	  that	  favor	  expression	  of	  this	  alternate	  cassette	  exon	  could	  reduce	  the	  amount	  of	  functional	  DAT	  expressed	  and	  may	  contribute	  to	  risk	  for	  schizophrenia.	  
DAT	  Structure/Function	  Relationships	  	   DA	   transport	   is	  an	   ion-­‐coupled	  process	  with	  a	   transport	   stoichiometry	  of	  2	  Na+,	   1	   Cl-­‐,	   and	   1	   DA	  molecule	   (McElvain	   and	   Schenk,	   1992;	   Kilty,	   1993;	   Gu	   et	   al.,	  1994).	   	   With	   this	   ion	   stoichiometry,	   DA	   transport	   is	   a	   voltage-­‐dependent,	  electrogenic	   process	  where	   hyperpolarization	   increases	   DA	   transport	   (Sonders	   et	  al.,	   1997).	   	   Electrophysiological	   studies	   reveal	   that	   DA	   transport	   through	   DAT	  actually	   produces	   a	   larger	   current	   flux	   than	   the	   charge	   transfer	   that	   the	   ion-­‐dependence	   of	   DA	   transport	   would	   predict	   (Sonders	   et	   al.,	   1997;	   Ingram	   et	   al.,	  2002).	   	   Subsequent	   research	   identified	   a	   channel-­‐like	   state	   for	   DAT	   that	   permits	  excess	  ion	  permeation	  during	  the	  DA	  transport	  cycle	  (Carvelli	  et	  al.,	  2004;	  Kahlig	  et	  al.,	  2005).	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  Figure	  3.	  Schematic	  illustration	  of	  DAT	  topology.	  	  The	  DAT	  protein	  has	  12	  TMDs	  and	  both	  N-­‐	  and	  C-­‐termini	  oriented	   to	   the	   intracellular	   	   side	  of	   the	  plasma	  membrane.	  	  EL2	  contains	  3	  N-­‐linked	  glycosylation	  sites.	  	  Several	  phosphorylation	  sites,	  shown	  as	  black	  circles	   labeled	  P,	  are	   found	  throughout	  the	  protein,	   including	  both	  N-­‐	  and	  C-­‐termini	  and	  intracellular	  loops.	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   Several	   studies	   have	   pursued	   structure/function	   relationships	   for	   DAT.	  	  Initially,	  DAT	  and	  NET	  chimeric	  proteins	  were	  studied	  in	  vitro	  and	  provided	  the	  first	  evidence	   for	   distinct	   functional	   domains	   of	   the	   transporter	   linked	   to	   substrate	  recognition,	   translocation,	   and	   affinity	   (Buck	   and	  Amara,	   1994;	   Giros	   et	   al.,	   1994;	  Syringas	  et	  al.,	  2000).	  Specifically,	   inhibitor	  selectivity	  was	  attributed	  to	  TMDs	  5-­‐8	  and	  substrate	  affinity	  determined	  by	  TMDs	  1-­‐3	  and	  10-­‐11	  (Buck	  and	  Amara,	  1994;	  Giros	  et	  al.,	  1994).	  Subsequent	  work	   found	  that	  TMDs	  1-­‐3	  and	  9-­‐12	  are	   important	  for	   the	  Na+	  and	  Cl-­‐	  dependence	  of	   substrate	   transport	  by	  DAT	  and	   the	  other	  SLC6	  monoamine	  transporters	  (Syringas	  et	  al.,	  2000).	  	   Another	   functional	   domain	   of	   DAT	   is	   the	   large	   extracellular	   loop	   between	  TMD3	   and	   TMD4	   (extracellular	   loop	   2;	   EL2).	   	   This	   region	   of	   the	   protein	   contains	  three	  N-­‐glycosylation	  sites	  that	  are	  essential	  for	  maturation	  and	  appropriate	  plasma	  membrane	  trafficking	  (Lis	  and	  Sharon,	  1993;	  Ramamoorthy	  et	  al.,	  1998).	  	  Mutation	  of	  the	  canonical	  glycosylation	  sites,	  as	  well	  as	  enzymatic	  degradation	  or	  blockade	  of	  glycosylation	   resulted	   in	   reduced	   surface	   expression,	   DA	   transport,	   and	   inhibitor	  sensitivity	  (Li	  et	  al.,	  2004).	  	  Recent	  studies	  have	  gone	  on	  to	  show	  that	  maintenance	  of	  DAT	  glycosylation	   is	   involved	   in	  DA	  neuron	  vulnerability	   in	  Parkinson’s	  disease	  (Afonso-­‐Oramas	   et	   al.,	   2009),	   suggesting	   that	   DAT	   glycosylation	   has	   implications	  beyond	  basic	  DAT	  function.	  In	  addition,	  EL2	  has	  a	  role	  in	  inhibitor	  binding,	  as	  DAT	  inhibitors	   but	   not	   substrates	   protect	   DAT	   from	   trypsin	   digestion	   (Vaughan	   and	  Kuhar,	   1996;	   Gaffaney	   and	   Vaughan,	   2004).	   EL2	   may	   have	   a	   role	   in	   substrate	  translocation,	  as	  well.	  	  Norregaard	  identified	  a	  zinc-­‐binding	  site	  in	  DAT	  (Norregaard	  et	  al.,	  1998);	  when	  a	  Zn2+	  ion	  is	  coordinated	  between	  histidine	  residues	  in	  EL2	  and	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EL4,	  DA	  transport	  is	  blocked.	  	  The	  authors	  speculate	  that	  constraining	  EL2	  via	  Zn2+	  binding	  may	  lead	  to	  structural	  changes	  in	  TMD3	  and/or	  TMD4.	  	   In	   order	   to	   further	   study	   how	   DAT	   interacts	   with	   both	   substrates	   and	  antagonists,	   mutagenesis	   studies	   have	   sought	   to	   identify	   the	   amino	   acid	   residues	  necessary	   for	   ligand	   coordination.	   	   In	   a	   series	   of	   studies,	   Lin	   and	   coworkers	  performed	  alanine	  substitutions	  for	  all	  phenylalanine	  (Lin	  et	  al.,	  1999),	  proline	  (Lin	  et	   al.,	   2000a),	   or	   tryptophan	   (Lin	   et	   al.,	   2000b)	   residues	   in	   or	   near	   DAT	   TMDs.	  	  Several	  of	  the	  engineered	  mutants	  show	  changes	  in	  substrate	  or	  antagonist	  binding	  affinity,	  suggesting	  that	   the	  mutated	  amino	  acids	  are	   important	   for	   ligand	  binding.	  	  Other	   experiments	   using	   similar	   mutagenesis	   strategies	   defined	   roles	   for	   Asp79	  (Kitayama	  et	  al.,	  1992)	  and	  Phe105	  (Wu	  and	  Gu,	  2003)	  in	  cocaine	  binding,	  as	  well.	  	   To	   date,	   the	   crystal	   structure	   for	   neither	   DAT	   nor	   any	   other	   SLC6	   family	  protein	   has	   been	   solved.	   	   However,	   Yamashita	   and	   colleagues	   crystallized	   the	  leucine	   transporter	   (LeuTAa),	   a	   bacterial	   homolog	   of	   the	   SLC6	   transport	   proteins,	  from	  Aquifex	  aeolicus	   (Yamashita	   et	   al.,	   2005).	   	   Although	   LeuTAa	   possesses	   the	   12	  TMD	  topology	  of	  DAT	  and	  other	  monoamine	  transporters,	  the	  N-­‐	  and	  C-­‐termini	  are	  both	  small	  and	  unstructured	  in	  the	  crystal	  structure.	  	  The	  observed	  arrangement	  of	  LeuTAa	  is	  displayed	  in	  Figure	  4.	  	  	  Computer	  models	  based	  on	  LeuTAa	  have	  predicted	  the	  cocaine	  binding	  site	  on	  DAT	  to	  be	  located	  between	  TMD	  1,	  3,	  6,	  and	  8,	  as	  well	  as	  conformational	   changes	   that	  occur	  when	   cocaine	  binds	   then	  moves	   to	  occlude	  DA	  transport	   (Beuming	   et	   al.,	   2008;	   Ravna	   et	   al.,	   2009;	   Huang	   et	   al.,	   2009).	   	   Several	  LeuTAa-­‐based	   DAT	   models	   have	   identified	   a	   second	   substrate	   binding	   pocket	  (Schmitt	   et	   al.,	   2010;	   Shan	   et	   al.,	   2011),	   binding	   sites	   for	   AMPH-­‐like	   drugs	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  Figure	  4.	  Predicted	  topology	  of	  DAT	  based	  on	  the	  crystal	  structure	  of	   the	  bacterial	  leucine	  transporter	  LeuTAa.	  TMDs	  1-­‐5	  and	  6-­‐10	  form	  a	  pseudo	  two-­‐fold	  axis	   in	  the	  plane	  of	   the	  plasma	  membrane	  (inverted	  pink	  and	  blue	  triangles)	  and	  fold	  over	  to	  form	   the	   substrate	   translocation	   pathway.	   	   The	   yellow	   triangle	   and	   blue	   circles	  depict	  leucine	  and	  Na+	  ions,	  respectively.	  Adapted	  from	  Yamashita	  et	  al.,	  2005.	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(Severinsen	  et	  al.,	  2012),	  benztropine-­‐based	  inhibitors	  (Bisgaard	  et	  al.,	  2011),	  and	  a	  non-­‐competitive	   inhibitor	   (Bulling	   et	   al.,	   2012),	   and	   predicted	   conformational	  changes	   required	   for	   DA	   binding	   and	   transport	   across	   the	   plasma	   membrane	  (Gedeon	   et	   al.,	   2010;	   Merchant	   and	   Madura,	   2012).	   	   Recently,	   LeuTAa	   was	   re-­‐crystallized	   in	   outward-­‐open	   and	   inward-­‐open	   states	   (i.e.	   no	   substrate	   bound)	  (Krishnamurthy	   and	   Gouaux,	   2012).	   	   By	   comparing	   the	   two	   transporter	  conformations,	   the	   authors	   predict	   similar	   conformational	   changes	   likely	   occur	  during	  DA	  transport	  as	  were	  suggested	  by	  previous	  computer	  simulations	  (Gedeon	  et	  al.,	  2012;	  Merchant	  and	  Madura,	  2012).	  
DAT	  Regulation	  	   Given	   DAT’s	   role	   for	   clearing	   DA	   upon	   synaptic	   release,	   efforts	   turned	   to	  defining	  how	  DAT	  itself	  is	  regulated.	  	  Kuhar’s	  group	  reported	  that,	  after	  irreversible	  inhibition	   of	   DAT,	   the	   time	   course	   for	   newly	   synthesized	   DAT	   to	   replace	   the	  inactivated	  transporters	  is	  very	  long,	  with	  only	  ~50%	  of	  transporters	  replaced	  after	  2-­‐3	   days	   (Fleckenstein	   et	   al.,	   1996;	   Kimmel	   et	   al.,	   2000).	   The	   time	   course	   of	  synthesis	  of	  new	  DATs	  is	  far	  too	  slow	  to	  support	  the	  rapid	  changes	  in	  DAT	  function	  or	  expression	  in	  response	  to	  various	  challenges	  (reviewed	  in	  Zahniser	  and	  Doolen,	  2001).	  Now,	  evidence	  exists	  that	  DAT	  is	  subject	  to	  rapid	  regulation	  by	  presynaptic	  receptors,	  interacting	  proteins,	  and	  various	  intracellular	  signaling	  networks	  to	  fine-­‐tune	  DA	  clearance	  capacity	   (Zahniser	  and	  Doolen,	  2001;	  Torres,	  2006;	  Chen	  et	  al.,	  2010).	  	   As	  reviewed	  above,	  presynaptic	  D2	  autoreceptors	  exert	   inhibitory	  influence	  on	  DA	  signaling	  by	  modulating	  DA	  neuron	  firing	  rate	  (Lacey	  et	  al.,	  1987;	  Beckstead	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et	  al.,	  2007;	  Jang	  et	  al.,	  2011),	  and	  DA	  synthesis	  and	  release	  (Lindgren	  et	  al.,	  2001;	  Anzalone	   et	   al.,	   2012;	   Zhang	   and	   Sulzer,	   2012).	   	   D2	   autoreceptors	   also	   directly	  regulate	   DAT	   activity	   (Meiergerd	   et	   al.,	   1993;	   Batchelor	   and	   Schenk,	   1998;	  Dickinson	  et	  al.,	  1999;	  Gulley	  and	  Zahinser,	  2003),	  an	  effect	  mediated	  via	  activation	  of	   extracellular	   signal-­‐regulated	   kinases	   (ERK1/2)	   (Bolan	   et	   al.,	   2007).	   	   Other	  studies	   have	   demonstrated	   that	   presynaptic	   metabotropic	   glutamate	   receptors	  (mGluRI)	  (Falkenberger	  et	  al.,	  2001)	  and	  nicotinic	  acetylcholine	  receptors	  (nAChR)	  (Hart	   and	   Ksir,	   1996;	   Middleton	   et	   al.,	   2004)	   regulate	   DAT	   function,	   as	   well.	  	  Furthermore,	   Lee	   and	   colleagues	   have	   reported	   a	   direct	   interaction	   between	   the	  DAT	   N-­‐terminus	   and	   the	   presynaptic	   D2S	   receptor	   (Lee	   et	   al.,	   2007)	   that	   can	  modulate	   DAT	   function.	   	   This	   interaction	   may	   be	   important	   for	   coordinating	   DA	  release	  and	  clearance	  at	  the	  synaptic	  membrane.	  Protein-­‐Protein	  Interactions	  	   Several	  DAT-­‐interacting	  proteins	  have	  been	   identified	   via	   yeast	   two-­‐hybrid	  (Y2H)	   screens	   that	   used	   portions	   of	   DAT	   as	   bait,	   and	   then	   confirmed	   observed	  interactions	   by	   co-­‐immunoprecipitation	   in	   cultured	   cells	   or	   brain	   tissue	  preparations	  (reviewed	  in	  Torres,	  2006).	  	  These	  interacting	  proteins	  are	  thought	  to	  regulate	   somatic	   export,	   synaptic	   localization,	   plasma	   membrane	   trafficking,	   and	  functional	  characteristics	  of	  DAT.	  	  None	  of	  the	  identified	  interactions,	  however,	  have	  been	  demonstrated	  to	  influence	  DAT	  function	  in	  vivo.	  	   In	  a	  Y2H	  study	  using	  the	  DAT	  C-­‐terminus	  as	  bait,	  Torres	  and	  colleagues	  first	  identified	  an	  interaction	  with	  Protein	  Interacting	  with	  C	  Kinase-­‐1	  (PICK1)	  (Torres	  et	  al.,	  2001).	  	  Since	  PICK1	  also	  interacts	  with	  protein	  kinase	  C	  (PKC)	  (Staudinger	  et	  al.,	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1995),	   this	   interaction	   may	   be	   important	   for	   mediating	   PKC	   regulation	   and	  trafficking	  of	  DAT.	   	  The	  same	  Y2H	  screen	  also	   identified	  Hic-­‐5	  as	  a	  DAT	  interactor	  (Carneiro	   et	   al.,	   2002).	   	   Hic-­‐5	   is	   an	   adhesion-­‐associated	   adaptor	   protein	   that	   has	  been	  shown	  to	  interact	  with	  several	  signaling	  molecules	  (reviewed	  in	  Shibanuma	  et	  al.,	  2012),	   so	   it	  may	  be	  an	   important	   integrator	   that	   connects	  DAT	   to	   intracellular	  signaling	  pathways.	  	   Another	  DAT	  C-­‐terminal	  interacting	  protein	  is	  α-­‐synuclein	  (Lee	  et	  al.,	  2001).	  	  This	  protein	  has	  been	  implicated	  in	  genetic	  forms	  of	  Parkinson’s	  disease	  (Chua	  and	  Tang,	   2006;	   Covy	   and	   Giasson,	   2011).	   	   DAT/α-­‐synuclein	   interactions	   have	   been	  shown	   to	   cluster	   DAT	   at	   the	   plasma	   membrane,	   increase	   transport	   activity,	   and	  enhance	  DA-­‐induced	  apoptosis	   (Lee	   et	   al.,	   2001),	   an	   effect	   attributed	   to	   increased	  oxidative	  stress	  resulting	  from	  accumulation	  of	  too	  much	  DA.	  	   In	  another	  Y2H	  screen,	  Fog	  and	  colleagues	  identified	  an	  interaction	  between	  calcium/calmodulin	  dependent	  kinase	  II	  (CaMKII)	  and	  the	  DAT	  C-­‐terminus	  (Fog	  et	  al.,	   2006).	   	   Further	   study	   revealed	   that	   CaMKII	   binds	   to	   the	   C-­‐terminus	   and	  phosphorylates	   DAT,	   likely	   at	   sites	   on	   the	   N-­‐terminal	   tail.	   	   Furthermore,	   CaMKII	  binding	  and	  DAT	  phosphorylation	  were	  shown	  to	  be	  necessary	   for	  AMPH-­‐induced	  DA	   efflux	   through	   DAT,	   providing	   evidence	   that	   DAT	   is	   stabilized	   in	   an	   “efflux-­‐willing”	  state.	  	   Most	  recently,	  the	  Ras-­‐like	  GTPase	  Rin	  was	  shown	  to	  interact	  with	  the	  DAT	  C-­‐terminus	  (Navaroli	  et	  al.,	  2011).	  	  In	  characterizing	  this	  interaction,	  it	  was	  suggested	  that	   the	   DAT/Rin	   interaction	   is	   necessary	   for	   PKC-­‐induced	   DAT	   internalization,	  though	  the	  underlying	  mechanism	  remains	  to	  be	  determined.	  	  Rin	  is	  also	  known	  to	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bind	   to	   and	   activate	   calmodulin	   (Lee	   et	   al.,	   1996).	   In	   light	   of	   the	   aforementioned	  DAT/CaMKII	  interaction,	  it	  is	  reasonable	  to	  speculate	  that	  Rin	  might	  have	  a	  role	  in	  activating	  DAT-­‐bound	  CaMKII.	  	   Researchers	  have	  used	  the	  Y2H	  approach	  with	  the	  DAT	  N-­‐terminal	  as	  bait,	  as	  well.	   	   Lee	   and	   colleagues	   identified	  Receptor	   for	   Activated	   C	  Kinase	   (RACK1)	   and	  syntaxin	  1A	  as	  DAT	  interactors	  (Lee	  et	  al.,	  2004).	   	  RACK1	  binds	  activated	  PKC	  and	  recruits	   it	   to	   the	   plasma	   membrane,	   thus	   putting	   PKC	   in	   close	   proximity	   to	   its	  substrates	   (Ron	   et	   al.,	   1994;	   Rodriguez	   et	   al.,	   1999).	   	   The	   precise	   role	   of	   the	  DAT/RACK1	   interaction	   is	   unclear,	   but	   may	   facilitate	   PKC	   regulation	   of	   DAT.	  	  Syntaxin	   1A	   is	   a	   component	   of	   the	   SNARE	   complex,	   the	   machinery	   needed	   for	  synaptic	  vesicle	  fusion	  and	  neurotransmitter	  release	  (Bennett	  et	  al.,	  1992;	  Wu	  et	  al.,	  1999).	   	   Cervinski	   and	   colleagues	   demonstrated	   the	   presence	   of	   DAT/syntaxin	   1A	  complexes	  in	  rat	  striatal	  synaptosomes	  and	  that	  syntaxin	  1A	  cleavage	  enhances	  DAT	  activity,	   supporting	   a	   role	   for	   these	   complexes	   in	   DA	   neurons	   (Cervinski	   et	   al.,	  2010).	   	   Interestingly,	   syntaxin	   1A	   also	   interacts	   with	   GABA	   transporters	   (GAT1)	  (Beckmann	  et	  al.,	  1998),	  glycine	  transporters	  (GLYT1)	  (Geerlings	  et	  al.,	  2000),	  NET	  (Sung	   et	   al.,	   2003),	   and	   SERT	   (Quick,	   2002),	   suggesting	   that	   interactions	   between	  syntaxin	  and	  transporters	  may	  be	  a	  conserved	  regulatory	  mechanism.	  Membrane	  Microdomain	  Sequestration	  	   Plasma	   membranes	   are	   not	   a	   homogenous	   environment.	   	   Within	   the	   lipid	  bilayer,	   sphingolipids	   and	   cholesterol	   can	   cluster	   together	   to	   form	  microdomains	  known	  as	  lipid	  rafts.	  	  These	  rafts	  impose	  order	  onto	  the	  plasma	  membrane	  and	  are	  proposed	   to	   function	   as	   anchors	   to	   localize	   and/or	   stabilize	   proteins	   at	   the	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membrane	   (Simons	   and	   Ikonen,	   1997;	   Ikonen,	   2001;	   Lingwood	   et	   al.,	   2009).	   By	  sequestering	   proteins	   to	   discrete	   regions	   of	   the	  membrane,	   lipid	   rafts	   are	   able	   to	  influence	   intracellular	   signaling	   (Brown	   and	   London,	   1998;	   Helms	   and	   Zurzolo,	  2004).	  	  Adkins	  and	  colleagues	  demonstrated	  DAT	  association	  with	  membrane	  rafts	  and	   that	   this	   membrane	   association	   limits	   DAT’s	   lateral	   mobility	   within	   the	  membrane	   and	   supports	   DA	   transport	   (Adkins	   et	   al.,	   2007).	   	   Other	   groups	   have	  confirmed	   this	   finding	   and	   shown	   that	   lipid	   raft	   association	   can	   affect	   DAT’s	  trafficking	   in	   response	   to	   PKC	   activation	   (Foster	   et	   al.,	   2008)	   and	   conformation	  (Hong	  and	  Amara,	  2010).	  	  In	  addition,	  DAT	  has	  been	  shown	  to	  interact	  with	  the	  raft-­‐associated	   protein	   flotillin-­‐1	   (Cremona	   et	   al.,	   2011),	   and	   that	   this	   interaction	   is	  required	  for	  localization	  to	  rafts	  and	  AMPH-­‐induced	  DA	  efflux	  (Cremona	  et	  al.,	  2011;	  Pizzo	   et	   al.,	   2013).	   	   	   Furthermore,	   flotillin-­‐1	   phosphorylation	   was	   found	   to	   be	  required	   for	   PKC-­‐mediated	   DAT	   internalization.	   	   This	   finding	   may	   explain	   the	  finding	   that	   PKC	   activation	   results	   in	   DAT	   internalization	   independent	   of	   DAT	  phosphorylation	  (Grånäs	  et	  al.,	  2003).	  	  	   DAT	  regulation	  by	  association	  with	  lipid	  rafts	  is	  particularly	  interesting	  due	  to	   the	   loss	   of	   raft	   association	   and	   functional	   dysregulation	   of	   a	   DAT	   variant,	  Arg615Cys	   (Sakrikar	   et	   al.,	   2012).	   This	   DAT	   mutant	   was	   identified	   in	   a	   human	  subject	   diagnosed	   with	   ADHD	   and	   will	   be	   addressed	   later	   in	   the	   context	   of	   rare,	  ADHD-­‐associated	  DAT	  variants.	  Intracellular	  Signaling	  	   In	   addition	   to	   regulation	   by	   interacting	   proteins	   and	   membrane	  microdomain	   association,	   DAT	   is	   regulated	   by	   covalent	   modifications	   including	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phosphorylation,	   ubiquitination,	   and	   lipid	   modification.	   	   The	   impact	   of	   these	  modifications	  on	  DAT	  trafficking	  and	  function	  are	  based	  largely	  on	  in	  vitro	  studies	  in	  cultured	   cells	   or	  ex	  vivo	   in	   brain	   synaptosomes	   (Vaughan	   et	   al.	   1997).	   	  Numerous	  model	   systems	   continue	   to	   be	   utilized	   to	   study	   DAT	   function,	   including	   the	  genetically	   tractable	   nematode,	   C.	   elegans	   (Nass	   et	   al.,	   2001,	   2005;	   Carvelli	   et	   al.,	  2004,	  2008;	  Hardaway	  et	  al.,	  2012),	  Drosophila	  melanogaster	  (Pörzgen	  et	  al.,	  2001;	  Chen	   et	   al.,	   2007;	  Makos	   et	   al.,	   2010;	   Vickrey	   et	   al.,	   2013),	   and	  DAT	  mutant	  mice	  (Chen	  et	  al.,	  2005;	  Zhou	  et	  al.,	  2009;	  Rao	  et	  al.,	  2012;	  Mergy	  et	  al.,	  2013).	  	   DAT	   contains	   several	   canonical	   serine/threonine	   phosphorylation	   sites	   on	  the	  N-­‐	  and	  C-­‐termini,	  as	  well	  as	  many	  potential	  non-­‐canonical	  phosphorylation	  sites.	  	  Several	  studies	  have	  shown	  that	  DAT	  activity	  is	  regulated	  by	  phosphorylation	  by	  a	  number	  of	  kinases	  including	  PKC	  (Huff	  et	  al.,	  1997;	  Zhang	  et	  al.,	  1997),	  PKA	  (Page	  et	  al.,	   2004),	   mitogen	   activated	   protein	   kinases	   (MAPKs)	   such	   as	   ERK	   (Bolan	   et	   al.,	  2007)	  and	  MEK	  (Lin	  et	  al.,	  2003;	  Moró),	  CaMKII	  (Page	  et	  al.,	  2004;	  Fog	  et	  al.,	  2006),	  and	   phosphoinositide	   3	   kinase	   (PI3K)	   (Carvelli	   et	   al.,	   2002).	   To	   date,	   limited	  evidence	  suggests	  that	  tyrosine	  kinase	  signaling	  can	  regulate	  DAT	  activity	  (Simon	  et	  al.,	   1997;	   Doolen	   and	   Zahniser,	   2001;	   Hoover	   et	   al.,	   2007),	   however,	   there	   is	   no	  evidence	  that	  DAT	  is	  directly	  phosphorylated	  by	  tyrosine	  kinases.	  	   PKC	  activation,	   either	  by	   application	  of	   phorbol	   esters	   such	   as	  phorbol	   12-­‐myristate	  13-­‐acetate	  (β-­‐PMA)	  (Huff	  et	  al.,	  1997;	  Vaughan	  et	  al.,	  1997;	  Zhang	  et	  al.,	  1997;	   Foster	   et	   al.,	   2008)	   or	   indirect	   stimulation	   via	   activation	   of	   substance	   P	  receptors	  (Grånäs	  et	  al.,	  2003),	  has	  been	  shown	  to	  produce	  downregulation	  of	  DAT	  transport	   activity	   and	   cell	   surface	   expression.	   	   It	   was	   initially	   thought	   that	   this	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downregulation	   was	   a	   direct	   result	   of	   PKC-­‐dependent	   DAT	   phosphorylation	   and	  subsequent	  intracellular	  sequestration	  of	  DAT	  (Zhang	  et	  al.,	  1997;	  Zhu	  et	  al.,	  1997;	  Melikian	   and	   Buckley,	   1999;	   Grånäs	   et	   al.,	   2003;	   Loder	   and	   Melikian,	   2003).	  	  Although	   PKC	   activation	   in	   striatal	   synaptosomes	   does	   increase	   DAT	  phosphorylation	   (Huff	   et	   al.,	   1997;	  Vaughan	  et	   al.,	   1997;	  Foster	   et	   al.,	   2002),	   later	  research	  demonstrated	   that	  deletion	  of	  N-­‐terminal	  phosphorylation	   sites	  does	  not	  abolish	  PKC-­‐mediated	  DAT	  downregulation	  (Grånäs	  et	  al.,	  2003).	  	  It	  is	  possible	  that	  N-­‐terminal	   phosphorylation	   is	   part	   of	   a	   redundant	   system	   in	   place	   to	   insure	  appropriate	   transporter	   trafficking.	   	   Thus,	   studies	   of	   regulation	  of	  DAT	   trafficking	  should	  be	  interpreted	  cautiously,	  as	  observed	  effects	  may	  be	  the	  result	  of	  alternate	  processes.	  	   After	   demonstrating	   that	   DAT	   phosphorylation	   was	   not	   required	   for	   PKC-­‐mediated	  DAT	  internalization,	  efforts	  turned	  to	  finding	  other	  mechanisms	  that	  could	  be	   in	   play.	   	   Ubiquitination	   is	   typically	   thought	   of	   as	   a	   signal	   leading	   to	   protein	  degradation	   (Hershko	   and	   Ciechanover,	   1992),	   however,	   attachment	   of	   single	   or	  short	   chain	  ubiquitin	  moieties	   rather	   than	   long	  ubiquitin	   chains	   can	   control	  other	  cellular	  events	  such	  as	  endocytosis	  and	  membrane	  trafficking	  (Hicke,	  2001;	  Hicke	  et	  al.,	  2005;	  Staub	  and	  Rotin,	  2006).	   	  Miranda	  and	  colleagues	  demonstrated	  that	  PKC	  activation	   leads	   to	   increases	   in	   DAT	   N-­‐terminal	   ubiquitination,	   and	   that	   the	  ubiquitin	  signal	  is	  required	  for	  DAT	  endocytosis	  (Miranda	  et	  al.,	  2005,	  2007).	  	   Although	   PKC	   does	   not	   directly	   control	   DAT	   trafficking,	   PKC-­‐induced	  phosphorylation	   does	   have	   a	   role	   in	   other	   processes,	   such	   as	   DAT-­‐mediated	   DA	  efflux	  (Kantor	  and	  Gnegy,	  1998;	  Cowell	  et	  al.,	  2000;	  Johnson	  et	  al.,	  2005).	  These	  data	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suggest	  that	  DAT	  is	  subject	  to	  trafficking-­‐dependent	  and	  -­‐independent	  regulation	  by	  PKC.	   	   This	   conclusion	   parallels	   observations	   that	   NET	   (Jayanthi	   et	   al.,	   2004)	   and	  SERT	  (Zhu	  et	  al.,	  2005;	  Steiner	  et	  al.,	  2008)	  undergo	  both	  trafficking-­‐dependent	  and	  trafficking-­‐independent	  regulation,	  as	  well.	  	   Interestingly,	   DAT	   is	   sensitive	   to	   insulin	   signaling.	   	   Carvelli	   and	   colleagues	  demonstrated	   that	   insulin	   treatment	   stimulates	  DAT	   activity	   in	   a	   PI3K-­‐dependent	  manner	  in	  serum-­‐starved,	  DAT-­‐transfected	  cells	  (Carvelli	  et	  al.,	  2002).	  	  Later	  studies	  showed	   that	   a	  dominant	  negative	   form	  of	  Akt	   (a	  kinase	   activated	  by	  PI3K)	  blocks	  insulin’s	  effect	  on	  DAT	  (Garcia	  et	  al.,	  2005).	   	  These	  findings	  coupled	  with	  data	  that	  hypoinsulinemic	  rats	  exhibit	  decreased	  DA	  uptake	  (Patterson	  et	  al.,	  1998)	  support	  the	  idea	  that	  insulin-­‐	  and	  PI3K-­‐linked	  signaling	  pathways	  regulate	  DAT	  function.	  	   The	   Galli	   lab	   has	   continued	   to	   study	   the	   role	   of	   PI3K/Akt	   signaling	   in	  transporter	   regulation,	   and	   implicated	   a	   downstream	   target	   of	   Akt,	   mTOR,	   in	   NE	  transport	   and	  NET	   trafficking	   (Robertson	   et	   al.,	   2010;	   Siuta	   et	   al.,	   2010).	   	   Beyond	  altered	   NET	   trafficking,	   they	   demonstrated	   that	   conditional	   mTOR	   KO	   mice	   had	  behavioral	  changes	  (disrupted	  pre-­‐pulse	   inhibition)	  that	  could	  be	  corrected	  by	  the	  NET	  antagonist	  desipramine	  (Siuta	  et	  al.,	  2010).	  In	  light	  of	  PI3K’s	  ability	  to	  regulate	  DAT,	   further	   exploration	   of	   the	   PI3K-­‐Akt-­‐mTOR-­‐DAT	   signaling	   pathway	   is	  warranted.	  	   Taken	   together,	   the	   studies	   described	   above	   present	   a	   complicated	   and	  incomplete	   understanding	   of	   regulation	   of	   DAT	   activities.	   Multiple	   signaling	  pathways	  and	  interacting	  proteins	  intersect	  at	  DAT.	  	  Further	  efforts	  to	  characterize	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DAT	   regulation	   will	   continue	   to	   inform	   our	   understanding	   of	   neuropsychiatric	  disorders	  such	  as	  addiction,	  schizophrenia,	  and	  ADHD.	  Psychostimulants	  	   Given	  the	  key	  role	  of	  DAT	  in	  controlling	  DA	  signaling,	  it	  is	  not	  a	  surprise	  that	  drugs	  targeting	  DAT	  have	  profound	  effects.	  	  These	  effects	  can	  be	  beneficial,	  as	  is	  the	  case	   with	   methylphenidate	   (e.g.	   Ritalin	   ®)	   and	   amphetamine	   formulations	   (e.g.	  Adderall	  ®)	  used	   to	   treat	  ADHD.	   	  However,	   other	  psychostimulants	   can	  be	  highly	  addictive	   and	   have	   profound	   negative	   consequences	   for	   the	   drug	   abuser,	   their	  family,	  and	  the	  community	  at	  large.	  	   Cocaine	   is	   the	  archetypical	  competitive	  DAT	  antagonist,	  simply	  blocking	  DA	  reuptake	   through	   DAT,	   whereas	   the	   mechanism	   of	   AMPH	   action	   is	   more	  complicated.	  	  In	  addition	  to	  blocking	  DA	  transport	  and/or	  inducing	  DA	  efflux,	  these	  drugs	   can	   both	   influence	   subcellular	   distribution	   of	   DATs	   (Saunders	   et	   al.,	   2000;	  Daws	   et	   al.,	   2002).	   	   Cocaine’s	   effects	   on	   DAT	   cell	   surface	   distribution	   are	  inconsistent;	  Daws	  and	  colleagues	  reported	  that	  cocaine	  application	  increases	  DAT	  surface	  expression	  and	  DA	  transport	  (Daws	  et	  al.,	  2002).	  	  However,	  Vaughan’s	  group	  observed	   no	   changes	   in	   DAT	   expression	   or	   activity	   after	   cocaine	   application	  (Gorentla	  and	  Vaughan,	  2005).	  Results	  from	  studies	  of	  the	  brains	  of	  cocaine	  abusers	  are	  inconsistent,	  as	  well,	  showing	  both	  reduced	  (Wilson	  et	  al.,	  1996)	  and	  increased	  (Mash	  et	   al.,	   2002)	  DAT	   levels.	   	   In	   the	   intact	  brain	  of	   a	   cocaine	  abuser,	   one	  might	  expect	   chronically	   elevated	   DA	   levels	   due	   to	   chronic	   DAT	   blockade	   by	   cocaine	   to	  result	  in	  downregulation	  of	  DAT.	  The	  data,	  however,	  indicate	  that	  this	  is	  not	  the	  case	  (Little	   et	   al.,	   1999,	   2002).	   	   Further	   investigation	   is	   certainly	   warranted,	   as	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understanding	  compensatory	  alterations	   in	  DAT	  expression	  and/or	   function	  could	  inform	  our	  understanding	  of	  drug	  addiction.	  	   AMPH	  has	  a	  far	  more	  complicated	  mechanism	  of	  action	  than	  cocaine.	  	  AMPH	  acts	  as	  a	  competitive	  inhibitor	  of	  DA	  uptake,	  but	  also	  acts	  as	  a	  DAT	  substrate,	  getting	  transported	  into	  neurons	  through	  DAT	  (Azzaro	  et	  al.,	  1974),	  where	  it	  acts	  as	  a	  weak	  base	   and	   disrupts	   vesicular	   proton	   gradients	   (Sulzer	   et	   al.,	   1995),	   resulting	   in	  release	   of	   vesicular	   DA	   into	   the	   cytoplasm.	   	   This	   excess	   cytosolic	   DA	   is	   then	  transported	  out	  of	  the	  neuron	  through	  DAT,	  a	  process	  known	  as	  DA	  efflux.	  	  AMPH-­‐induced	  DA	  efflux	  can	  also	  be	  observed	  in	  cultured	  cells	  transfected	  with	  DAT	  and	  loaded	  with	  DA	  (Khoshbouei	  et	  al.,	  2003).	  	   Prolonged	  exposure	  to	  AMPH	  leads	  to	  a	  reduction	  in	  DAT	  surface	  expression	  and	   DA	   transport	   (Saunders	   et	   al.,	   2000;	   Gulley	   et	   al.,	   2002).	   	   This	   process	   is	  dependent	   on	  AMPH	   transport	   and	  PKC	   activity,	   as	   cocaine	   or	   PKC	   inhibition	   can	  block	  AMPH	  effects	  (Kantor	  and	  Gnegy,	  1998;	  Saunders	  et	  al.,	  2000).	  	  AMPH-­‐induced	  DA	  efflux	  is	  regulated	  by	  both	  PKC	  (Kantor	  and	  Gnegy,	  1998)	  and	  CaMKII	  (Fog	  et	  al.,	  2006).	  	  Activation	  of	  either	  kinase	  results	  in	  DAT	  phosphorylation	  on	  the	  N-­‐terminal	  tail	   that	   is	   required	   for	   AMPH-­‐induced	   efflux;	   deletion	   of	   the	   entire	   N-­‐terminus	  (Foster	   et	   al.,	   2002;	   Grånäs	   et	   al.,	   2003)	   or	   alanine	   substitution	   for	   all	   of	   the	   N-­‐terminal	  serine	  residues	  (Khoshbouei	  et	  al.,	  2004)	  abolishes	  AMPH-­‐induced	  efflux.	  	  It	  appears	  that	  AMPH	  acts	  to	   inhibit	  DA	  clearance,	  but	  eventually	  gets	  transported	  into	  neurons	  where	   it	   induces	  DA	  release	  and	  activation	  of	  PKC	  and	  CaMKII.	   	  The	  activated	  kinases	  then	  phosphorylate	  DAT	  and	  stabilize	  an	  “efflux-­‐willing”	  state,	  At	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the	   same	   time,	   AMPH	   is	   emptying	   DA	   from	   vesicles	   and	   the	   efflux-­‐willing	   DAT	  transports	  DA	  into	  the	  synapse.	  
DAT	  and	  the	  DA	  System	  in	  Disease	  
Parkinson’s	  Disease	  	   Dopaminergic	   dysfunction	   is	   associated	   with	   several	   neuropsychiatric	  disease	  states.	  Perhaps	  the	  best	  studied	  is	  Parkinson’s	  disease	  (PD)	  (Temlett,	  1996).	  	  PD	  involves	  the	  death	  of	  SN	  DA	  neurons	  and	  the	  resulting	  loss	  of	  dopaminergic	  tone	  leads	   to	   involuntary	  movements	   and	  motor	   tremors	   (Simões	   et	   al.,	   2012).	   	   Other	  motor	  symptoms	  include	  bradykinesia,	  rigidity,	  shuffling	  gait,	  and	  balance	  problems	  (reviewed	   in	   Fritsch	   et	   al.,	   2012).	   	   In	   addition,	   patients	  with	  PD	  often	   suffer	   from	  depression	   (Chen	   and	   Marsh,	   2013;	   Lord	   et	   al.,	   2013),	   affective	   disturbances	  (Aminian	   and	   Strafella,	   2013),	   and	   cognitive	   impairment	   (Hanganu	   et	   al.,	   2013;	  Kudlicka	   et	   al.,	   2013;	   Kulisevsky	   et	   al.,	   2013).	   Supplementation	   with	   the	   DA	  precursor	   L-­‐DOPA	   is	   the	   most	   effective	   treatment	   for	   the	   motor	   symptoms	  associated	  with	  PD	  (Poskanzer,	  1969;	  Worth,	  2013).	  
Drug	  Abuse	  and	  Addiction	  	   The	  DA	  system	   is	  also	   implicated	   in	  drug	  abuse	  and	  addiction	   (Kalivas	  and	  Volkow,	  2005).	   	  A	   large	  body	  of	  research	   implicates	  dopaminergic	   (Comings	  et	  al.,	  1994;	  Noble	  et	  al.,	  2000;	  Gorwood	  et	  al.,	  2012)	  and	  other	  (Wang	  et	  al.,	  2012)	  genes	  with	  addiction.	   	   Furthermore,	  psychostimulant	  drugs	   such	  as	   cocaine	   (Giros	  et	   al.,	  1993),	   amphetamine	   (Sulzer	   et	   al.,	   1993),	   and	  methamphetamine	   (Fleckenstein	   et	  al.,	   1997)	   act	   directly	   on	   the	   DAT.	   	   Although	   it	   appears	   straightforward,	   drugs	   of	  abuse	  also	  elicit	   circuit-­‐level	   changes	   in	   the	  brain	   (Hanlon	  and	  Canterberry,	  2012;	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Jentsch	  and	  Pennington,	  2013;	  Keramati	  and	  Gutkin,	  2013)	  and	  form	  an	  exquisitely	  complex	  disorder.	  
Schizophrenia	  and	  Bipolar	  Disorder	  	   Dopaminergic	   signaling	   is	   also	   considered	   a	   primary	   factor	   underlying	  affective	  disorders	  such	  as	  schizophrenia	  and	  bipolar	  disorder	  (Diehl	  and	  Gershon,	  1992;	  Manji	  and	  Lenox,	  2000;	  Jones	  and	  Craddock,	  2001;	  Ross	  et	  al.,	  2006;	  Eyles	  et	  al.,	  2012;	  Kuepper	  et	  al.,	  2012).	   	  Numerous	  genetic	   linkage	  and	  association	  studies	  have	   connected	   dopamine-­‐related	   genes	   to	   these	   disorders	   (Lewis	   et	   al.,	   2003;	  Seguardo	  et	  al.,	  2003;	  Owen	  et	  al.,	  2004).	  	  In	  addition,	  a	  variant	  of	  COMT,	  Val158Met,	  has	   been	   associated	   with	   schizophrenia	   (Kunugu	   et	   al.,	   1997;	   Nolan	   et	   al.,	   2004;	  Ohnishi	   et	   al.,	   2006),	   though	   further	   studies	   did	   not	   observe	   any	   association	  (Turnbridge	   et	   al.,	   2006;	   Hosák,	   2007;	   Singh	   et	   al.,	   2012).	   Interestingly,	   the	   DAT	  Ala559Val	  variant	  that	  is	  the	  focus	  of	  the	  research	  to	  be	  described	  herein	  was	  first	  reported	   in	   a	   patient	   with	   bipolar	   disorder	   (Horschitz	   et	   al.,	   2005).	   	   Lastly,	  dopamine’s	  role	  in	  bipolar	  disorder	  and	  schizophrenia	  is	  supported	  by	  the	  fact	  that	  antipsychotic	  drugs	  used	  to	  treat	  the	  disorders	  primarily	  target	  D2	  receptors	  (Boyd	  and	  Mailman,	  2012;	  Ginovart	  and	  Kapur,	  2012).	  Early	  studies	  observed	  a	  correlation	  between	  antipsychotic	  efficacy	  and	  drug	  affinity	  for	  D2	  receptors	  (Seeman	  and	  Lee,	  1975;	   Creese	   et	   al.,	   1976),	   but	   not	   other	   DA	   receptor	   subtypes	   (Seeman,	   1987).	  	  Further	   research	   revealed	   that	   antipsychotics	   were	   most	   effective	   when	   greater	  than	  65%	  of	  striatal	  D2	  receptors	  are	  blocked,	  suggesting	  that	  antipsychotic	  effects	  are	  driven	  by	  D2	  antagonism	  (Farde	  et	  al.,	  1992;	  Kapur	  et	  al.,	  2000).	  Clearly,	  these	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few	  examples	  support	  the	  role	  of	  dopaminergic	  dysfunction	  in	  bipolar	  disorder	  and	  schizophrenia,	  but	  are	  a	  mere	  peek	  into	  a	  very	  active	  research	  field.	  
Dopamine	  Transporter	  Deficiency	  Syndrome	  (DTDS)	  	   Loss	  of	  DAT	   function	   leads	   to	  a	   severe	   clinical	  phenotype,	   as	  well.	   	  Though	  rare,	   humans	   with	   two	   loss-­‐of-­‐function	   DAT	   alleles,	   DTDS,	   develop	   a	   complex	  movement	   disorder	   characterized	   by	   infantile	   hyperkinesia	   that	   evolved	   into	  generalized	  dystonia	  and	  parkinsonian	  symptomatology	  (Kurian	  et	  al.,	  2009,	  2011).	  Several	  missense	  mutations	  were	   identified	   from	  these	  patients	  and	  deficits	   in	  DA	  transport	   were	   attributed	   to	   deficits	   in	   DAT	   expression,	   DA	   affinity	   for	   DAT,	   or	  glycosylation	   and	   subsequent	   trafficking	   to	   the	   plasma	   membrane.	   	   These	   DAT	  variants	  may	  prove	  useful	  for	  future	  studies	  of	  DAT	  structure-­‐function	  relationships	  or	  design	  of	  new	  neuromodulatory	  therapeutic	  strategies.	  
ADHD	  	   Alterations	  in	  DA	  signaling	  and	  DAT	  function	  have	  also	  been	  associated	  with	  attention	   deficit	   hyperactivity	   disorder	   (ADHD).	   ADHD	   is	   the	   most	   commonly	  diagnosed	   neuropsychiatric	   disorder,	   affecting	   an	   estimated	   4-­‐12%	   of	   school-­‐age	  children	   (Biederman	   and	   Faraone,	   2005;	   Polanczyk	   et	   al.,	   2007;	   Willcutt,	   2012).	  	  Adult	  ADHD	  is	  also	  fairly	  common,	  estimated	  at	  4-­‐5%	  of	  adults	  (Kessler	  et	  al.,	  2006;	  Fayyad	  et	  al.,	  2007;	  de	  Graaf	  et	  al.,	  2008),	  though	  more	  recent	  studies	  suggest	  rates	  of	   adult	   ADHD	   may	   actually	   be	   greater	   than	   10%	   (Garnier-­‐Dykstra	   et	   al.,	   2010;	  Cahill	   et	   al.,	   2012).	   The	   disorder	   is	   characterized	   by	   motor	   hyperactivity,	  impulsivity,	  and/or	  inattention	  (American	  Psychiatric	  Association,	  1994).	  	  There	  are	  no	   biomarkers	   for	   ADHD,	   so	   diagnosis	   is	   based	   on	   clinical	   observation	   as	  well	   as	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parent	  and	  teacher	  reports	  (Wolraich	  et	  al.,	  2003;	  Visser	  et	  al.,	  2013;	  Wolraich	  et	  al.,	  2013).	  Also	  of	  note,	  ADHD	  diagnoses	  exhibit	  an	  approximately	  3:1	  male:female	  bias	  (Gaub	  and	  Carlson,	  1997;	  Getahun	  et	  al.,	  2013a).	  	  It	  is	  unclear	  if	  this	  sex	  bias	  arises	  from	   reinforcement	   of	   behavioral	   patterns	   or	   sex-­‐linked	   biological	   factors	  underlying	   the	   disorder.	   	   Interestingly,	   rates	   of	   ADHD	   diagnosis	   span	   different	  cultural	  groups,	  as	  studies	  of	  populations	  in	  Africa	  (Bakare,	  2012),	  Asia	  (Chien	  et	  al.,	  2012),	   and	   Europe	   (Bianchini	   et	   al.,	   2013;	   Ezpeleta	   et	   al.,	   2013)	   report	   similar	  prevalence.	  	   Many	  lines	  of	  evidence	  implicate	  DAT	  and	  DA	  receptors	  in	  ADHD.	   	  Previous	  studies	  have	  demonstrated	  an	  association	  between	  ADHD	  and	  genes	  supporting	  DA	  signaling,	   including	  D1	   (Bobb	   et	   al.,	   2005;	  Ribases	   et	   al.,	   2012),	  D2	   (Nyman	  et	   al.,	  2007),	   D4	   (Roman	   et	   al.,	   2001;	   Bidwell	   et	   al.,	   2011)	   and	   D5	   (Manor	   et	   al.,	   2004)	  receptors,	  though	  alterations	  of	  receptor	  function	  in	  ADHD	  remain	  unclear.	  Several	  studies	  have	  also	  observed	  association	  between	  ADHD	  and	  the	  DAT	  gene	  (Cook	  et	  al.,	   1995;	   Gill	   et	   al.,	   1997;	  Waldman	   et	   al.,	   1998;	   Barr	   et	   al.,	   2001).	   Furthermore,	  positron	  emission	  tomography	  (PET)	  methods	  have	  afforded	  a	  direct	   inspection	  of	  DAT	   levels	   in	   the	   brain	   of	   human	   ADHD	   subjects	   (Varrone	   and	   Halldin,	   2010;	  Zimmer,	  2009).	  However,	  the	  findings	  with	  this	  approach	  have	  been	  mixed,	  possibly	  due	   to	  prior	  drug	  exposure	   in	   some	  studies	   (Fusar-­‐Poli	   et	   al,	   2012).	  Thus,	   studies	  have	  observed	  increased	  DAT	  binding	  in	  the	  basal	  ganglia	  of	  both	  children	  (Cheon	  et	  al.,	  2005)	  and	  adults	  (Dougherty	  et	  al.,	  1999;	  Dresel	  et	  al.,	  2000;	  Krause	  et	  al.,	  2000),	  although	   others	   have	   seen	   no	   change	   (van	   Dyck	   et	   al.,	   2002)	   or	   decreased	   DAT	  density	  in	  ADHD	  (Volkow	  et	  al.,	  2007).	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   The	   clear	   link	   between	   DAT	   and	   ADHD	   led	   researchers	   to	   use	   DAT	   as	   a	  candidate	  gene	   for	   further	  study.	  Five	  studies	  have	  examined	  the	  coding	  sequence	  and	  splice	  junctions	  of	  the	  human	  dopamine	  transporter	  (hDAT)	  for	  polymorphisms	  (Cargill	  et	  al.,	  1999;	  Grünhage	  et	  al.,	  2000;	  Vandenbergh	  et	  al.,	  2000;	  Mazei-­‐Robison	  et	   al.,	   2005;	   Mergy	   MA	   and	   Blakely	   RD,	   unpublished	   data).	   Six	   non-­‐synonymous	  variants	   were	   identified	   between	   the	   four	   studies:	   Val24Met	   (V24M),	   Val55Ala	  (V55A),	   Arg237Gln	   (R237Q),	   Val382Ala	   (V382A),	   Ala559Val	   (A559V),	   and	  Glu602Gly	  (E602G).	  	  In	  addition,	  in	  a	  study	  of	  inattentive	  characteristics	  in	  children	  diagnosed	  with	  ADHD	  (Bellgrove	  et	  al.,	  2009),	  a	  seventh	  coding	  variant,	  Arg615Cys	  (R615C),	  was	  identified	  (Sakrikar	  et	  al.,	  2012).	  Screening	  of	  proband	  DNAs	  for	  new	  DAT	  coding	  variants	   is	   still	  ongoing	   in	  various	  diseases	   including	  bipolar	  disorder	  and	  autism	  with	  comorbid	  ADHD	  (Rommelse	  et	  al.,	  2011;	  Davis	  and	  Kollins,	  2012;	  Mahajan	  et	  al.,	  2012).	  	  Disease-­‐associated	   DAT	   coding	   variants	   are	   listed	   in	   Table	   1	   and	   their	  locations	  on	  the	  DAT	  protein	  are	  shown	  in	  Figure	  5.	  Furthermore,	  recent	  advances	  in	  whole-­‐exome	  and	  whole-­‐genome	  sequencing	  (1000	  Genomes	  Project	  Consortium,	  2010)	  have	  resulted	  in	  a	  plethora	  of	  new	  DAT	  coding	  variants	  being	  deposited	  into	  databases.	   	   Since	  most	   exome	   screening	  projects	   are	  merely	   searching	   for	   genetic	  variation,	  the	  sample	  population	  is	  not	  associated	  with	  any	  particular	  disorder.	  DAT	  coding	   variants	   without	   known	   disease	   association	   are	   as	   follows	   (D	   =	   found	   in	  dbSNP	  database,	  G	  =	   found	  by	  1000	  Genomes,	  N	  =	   found	   in	  National	  Heart,	   Lung,	  and	  Blood	  Institute	  (NHLBI)	  Exome	  Sequencing	  Project):	  	  K3N	  (D,	  G,	  N),	  M11I	  (D,	  G,	  N),	  M11V	  (D,	  G),	  S12P	  (D,	  G,	  N),	  V14M	  (D,	  G),	  A16T	  (G),	  P17L	  (G,N),	  E20(stop)	  (D),	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Table	   1.	   Disease-­‐associated	   DAT	   coding	   variants.	   ADHD	   =	   attention	   deficit	  hyperactivity	  disorder;	  DTDS	  =	  dopamine	  transporter	  deficiency	  syndrome.	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  Figure	   5.	   Location	   of	   disease-­‐associated	   hDAT	   variants.	   ADHD-­‐associated	   variants	  are	   marked	   with	   red	   circles,	   ASD-­‐associated	   variants	   with	   yellow	   circles,	   bipolar	  disorder-­‐associated	   variants	   with	   green	   circles,	   DAT	   deficiency	   syndrome-­‐associated	   variants	   with	   orange	   circles,	   and	   variants	   without	   disease	   association	  with	  white	  circles.	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E20V	  (G,	  N),	  I32M	  (G,	  N),	  V24A	  (G),	  	  G39R	  (G),	  L42F	  (D,	  G),	  P50L	  (D,	  G,	  N),	  S53R	  (D,	  G,	  N),	  V73I	  (D,	  G,	  N),	  L104I	  (D,	  G,	  N),	  G121S	  (G),	  V131I	  (D,	  G),	  L138P	  (G),	  L138R	  (G),	  A161T	   (G),	   A163V	   (G),	   A192T	   (D,	   G),	   S198T	   (G),	   S202L	   (D,	   G),	   S202W	   (D,	   G,	   N),	  G209R	  (G,	  N),	  V221M	  (D,	  G,	  N),	  R237W	  (G,	  N),	  V245A	  (D,	  G),	   I268V	  (G,	  N),	  T271N	  (G),	  V275L	  (D,	  G,	  N),	  L281P	  (G),	  G289R	  (G),	  G293S	  (G),	  V300I	  (D,	  G,	  N),	  E307K	  (D,	  G),	  A308V	   (G),	   A314V	   (G),	   D345G	   (G,	   N),	   A346T	   (G,	   N),	   A346V	   (D,	   G,	   N),	   F362L	   (G),	  L368Q	  (G),	  Q373R	  (D,	  G,	  N),	  G380R	  (G,	  N),	  P395L	  (G)	  G433R	  (G),	  D436N	  (G),	  R445G	  (G),	   A455V	   (G,	   N),	   V464I	   (D,	   G,	   N),	   V471I	   (D,	   G),	   I490V	   (D,	   G,	   N),	   V501A	   (G,	   N),	  Q509H	  (D,	  G),	  R515W	  (G),	  S517T	  (G),	  G538A	  (D),	  V538I	  (G,	  N),	  R544S	  (G),	  P545T	  (G,	  N),	  H547Q	  (D,	  N),	  A559T	  (D,	  G),	  A576E	  (G),	  K579R	  (G,	  N),	  R588Q	  (G,	  N),	  G607W	  (G),	  R610H	  (D,	  G),	  T613M	  (G,	  N),	  K619N	  (D,	  G,	  N).	  	  Of	  the	  coding	  variants	  that	  have	  been	  characterized	  in	  any	  way,	  V24M,	  V55A,	  R237Q,	   and	   E602G	   do	   not	   demonstrate	   any	   changes	   in	   transporter	   expression	   or	  dopamine	   transport	   capacity.	   	   V382A	   hDAT,	   however,	   shows	   reduced	   protein	  expression,	   reduced	   capacity	   for	  both	  DA	  and	  NE	   transport,	   and	  a	   loss	  of	  phorbol	  ester	   (PMA)-­‐induced	   trafficking	   (Mazei-­‐Robison	   and	   Blakely,	   2005).	   	   The	   authors	  suggest	  that,	  upon	  PMA	  treatment,	  V382A	  hDAT	  stabilizes	  an	  inactive	  conformation	  in	  the	  plasma	  membrane	  but	  is	  not	  appropriately	  internalized.	  	   The	   A559V	   hDAT	   variant	   also	   displays	   a	   unique	   phenotype.	   In	   vitro	  characterization	  of	  DAT	  Val559	   (note:	   the	   genetic	   variant	   is	   referred	   to	   as	  A559V	  hDAT,	   however	   the	   mutant	   DAT	   protein	   is	   named	   based	   on	   the	   amino	   acid	   at	  position	   559;	   Ala559	   refers	   to	   WT	   DAT	   and	   Val559	   refers	   to	   the	   mutant	   DAT	  encoded	  by	  the	  mutant	  A559V	  DAT	  gene)	  revealed	  normal	   levels	  of	  both	  total	  and	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cell-­‐surface	   DAT	   expression,	   as	   well	   as	   normal	   DA	   uptake	   in	   a	   heterologous	  expression	   system	   (Mazei-­‐Robison	   et	   al.,	   2008).	   	   	  However,	   amperometric	   studies	  revealed	   that	   DAT	   Val559	   in	   transfected	   cells	   exhibited	   a	   spontaneous,	   DAT-­‐mediated	  outward	  “leak”	  of	  cytoplasmic	  DA	  under	  basal	  conditions,	  a	  phenomenon	  termed	  anomalous	  DA	  efflux	  (ADE),	  as	  well	  as	  elevated	  voltage-­‐dependent	  DA	  efflux.	  	  Furthermore,	   the	   ability	   of	   AMPH	   to	   induce	   DAT-­‐mediated	   efflux	   (Sulzer	   et	   al.,	  2005)	   was	   lost	   in	   DAT	   Val559-­‐transfected	   cells.	   	   Instead,	   AMPH	   acts	   like	   the	  competitive	  DAT	  antagonists	  methylphenidate	   and	   cocaine	   to	  block	  ADE.	   	   Further	  research	  has	  demonstrated	  that	  DAT	  Val559	  displays	  increased	  channel	  activity	  and	  that	  ADE	   is	  dependent	  on	  D2	  receptor	  signaling	  and	   increased	  phosphorylation	  of	  the	  DAT	  N-­‐terminus	  (Bowton	  et	  al.,	  2010).	  	   	  The	   most	   recently	   identified	   hDAT	   coding	   variant,	   R615C,	   also	   displays	  functional	  alterations.	  	  Although	  R615C	  hDAT	  expresses	  at	  WT	  levels,	  surface	  R615C	  DAT	  is	  reduced	  by	  ~50%	  and	  the	  dopamine	  transport	  Vmax	  is	  significantly	  reduced	  (Sakirkar	   et	   al.,	   2012).	   Despite	   reduced	   surface	   expression,	   upon	   treatment	   with	  AMPH,	   R615C	   supports	   similar	   amounts	   of	   DA	   efflux	   as	   the	   WT	   transporter,	   a	  finding	  attributed	   to	   a	   loss	  of	  AMPH-­‐induced	   transporter	   internalization	  observed	  with	  WT	  DAT	   (Saunders	   et	   al.,	   2000;	   Chen	   et	   al.,	   2010).	   	   Sakrikar	   and	   colleagues	  went	  on	  to	  demonstrate	  that	  internalization	  and	  recycling	  rates	  for	  DAT	  Cys615	  are	  significantly	   elevated.	   Furthermore,	   DAT	   Cys615	   interaction	   with	  calcium/calmodulin-­‐dependent	   protein	   kinase	   II	   (CaMKII)	   is	   increased,	   leading	   to	  increased	  CaMKII-­‐mediated	  basal	   phosphorylation	  of	  DAT’s	  N-­‐terminal	   tail.	   	   Since	  DAT	   association	   with	   membrane	   microdomains	   is	   required	   for	   PKC-­‐mediated	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internalization	  and	  CaMKII-­‐mediated	  DA	  efflux	  (Cremona	  et	  al.,	  2011),	   the	  authors	  examined	   DAT	   Cys615	   localization	   to	   membrane	   rafts	   and	   found	   a	   reduced	  association	   with	   raft	   markers.	   	   These	   findings	   suggest	   that	   DAT	   localization	   and	  function	  within	  membrane	  microdomains	  may	  provide	  another	  mechanism	  of	  DAT	  dysfunction	  in	  ADHD.	  	   Although	   fascinating	   from	   a	   mechanistic	   perspective,	   in	   vitro	   studies	   of	  ADHD-­‐associated	   DAT	   variants	   in	   transfected	   cells	   have	   obvious	   limitations	   with	  respect	   to	  perturbations	  of	  DA	  signaling	   in	   the	   intact	  CNS.	   	  Animal	  models	  of	   rare	  DAT	   variants	   are	   the	   next	   step	   for	   understanding	   DAT-­‐mediated	   changes	   in	   DA	  signaling	  in	  vivo.	  
Animal	  Models	  of	  ADHD	  	   Animal	  models	  are	  a	  valuable	  tool	  for	  studying	  disease	  mechanisms.	  	  Rodent	  models	   of	   ADHD	   are	   typically	   focused	   on	   recapitulating	   the	   symptoms	   seen	   in	  human	  subjects	  with	  ADHD	  –	  locomotor	  hyperactivity,	  impulsivity,	  and	  inattention	  –	  and	   the	   response	   to	  psychostimulant	   therapy	   (amphetamine	  or	  methylphenidate).	  	  Here,	   I	   will	   review	   animal	  models	   of	   ADHD	   based	   on	  manipulations	   of	   candidate	  genes	   to	   generate	   transgenic	   animals,	   lesion-­‐based	   approaches	   that	   target	   brain	  regions	  or	  circuits	  relevant	  to	  ADHD,	  developmental	  insult	  models,	  and	  models	  bred	  to	  select	  for	  ADHD-­‐like	  phenotypes.	  	  The	  models	  and	  findings	  addressed	  below	  are	  summarized	  in	  Table	  2.	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  Table	  2.	  Animal	  models	  of	  ADHD.	  +	  =	  phenotype	  observed	  in	  model,	  -­‐	  =	  phenotype	  absent	  from	  model,	  ND	  =	  phenotype	  not	  determined	  for	  model.	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Transgenic	  Mouse	  Models	  DAT	  Knockout	  	   Since	  the	  DAT	  gene	  has	  been	  associated	  with	  ADHD	  (Gill	  et	  al.,	  1997;	  Barr	  et	  al.,	  2001),	  imaging	  studies	  in	  human	  subjects	  with	  ADHD	  have	  suggested	  alterations	  in	   DAT	   density	   (Swanson	   et	   al.,	   2007),	   and	   the	   DAT	   is	   the	   primary	   target	   for	  psychostimulant	   therapies	   for	  ADHD,	   it	  was	  a	  prime	  candidate	   for	  generation	  of	  a	  knockout	   (KO)	  mouse	  model.	   	   Perhaps	   one	   of	   the	  most	  widely	   studied	  models	   of	  ADHD,	   the	   DAT	   KO	   mouse	   (Giros	   et	   al.,	   1996)	   displays	   a	   fivefold	   elevation	   in	  extracellular	  DA	  concentrations	  due	  to	  the	   inability	  to	  recapture	  released	  DA	  from	  the	  synapse.	   	  Subsequent	  characterization	  demonstrated	  that	  DAT	  KO	  mice	  have	  a	  greater	  than	  95%	  reduction	  in	  total	  tissue	  levels	  of	  DA,	  greater	  than	  90%	  reduction	  in	   tyrosine	   hydroxylase	   (TH)	   expression	   (Jones	   et	   al.,	   1998),	   and	   significant	  reductions	  in	  D2R	  mRNA	  levels	  (~50%)	  (Giros	  et	  al.,	  1996)	  and	  protein	  expression	  (~55%)	   (Jones	   et	   al.,	   1999).	   	   Interestingly,	   these	   changes	   are	   accompanied	   by	   a	  reduction	   in	   striatal	  volume	  and	   the	   total	  number	  of	  neurons	   (Cyr	  et	  al.,	  2005)	  as	  well	  as	  a	  loss	  of	  dendritic	  spines	  in	  proximal	  portions	  of	  dendrites	  (Berlanga	  et	  al.,	  2011).	   Taken	   together,	   these	   finding	   demonstrate	   that	   deletion	   of	   DAT	   results	   in	  significant	  structural	  and	  biochemical	  changes	  that	  alter	  DA	  signaling.	  	   The	   biochemical	   changes	   in	   the	   DAT	   KO	   mouse	   manifest	   in	   several	  behavioral	   alterations,	   most	   notably	   extreme	   (5-­‐6	   fold	   increase)	   locomotor	  hyperactivity	   in	   a	   novel	   environment	   (Giros	   et	   al.,	   1996).	   Interestingly,	   although	  AMPH’s	  ability	  to	  cause	  DA	  efflux	  is	  lost	  in	  striatal	  slices	  from	  DAT	  KO	  mice	  (Giros	  et	  al.,	  1996),	   these	  mice	   still	   show	  a	   reduction	   in	   locomotor	  activity	   following	  AMPH	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treatment	   (Gainetdinov	  et	  al.,	  1999),	  an	  effect	  attributed	   to	  serotonergic	  signaling.	  Furthermore,	  DAT	  KO	  mice	  display	  increased	  impulsivity	  as	  measured	  by	  a	  greater	  number	  of	  head	  dips	  over	  an	  unprotected	  edge	  of	  the	  elevated	  plus	  maze	  (Carpenter	  et	   al.,	   2012)	   and	  a	   reduced	   cliff	   avoidance	   reaction	   (Yamashita	   et	   al.,	   2013).	   	  DAT	  KOs	  also	  have	  impaired	  cognitive	  function	  as	  assessed	  in	  the	  eight-­‐arm	  radial	  maze	  (Gainetdinov	  et	  al.,	  1999)	  and	  the	  Morris	  water	  maze	  (Morice	  et	  al.,	  2007),	  impaired	  social	  interactions	  with	  other	  mice	  (Rodriguiz	  et	  al.,	  2004),	  increases	  in	  stereotyped	  and	  perseverative	  behaviors	   (Gainetdinov	  et	  al.,	  1999;	  Rodriguiz	  et	  al.,	  2004),	  and	  deficits	  in	  sensorimotor	  gating	  as	  determined	  by	  a	  reduction	  of	  prepulse	  inhibition	  of	  the	  acoustic	  startle	  response	  (Yamashita	  et	  al.,	  2006;	  Arime	  et	  al.,	  2012).	  	   Due	  to	  the	  extreme	  behavioral	  phenotypes	  of	  a	  complete	  deletion	  of	  DAT,	  it	  has	  been	  suggested	  that	  the	  DAT	  KO	  is	  not	  a	  model	  for	  ADHD,	  but	  perhaps	  a	  better	  model	   for	   schizophrenia	   (Spielewoy	   et	   al.,	   2000;	  Wong	   et	   al.,	   2012).	   Due	   to	   poor	  performance	  in	  the	  forced	  swim	  test,	  the	  DAT	  KO	  mouse	  has	  even	  been	  suggested	  as	  a	  model	  for	  depression	  (Perona	  et	  al.,	  2008).	  A	  major	  caveat	  of	  the	  DAT	  KO	  mouse,	  however,	  is	  that	  homozygous	  loss-­‐of-­‐function	  of	  DAT	  (DTDS)	  in	  humans	  results	  in	  a	  complex	   motor	   phenotype	   characterized	   by	   infantile	   dystonia	   and	   Parkinsonian	  symptoms	   (Kurian	   et	   al.,	   2011).	   	   Despite	   displaying	   ADHD-­‐like	   symptoms	   and	  responding	  to	  psychostimulant	  medications,	  the	  DAT	  KO	  mouse	  most	  closely	  models	  the	  symptoms	  seen	  in	  humans	  without	  a	  functional	  DAT.	  DAT	  Knockdown	  	   Since	  the	  DAT	  KO	  mouse	  is	  such	  an	  extreme	  perturbation	  to	  the	  DA	  system,	  efforts	  were	  made	  to	  create	  a	  more	  moderate	  disruption	  in	  DAT	  function.	  	  This	  led	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to	  the	  creation	  of	  the	  DAT	  knockdown	  (KD)	  mouse	  that	  has	  an	  approximately	  90%	  reduction	  in	  DAT	  expression	  (Zhuang	  et	  al.,	  2001).	  	  The	  restoration	  of	  just	  a	  10%	  of	  DAT	  expression	  greatly	  attenuated	  many	  of	  the	  features	  observed	  in	  DAT	  KO	  mice.	  	  For	   instance,	  extracellular	  DA	  is	  elevated	  two-­‐fold,	  spontaneous	   locomotor	  activity	  is	   between	   DAT	   KO	   and	   WT	   levels,	   and	   psychostimulant	   treatment	   improves	  locomotor	  hyperactivity.	  	  A	  significant	  DAT	  reduction,	  however,	  is	  not	  a	  key	  feature	  of	  ADHD,	  as	  evidenced	  by	  several	  brain	  imaging	  studies	  showing	  increased	  (Spencer	  et	  al.,	  2007)	  or	  unchanged	  DAT	  density	  (van	  Dyck	  et	  al,	  2002)	  in	  ADHD	  subjects.	  The	  DAT	  KD	  has	  been	  of	  limited	  utility	  for	  studying	  the	  disorder,	  although	  some	  groups	  have	  utilized	  the	  DAT	  KD	  as	  a	  model	  for	  bipolar	  mania	  (Ralph-­‐Williams	  et	  al.,	  2003;	  Young	  et	  al.,	  2011).	  GIT1	  Knockout	  	   Another	  putative	  model	  for	  ADHD	  is	  the	  G	  protein-­‐coupled	  receptor	  (GPCR)	  kinase-­‐interacting	   protein	   1	   (GIT1)	   KO	   mouse.	   	   An	   intronic	   single	   nucleotide	  polymorphism	  (SNP)	  that	  causes	  reduced	  GIT1	  gene	  expression	  was	  associated	  with	  ADHD	  in	  a	  Korean	  population	  (Won	  et	  al.,	  2011).	   	  GIT1	  KO	  mice	  display	  a	  two-­‐fold	  increase	  in	  spontaneous	  locomotor	  activity	  as	  well	  as	  deficits	  in	  recognition	  memory	  (novel	  object	  recognition	  paradigm)	  and	  spatial	  learning	  and	  memory	  (Morris	  water	  maze).	   GIT1	   KO	   mice	   display	   similar	   alterations	   to	   electroencephalogram	   (EEG)	  rhythms	   in	   the	   theta	   range	   	   (4-­‐8	  Hz)	   as	   human	   subjects	  with	  ADHD	   (Barry	   et	   al.,	  2003).	   	  The	  aforementioned	   characteristics	  were	   all	   reversed	  by	  AMPH	   treatment	  (Won	  et	  al.,	  2011),	  providing	  predictive	  as	  well	  as	  face	  validity	  to	  this	  model.	  
	   41	  
	   Due	   to	   GIT1’s	   role	   in	   regulating	   G	   protein-­‐coupled	   receptors	   (reviewed	   in	  Hoefen	  and	  Berk,	  2006)	  and	   the	  association	  of	  DA	   receptors	   (all	  GPCRs)	   to	  ADHD	  (Gill	  et	  al.,	  1997;	  Barr	  et	  al.,	  2001;	  Manor	  et	  al.,	  2004;	  Bobb	  et	  al.,	  2005;	  Nyman	  et	  al.,	  2007;	   Bidwell	   et	   al.,	   2011),	   Won	   and	   colleagues	   investigated	   several	   signaling	  pathways	  to	  see	  if	  neurotransmission	  was	  altered	  in	  GIT1	  KO	  mice.	  	  They	  found	  that	  excitatory	   transmission	   was	   normal,	   but	   that	   presynaptic	   mechanisms	   regulating	  inhibitory	   transmission	   were	   altered	   in	   GIT1	   KO	  mice.	   	   These	   findings	   suggest	   a	  possible	   imbalance	   between	   excitation	   and	   inhibition	  may	   be	   contributing	   to	   the	  ADHD-­‐like	  symptoms	  seen	   in	  GIT1	  KO	  mice.	  Such	  changes	   in	  excitatory/inhibitory	  balance	  are	  an	   interesting	  departure	  from	  the	  dopamine	  theory	  of	  ADHD.	   	  Further	  studies	  are	  needed	  to	  understand	  the	  precise	  mechanisms	  underlying	  the	  ADHD-­‐like	  symptoms	   and	   how	   deficits	   in	   inhibitory	   neurotransmission	   on	   dopaminergic	  neurons	  might	  modulate	  the	  behaviors	  affected	  in	  ADHD.	  Neurokinin	  Receptor	  1	  Knockout	  	   The	  substance	  P-­‐preferring	  neurokinin	  receptor	  (NK1R)	  KO	  mouse	  was	  first	  reported	   to	  exhibit	   locomotor	  hyperactivity	   (Herpfer	  et	  al.,	  2005),	   though	  was	  not	  touted	  as	  a	  model	  for	  ADHD.	  	  More	  recent	  research	  identified	  four	  single	  nucleotide	  polymorphisms	  (SNPs)	  in	  the	  TACR1	  (human	  NK1R)	  gene	  that	  are	  associated	  with	  ADHD	  (Yan	  et	  al.,	  2010),	  thus	  generating	  interest	  in	  the	  NK1R	  KO	  mouse	  as	  an	  ADHD	  model.	   In	   addition	   to	   hyperactivity,	   the	   performance	   of	   NK1R	   KO	  mice	   on	   the	   5-­‐choice	   serial	   reaction	   time	   task	   (5-­‐CSRTT)	   reveals	   inattentive,	   impulsive,	   and	  perseverative	   behaviors,	   as	   well	   (Yan	   et	   al.,	   2011).	   	   Upon	   treatment	   with	   AMPH,	  hyperlocomotion	   and	   perseveration	   were	   improved	   (Yan	   et	   al.,	   2010,	   2011),	   but	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impulsive	   responding	  was	  exacerbated	   (Yan	  et	  al.,	   2011).	   	  Furthermore,	  NK1R	  KO	  mice	   have	   deficits	   in	   AMPH-­‐induced	   DA	   efflux	   in	   the	   striatum,	   but	   not	   prefrontal	  cortex	  (Yan	  et	  al.,	  2010)	  and	  it	  was	  speculated	  that	  the	  loss	  of	  NK1R	  on	  cholinergic	  interneurons	   may	   contribute	   to	   altered	   striatal	   DA	   signaling.	   Although	   NK1R	   KO	  mice	   exhibit	   the	   core	   behavioral	   features	   of	   ADHD,	   the	   lack	   of	   improvement	   in	  inattentive	  and	   impulsive	  symptoms	  after	  AMPH	  treatment	  raises	  questions	  about	  the	  validity	  of	  this	  model.	  Steroid	  Sulfatase	  Knockout	  	   Steroid	  sulfatase	  (STS)	  is	  an	  X-­‐linked	  gene	  that	  is	  responsible	  for	  converting	  the	   sulfated	   steroid	   hormone	  dehydroepiandosterone	   (DHEAS)	   to	   its	   non-­‐sulfated	  form,	  DHEA,	  in	  the	  brain	  (Compagnone	  et	  al.,	  1997),	  and	  thus	  modulating	  GABAergic	  signaling	  (Park-­‐Chung	  et	  al.,	  1999).	  Furthermore,	  deletion	  of	  the	  STS	  gene	  (Tobias	  et	  al.,	  2001;	  Doherty	  et	  al.,	  2003)	  and	  DHEA/DHEAS	   levels	   (Strous	  et	  al.,	  2001)	  have	  previously	   been	   associated	  with	   attention	   problems,	   and	  was	   thus	   suggested	   as	   a	  candidate	   gene	   for	   ADHD	   (Davies	   et	   al.,	   2007).	   Subsequent	   work	   using	   either	  pharmacological	   manipulation	   or	   genetic	   deletion	   of	   STS	   in	   mice	   revealed	  performance	   deficits	   on	   the	   5-­‐CSRTT	   (Davies	   et	   al.,	   2009)	   and	   locomotor	  hyperactivity	  (Trent	  et	  al.,	  2012).	  To	  date,	  however,	   the	  effects	  of	  amphetamine	  or	  methylphenidate	   on	   5-­‐CSRTT	   performance	   or	   locomotor	   activity	   have	   not	   been	  tested.	   	  Recently,	  two	  SNPs	  in	  STS	  were	  associated	  with	  ADHD	  risk	  and	  inattentive	  symptoms	   (Stergiakouli	   et	   al.,	   2011),	   but	   the	   precise	  mechanisms	   underlying	   the	  connection	  between	  STS	  and	  ADHD	  remain	  to	  be	  determined.	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p35	  Knockout	  	   Cyclin	   dependent	   kinase	   5	   (Cdk5),	   along	  with	   its	   cofactor	   p35	   (Lew	   et	   al.,	  1994;	  Tsai	  et	  al.,	  1994),	  regulates	  dopaminergic	  signaling	  through	  phosphorylation	  of	  DARPP-­‐32	  (Bibb	  et	  al.,	  1999).	  While	  Cdk5	  KO	  mice	  are	  not	  viable	  (Ohshima	  et	  al.,	  1996;	   Gilmore	   et	   al.,	   1998),	   p35	   KO	   mice	   do	   survive,	   but	   display	   severe	  morphological	  defects	  including	  inversion	  of	  cortical	  lamination	  and	  reduced	  corpus	  callosum	   volume	   (Chae	   et	   al.,	   1997;	   Kwon	   and	   Tsai,	   1998).	   	   Despite	   such	   severe	  abnormalities,	   two	   independent	   groups	   found	   that	   p35	   KO	   mice	   display	  spontaneous	   locomotor	  hyperactivity	  (Drerup	  et	  al.,	  2010;	  Krapacher	  et	  al.,	  2010).	  	  Both	   amphetamine	   and	   methylphenidate	   elicit	   a	   paradoxical	   calming	   effect,	   as	  observed	   in	   ADHD.	   	  While	   p35	   KO	  mice	   do	   display	   a	   key	   clinical	   phenotype	   and	  pharmacological	   responses	   relevant	   to	   ADHD,	   the	   major	   caveat	   of	   structural	  abnormalities	   still	   remains,	   and	   testing	   for	   other	   features	   of	   ADHD	   such	   as	  inattention	  and	  impulsivity	  are	  needed.	  Guanylyl	  Cyclase	  C	  Knockout	  	   Although	   originally	   identified	   as	   a	   membrane	   receptor	   for	   the	   peptides	  guanyline	   and	   uroguanyline	   in	   the	   gut	   (Currie	   et	   al.,	   1992;	   Hamra	   et	   al.,	   1993),	  guanylyl	  cyclase	  C	  (GC-­‐C)	  was	  later	  found	  to	  be	  selectively	  expressed	  in	  DA	  neurons	  in	   the	  midbrain	   (Lein	  et	   al.,	   2007).	   	  GC-­‐C	  KO	  mice	  display	  a	   greater	   than	   two-­‐fold	  increase	   in	   locomotor	   activity	   as	   well	   as	   attention	   deficits,	   both	   of	   which	   are	  corrected	  by	  treatment	  with	  a	  low	  dose	  of	  AMPH	  (Gong	  et	  al.,	  2011).	  	  Furthermore,	  protein	  kinase	  G	  (PKG)	  activators	  can	  alleviate	  the	  locomotor	  hyperactivity	  of	  GC-­‐C	  KO	  mice,	  suggesting	  another	  possible	  therapeutic	  target	  for	  modulating	  DA	  signaling	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in	   ADHD.	   	   Further	   research	   is	   needed	   to	   understand	   how	   PKG	   signaling	   might	  impact	  ADHD-­‐like	  behavior	  in	  other	  model	  systems.	  Coloboma/SNAP-­‐25	  Knockout	  	   The	   coloboma	   (Cm)	   mutation	   consists	   of	   a	   2	   cM	   deletion	   of	   mouse	  chromosome	   2	   that	   includes	   the	   synaptosomal-­‐associated	   protein	   25	   kDa	   (SNAP-­‐25)	  locus	  (Hess	  et	  al.,	  1992).	  	  Further	  fine	  mapping	  identified	  the	  genes	  for	  SNAP-­‐25	  and	   brain-­‐specific	   phospholipase	   C-­‐β1	  within	   the	   Cm	   deletion	   (Hess	   et	   al.,	   1994).	  	  SNAP-­‐25	  is	  widely	  expressed	  in	  neurons	  (Oyler	  et	  al.,	  1989)	  and	  is	  suggested	  to	  have	  a	  key	  role	  in	  synaptogenesis	  and	  synaptic	  remodeling	  (Geddes	  et	  al.,	  1990;	  Catsicas	  et	  al.,	  1991;	  Oyler	  et	  al.,	  1991).	  Cm	  mice	  exhibit	  profound	   locomotor	  hyperactivity	  (Hess	  et	  al.,	  1992),	  thus	  making	  them	  a	  possible	  model	  for	  ADHD.	  	   Total	  levels	  of	  DA	  in	  Cm	  mice	  are	  not	  different	  from	  WT	  controls	  (Jones	  et	  al.,	  2001),	  but	   in	  vivo	  microdialysis	  studies	  showed	  a	  nearly	  two-­‐fold	  increase	  in	  basal	  
extracellular	   DA	   in	   Cm	  mice	   (Fan	   and	   Hess,	   2007).	   	   SNAP-­‐25	   plays	   a	   key	   role	   in	  vesicular	   fusion	   and	   neurotransmitter	   release	   (Bark	   et	   al.,	   1995;	   Schiavo	   et	   al.,	  1997);	  Cm	  mice	  display	  a	  decreased	  capacity	  for	  K+-­‐induced	  DA	  release	  (Raber	  et	  al.,	  1997).	   	   In	   addition	   to	   locomotor	   hyperactivity,	   Cm	  mice	   display	   deficits	   in	   latent	  inhibition	  and	  are	  highly	   impulsive	   (Bruno	  et	  al.,	  2007),	   thus	  manifesting	   the	  core	  clinical	   features	   of	   ADHD.	   While	   Cm	   mice	   display	   ADHD-­‐like	   behaviors,	   their	  response	  to	  psychostimulant	  treatment	  varies:	  amphetamine	  decreases	  locomotion	  in	   Cm	  mice,	   but	  methylphenidate	   enhances	   locomotor	   activity	   (Hess	   et	   al.,	   1996).	  	  Subsequent	   studies	   suggested	   that	   the	   behavioral	   characteristics	   and	   AMPH	  response	  of	  Cm	  mice	  arise	  from	  dysregulation	  of	  DA	  D2	  receptors	  (Fan	  et	  al.,	  2010).	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   Interestingly,	  transgenic	  replacement	  of	  SNAP-­‐25	  in	  Cm	  mice	  will	  rescue	  the	  behavioral	  deficits	  observed	  in	  these	  animals	  (Hess	  et	  al.,	  1996).	  	  However,	  although	  the	  Cm	  mutation	  is	  semi-­‐dominant	  (that	   is,	  Cm/Cm	  homozygotes	  are	  not	  viable	  so	  all	  Cm	  phenotypes	  are	  measured	  in	  Cm/+	  heterozygotes)	  (Hess	  et	  al.,	  1994),	  SNAP-­‐25	   heterozygotes	   do	   not	   display	   any	   of	   the	   behavioral	   abnormalities	   seen	   in	   Cm	  mice	   (Oliver	   and	  Davies,	   2009).	   	   This	   finding	   suggests	   that	   SNAP-­‐25	   is	   not	   solely	  responsible	   for	   the	   behavioral	   deficits	   observed	   in	   Cm	  mice.	   	   Further	   studies	   are	  needed	  to	  define	  the	  roles	  of	  genes	  other	  than	  SNAP-­‐25	  that	  are	  disrupted	  by	  the	  Cm	  mutation,	   as	   they	   may	   have	   important	   roles	   in	   mediating	   the	   phenotypes	   of	   Cm	  mice.	  Thyroid	  Receptor	  βPV	  	   Thyroid	   receptor	   (TR)	   βPV	   mutant	   mice	   were	   originally	   developed	   to	  understand	   the	   effects	   of	   a	  mutant	   thyroid	   hormone	   receptor	   from	   patients	  with	  severe	  resistance	  to	  thyroid	  hormone	  (RTH)	  on	  growth	  and	  development	  (Zhu	  et	  al.,	  1999;	  Kaneshige	   et	   al.,	   2000).	   TRβPV	  mice	  display	   locomotor	   hyperactivity,	   albeit	  mild	  and	  significantly	  greater	  than	  WT	  controls	  only	  after	  multiple	  sessions	  (Siesser	  et	   al.,	   2005),	   as	  well	   as	   attention	  deficits	   and	   increased	   impulsivity	   (Siesser	   et	   al.,	  2006).	  	  In	  addition,	  TRβPV	  mice	  have	  elevated	  striatal	  DA	  turnover.	  	  The	  locomotor	  hyperactivity	  of	  TRβPV	  mice	  is	  ameliorated	  by	  methylphenidate	  treatment,	  as	  well,	  but	   only	   at	   high	   (>	   30	   mg/kg)	   doses	   (Siesser	   et	   al.,	   2005,	   2006).	   	   Interestingly,	  human	  subjects	  with	  RTH	  frequently	  have	  comorbid	  ADHD	  (Hauser	  et	  al.,	  1993),	  but	  it	   remains	   unclear	   how	   dysfunctional	   thyroid	   hormone	   signaling	   manifests	   as	  ADHD-­‐like	  symptoms.	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Other	  Genetic	  Models	  	   In	   addition	   to	   the	  models	   described	   above,	   several	   new	  mouse	  models	   for	  ADHD	   have	   been	   suggested,	   but	   have	   not	   been	   well	   studied.	   	   Those	   models	   are	  described	  below:	  Grin1	  Knock-­‐in	  Furuse	   and	   colleagues	   reported	   locomotor	   hyperactivity	   that	   was	  ameliorated	  by	  methylphenidate	  treatment	  in	  mice	  harboring	  a	  mutation	  in	  Grin	  1	  (NMDA	  receptor	  subunit	  1)	  (Furuse	  et	  al.,	  2010).	  	  Further	  characterization	  revealed	  deficits	   in	   sensorimotor	   gating,	   working	   memory	   problems,	   reduced	   anxiety-­‐like	  behaviors,	  and	  deficient	  contextual	  and	  cued	   fear	   learning	   (Umemori	  et	  al.,	  2013).	  	  The	  behavioral	  changes	  observed	  are	  not	  exclusive	  to	  ADHD,	  thus	  the	  Grin1	  mutant	  mouse	   may	   prove	   a	   useful	   model	   for	   other	   neuropsychiatric	   disorders	   such	   as	  schizophrenia	  and	  bipolar	  disorder,	  as	  well.	  SynCAM1	  Dominant	  Negative	  	   SynCAM1	   is	   a	   synaptic	   adhesive	   protein	   that	   plays	   a	   significant	   role	   in	  astrocyte-­‐to-­‐astrocyte	  and	  astrocyte-­‐to-­‐neuron	  adhesive	  communication	  (Sandau	  et	  al.,	  2011b)	  and	  is	  important	  for	  female	  sexual	  development	  (Sandau	  et	  al.,	  2011a).	  In	  order	   to	   understand	   the	   role	   of	   SynCAM1	   function	   in	   astrocytes,	   Sandau	   and	  colleagues	   generated	   transgenic	  mice	   that	   express	   an	   astrocyte-­‐specific	   dominant	  negative	   SynCAM1	   (DNSynCAM1)	   (Sandau	   et	   al.,	   2012).	   	   During	   the	   course	   of	  studies	   relating	   to	   female	   reproductive	   function,	   the	   DNSynCAM1	  mice	   displayed	  high	   levels	   of	   locomotor	   activity	   and	   impulsive	   behaviors,	   reminiscent	   of	   ADHD.	  	  Formal	   characterization	   revealed	   elevated	   locomotor	   activity	   and	   disruption	   of	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diurnal	   patterns	   of	   locomotor	   activity	   and	   reduced	   anxiety.	   	   Furthermore,	   AMPH	  treatment	  normalized	   locomotor	  hyperactivity.	   	   Since	  DNSynCAM1	  was	   specific	   to	  astrocytes,	  these	  findings	  suggest	  that	  astrocytic	  signaling	  may	  contribute	  to	  ADHD	  phenotypes.	  Casein	  Kinase	  1	  Overexpression	  	   Casein	   kinase	   1	   δ	   (CK1δ)	   is	   a	   brain-­‐enriched	   protein	   kinase	   that	   has	   been	  associated	   with	   bipolar	   disorder	   (Matsunaga	   et	   al.,	   2012)	   and	   implicated	   in	  psychostimulant-­‐induced	  behaviors	  (Li	  et	  al.,	  2011)	  via	  phosphorylation	  of	  DARPP-­‐32,	   a	   key	   integrator	   of	   dopaminergic	   and	   glutamatergic	   signals	   (Desdouits	   et	   al.,	  1995;	  Greengard	  et	   al.,	   1998;	  Le	  Novère	  et	   al.,	   2008).	   	   In	  order	   to	  understand	   the	  importance	  of	  CK1δ	  signaling	   in	  vivo,	  Zhou	  and	  colleagues	  generated	  a	  mouse	  with	  inducible	  overexpression	  of	  CKI1δ	  in	  the	  striatum,	  cortex,	  and	  hippocampus	  (Zhou	  et	  al.,	  2010).	   	  These	  mice	  display	  locomotor	  hyperactivity	  that	  is	  reduced	  by	  either	  AMPH	   or	   MPH	   treatment,	   as	   well	   as	   reduced	   anxiety.	   	   Interestingly,	   CK1δ	  overexpression	   did	   not	   alter	   glutamatergic	   signaling,	   but	   did	   result	   in	   significant	  reductions	  in	  D1R	  and	  D2R	  expression.	  	  These	  findings	  suggest	  that	  CK1δ	  may	  play	  a	  role	  in	  regulating	  dopaminergic	  signaling	  that	  could	  contribute	  to	  ADHD.	  
Selectively	  Bred	  Models	  Spontaneously	  Hypertensive	  Rat	  	   One	   of	   the	   most	   frequently	   studied	   ADHD	   models	   is	   the	   spontaneously	  hypertensive	   rat	   (SHR).	   	  Originally	   derived	   from	   selective	   breeding	   of	  Wistar	   rats	  (Okamoto	  and	  Aoki,	  1963)	  and	  used	  to	  study	  essential	  hypertension	  (Yamori,	  1977),	  researchers	   soon	   recognized	   the	   spontaneous	  hyperactivity	  of	   SHRs	   (McCarty	  and	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Kopin,	   1979).	   	   It	   was	   then	   demonstrated	   that	   SHRs	   display	   the	   paradoxical	  locomotor	  response	  to	  AMPH	  (Myers	  et	  al.,	  1982)	  and	  MPH	  (Wultz	  et	  al.,	  1990)	  and	  the	  SHR	  was	  suggested	  as	  a	  model	   for	  ADHD.	   	  Further	  studies	  have	  demonstrated	  increased	   impulsivity	   (Sagvolden	   et	   al.,	   1992b;	   Fox	   et	   al.,	   2008;	   Sagvolden	   2011),	  impaired	  attention	  (Sagvolden	  and	  Xu,	  2008;	  Sagvolden	  2011),	  and	  cognitive	  deficits	  (Clements	   and	   Wainwright,	   2006;	   Kantak	   et	   al.,	   2008;	   Brackney	   et	   al.,	   2012).	  	  Accordingly,	   the	   SHR	   has	   been	   lauded	   as	   the	   best	   validated	   model	   of	   ADHD	  (Sagvolden,	  2011).	  	   While	   the	   SHR	  displays	   a	   number	  of	  ADHD-­‐like	   characteristics,	   these	   traits	  are	  not	  all	  improved	  by	  psychostimulant	  treatment.	  	  For	  instance,	  psychostimulants	  improve	  SHR	  performance	  on	  attention	  tasks	   in	  some	  studies	  (Kantak	  et	  al.,	  2008;	  Sagvolden	  et	  al.,	  2011)	  but	  not	  in	  others	  (van	  den	  Bergh	  et	  al.,	  2006;	  Ferguson	  et	  al.,	  2007).	   Similarly,	   AMPH	   typically	   reduces	   locomotor	   hyperactivity	   (Sagvolden	   and	  Xu,	   2008),	   but	   has	   been	   shown	   to	   potentiate	   locomotor	   behavior	   in	   some	   studies	  (Calzavara	   et	   al.,	   2011).	   	   Finally,	   SHRs	   display	   deficits	   in	   sensorimotor	   gating,	   as	  measured	  by	  prepulse	  inhibition	  (Li	  et	  al.,	  2007;	  Levin	  et	  al.,	  2011),	  but	  humans	  with	  ADHD	  typically	  do	  not	  (Feifel	  et	  al.,	  2009;	  Hanlon	  et	  al.,	  2009;	  Holstein	  et	  al.,	  2011),	  unless	   the	   task	   requires	   sustained	   attention	   (Hawk	   et	   al.,	   2003).	   	   The	  PPI	   deficits	  observed	  in	  SHRs	  are	  perhaps	  a	  better	  model	  for	  schizophrenia	  than	  ADHD	  (Levin	  et	  al.,	  2011).	  	   A	  major	  caveat	  to	  using	  the	  SHR	  to	  model	  ADHD	  is	  the	  lack	  of	  understanding	  as	  to	  the	  mechanisms	  underlying	  the	  observed	  behavior	  changes.	  Li	  and	  colleagues	  demonstrated	  a	  reduction	  of	  D4	  receptor	  expression	  in	  the	  prefrontal	  cortex	  (Li	  et	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al.,	  2007),	  an	   interesting	  finding	  in	   light	  of	  the	  association	  of	  the	  D4	  receptor	  gene	  and	  ADHD	   (Bidwell	   et	   al.,	   2011).	   In	   addition,	   SHRs	  have	   elevated	  DAT	   expression	  (Roessner	   et	   al.,	   2010),	  while	   human	   imaging	   studies	   suggest	   a	   reduction	   in	   DAT	  density	  in	  ADHD	  subjects	  (Volkow	  et	  al.,	  2009).	  	  The	  SHR	  is	  certainly	  a	  valuable	  tool	  for	   understanding	   how	   perturbations	   in	   DA	   signaling	   manifest	   behaviorally,	   but	  perhaps	  is	  not	  an	  ideal	  model	  for	  ADHD.	  Genetically	  Hypertensive	  Rat	  	   In	  an	  effort	  to	  demonstrate	  that	  the	  hyperactivity	  observed	  in	  SHRs	  is	  not	  an	  artifact	  of	  background	  strain	   (Wistar-­‐Kyoto,	  WKY),	  Wickens	  and	  colleagues	  report	  the	   independently	   generated	   New	   Zealand	   genetically	   hypertensive	   (GH)	   rat	  (Wickens	   et	   al.,	   2004).	   GH	   rats	   do	   not	   display	   basal	   locomotor	   hyperactivity,	   but	  have	   similar	   levels	   of	   lever	   pressing	   when	   tested	   on	   a	   fixed-­‐interval	   schedule	   to	  SHRs.	   	   This	   finding	   suggests	   that	   GH	   rats,	   like	   SHRs,	   are	   abnormally	   sensitive	   to	  reward.	   	  Further	  research	  demonstrated	  that	  both	  GH	  rats	  and	  SHRs	  have	  a	  strong	  preference	   for	   immediate	   reinforcement	   (Sutherland	   et	   al.,	   2009),	   a	   finding	  consistent	  with	   studies	   of	   humans	  with	  ADHD	   (Tripp	   and	  Alsop,	   2001).	   Thus,	   GH	  rats	   may	   be	   a	   valuable	   complementary	   model	   to	   SHRs	   for	   studying	   delayed	  reinforcement	  deficits	  in	  ADHD.	  Naples	  High	  Excitability	  Rat	  	   In	  order	  to	  understand	  hippocampal	  function,	  selective	  breeding	  for	  high	  and	  low	  arousal	   in	  response	  to	  novelty	  was	  undertaken	  and	  resulted	  in	  the	  creation	  of	  the	   Naples	   High	   Excitability	   (NHE)	   and	   Naples	   Low	   Excitability	   (NLE)	   rat	   strains	  (Cerbone	   et	   al.,	   1993).	   	   NHE	   rats	   display	   increased	   locomotor	   activity,	   deficits	   in	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unreinforced	  learning,	  and	  impaired	  attention	  (Cerbone	  et	  al.,	  1993;	  Viggiano	  et	  al.,	  2002a,	  b).	  	  Furthermore,	  NHE	  rats	  have	  larger	  dopaminergic	  neurons	  and	  higher	  TH	  expression	  in	  the	  VTA	  without	  any	  changes	  in	  the	  substantia	  nigra	  (Viggiano	  et	  al.,	  2002a),	  suggesting	  an	  imbalance	  between	  nigrostriatal	  and	  mesolimbic	  DA	  circuits.	  	  While	   the	   NHE	   rat	   displays	   some	   characteristics	   of	   ADHD	   as	   well	   as	   underlying	  changes	  in	  the	  brain,	  it	  has	  not	  proven	  to	  be	  a	  very	  productive	  model	  for	  ADHD.	  Wistar-­‐Kyoto	  Hyperactive	  Rat	  	   In	   order	   to	   separate	   hypertensive	   and	   hyperactive	   traits,	   SHRs	   were	   bred	  with	   their	  progenitor	  Wistar-­‐Kyoto	  strain,	   the	  selectively	  bred	   for	  hypertensive	  or	  hyperactive	   phenotypes,	   resulting	   in	   Wistar-­‐Kyoto	   Hyperactive	   (WKHA)	   and	  Wistar-­‐Kyoto	  Hypertensive	  (WKHT)	  rats	  (Hendley	  and	  Ohlsson,	  1991).	  	  WKHA	  rats	  display	  elevated	  hyperactivity,	   reduced	  anxiety	  behavior,	  and	   impaired	  attentional	  processing	  (Hendley	  and	  Ohlsson,	  1991;	  Sagvolden	  et	  al.,	  1992a;	  Courvoisier	  et	  al.,	  1996;	  Chess	  et	  al.,	  2005).	   	  Subsequent	  analysis	   identified	  a	  quantitative	   trait	   locus	  on	   rat	   chromosome	   8,	   linking	   locomotor	   hyperactivity	   to	   a	   chromosomal	   region	  containing	  genes	   for	   the	  α3	  nicotinic	  acetylcholine	  receptor	  and	  serotonin	  5-­‐HT1B	  receptor	   genes	   (Moisan	   et	   al.,	   1996).	   The	   genes	   are	   not	   typically	   considered	  candidates	  for	   influencing	  hyperactivity,	  however,	   it	  was	  shown	  that	  an	  antagonist	  of	   the	   5-­‐HT1B	   receptor	   can	   block	   locomotor	   hyperactivity	   induced	   by	   a	   5-­‐HT1B	  agonist,	  but	  not	  locomotor	  hyperactivity	  induced	  by	  AMPH	  treatment	  (Chaouloff	  et	  al.,	   1999).	   These	   findings	   suggest	   that	   serotonergic	   signaling	   can	   contribute	   to	  hyperactivity	   in	  WKHA	  rats,	  but	   it	   is	  unclear	   if	  serotonin	  receptors	  are	   involved	  in	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the	  tonic	  hyperactivity	  of	  these	  animals.	  It	  was	  later	  demonstrated	  the	  hyperactivity	  of	  WKHA	  rats	  is	  not	  improved	  upon	  methylphenidate	  treatment	  (Drolet	  et	  al.,	  2002).	  Wig	  Rat	  	   “Wiggling”	  rats	  were	  initially	  identified	  as	  a	  spontaneously	  hyperactive	  sub-­‐strain	   of	   the	   Long-­‐Evans	   Cinnamon	   rat,	   a	   rat	   strain	   that	   spontaneously	   develops	  acute	   hepatitis	   and	   hepatocellular	   carcinoma	   (Kamimura	   et	   al.,	   2001).	   Initial	  characterization	  revealed	  locomotor	  hyperactivity,	   impaired	  working	  memory,	  and	  impulsivity.	   	   Furthermore,	   the	   hyperactive	   trait	   was	   transmitted	   in	   an	   autosomal	  recessive	  pattern	  that	  is	  not	  linked	  to	  the	  causative	  gene	  for	  hepatitis.	   	  Subsequent	  research	  confirmed	  the	  hyperactive	  phenotype	  observed	   in	  Wig	  rats	  (Masuo	  et	  al.,	  2007),	   and	   found	   an	   increase	   in	   DAT	   gene	   expression	   in	   the	   dorsal	   midbrain,	  suggesting	   that	   abnormal	   development	   of	   dopamine	   neurons	   may	   underlie	   the	  locomotor	   hyperactivity.	   Furthermore,	   methamphetamine	   exacerbated	   locomotor	  activity,	   indicating	   that	   Wig	   rats	   do	   not	   display	   a	   paradoxical	   response	   to	  psychostimulants.	   Most	   recently,	   Hirano	   and	   colleagues	   reported	   several	  differentially	  expressed	  genes	  and	  proteins	  in	  the	  brain	  of	  the	  Wig	  rat	  (Hirano	  et	  al.,	  2008).	   	   Tyrosine	   hydroxylase	   was	   the	   only	   dopamine-­‐related	   gene	   differentially	  expressed	   in	  Wig	   rats,	  but	   the	  other	  genes	  and	  proteins	   identified	  could	  be	  useful	  targets	  for	  future	  studies	  into	  the	  pathogenesis	  of	  ADHD.	  
Lesion	  and	  Insult	  Models	  6-­‐Hydroxydopamine	  	   The	   compound	   6-­‐hydroxydopamine	   (6-­‐OHDA)	   is	   a	   neurotoxin	   that	   targets	  catecholaminergic	  neurons,	  leading	  to	  degeneration	  of	  nerve	  terminals	  and	  eventual	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neuron	   death	   (Tranzer	   and	   Thoenen,	   1968;	   Uretsky	   and	   Iversen,	   1969,	   1970).	  	  Behavioral	   characterization	   of	   6-­‐OHDA-­‐treated	   rats	   revealed	   locomotor	  hyperactivity	   in	   juvenile,	   but	   not	   adult,	   animals	   (Evetts	   et	   al.,	   1970;	   Lipton	   et	   al.,	  1980;	  Pappas	  et	  al.,	  1980;	  Shaywitz	  et	  al.,	  1981),	  as	  well	  as	  a	  paradoxical	  response	  to	  amphetamine,	  methylphenidate,	   and	   atomoxetine	   (Shaywitz	   et	   al.,	   1976a;	  Wool	   et	  al.,	   1987;	   Luthman	   et	   al.,	   1989;	   Davids	   et	   al.,	   2002b;	   Moran-­‐Gates	   et	   al.,	   2005).	  Furthermore,	   even	   though	   6-­‐OHDA	   affects	   both	   noradrenergic	   and	   dopaminergic	  neurons,	  it	  was	  shown	  that	  loss	  of	  DA	  signaling	  after	  6-­‐OHDA	  lesion	  was	  responsible	  for	  the	  behavioral	  defects	  observed	  in	  these	  animals	  (Shaywitz	  et	  al.,	  1984).	  As	  such,	  6-­‐OHDA-­‐treated	  juvenile	  rats	  were	  put	  forth	  as	  a	  model	  for	  ADHD	  (Shaywitz	  et	  al.,	  1976b;	   Kostrzewa	   et	   al.,	   1994)	   and	   lauded	   for	   both	   face	   and	   predictive	   validity	  (Sagvolden	  et	  al.,	  2005;	  van	  der	  Kooij	  and	  Glennon,	  2007).	  	   Subsequent	  work	  in	  both	  mice	  and	  rats	  has	  focused	  on	  the	  brain	  response	  to	  6-­‐OHDA	  lesion.	   	  Masuo	  and	  colleagues	  reported	  on	  gene	  expression	  changes	  in	  the	  striatum	   and	  midbrain,	   finding	   increases	   in	   striatal	   glutamate	   transporter	   (GluT)	  and	   midbrain	   DAT	   and	   D4	   dopamine	   receptor	   expression	   (Masuo	   et	   al.,	   2002).	  	  Induction	   of	   DAT	   expression	   was	   in	   agreement	   with	   other	   studies	   showing	  increased	  DAT	  expression	   in	  ADHD	  subjects	  (Dougherty	  et	  al.,	  1999;	  Madras	  et	  al.,	  2002).	  	  Further	  studies	  demonstrated	  that	  the	  D4	  receptor	  is	  essential	  for	  mediating	  locomotor	  hyperactivity	  in	  6-­‐OHDA-­‐lesioned	  mice	  (Avale	  et	  al.,	  2004a).	  	  	   Several	  studies	  have	  also	  investigated	  alterations	  in	  serotonin	  signaling	  after	  6-­‐OHDA	   lesions.	   	   Davids	   and	   colleagues	   reported	   that	   selective	   serotonin	  transporter	   (SERT)	   inhibitors	   (SSRIs)	   reduce	   the	   hyperlocomotion	   of	   6-­‐OHDA-­‐
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lesioned	  rats	   (Davids	  et	  al.,	  2002a),	  a	   finding	  reminiscent	  of	   the	  effect	  of	  SSRIs	  on	  DAT	   KO	   mice	   (Gainetdinov	   et	   al.,	   1999).	   In	   addition,	   6-­‐OHDA	   lesion	   leads	   to	  increased	  SERT	  binding	  in	  the	  striatum	  (Zhang	  et	  al.,	  2002)	  and	  induces	  sprouting	  of	  serotonergic	  axons	  and	   increases	  5-­‐HT	   levels	   in	   the	  striatum	  (Avale	  et	  al.,	  2004b).	  	  In	  light	  of	  a	  growing	  body	  of	  evidence	  implicating	  alterations	  in	  serotonin	  signaling	  to	   ADHD	   (Comings	   et	   al.,	   2000;	   Arnsten,	   2006;	   Sonuga-­‐Barke	   et	   al.,	   2011),	   this	  model	  may	  continue	  to	  be	  a	  useful	  tool.	  	   In	   spite	   of	   the	   obvious	   face	   and	   predictive	   validity	   of	   6-­‐OHDA-­‐lesioned	  rodents,	   the	   nature	   of	   the	   insult	   has	   limited	   relevance	   to	   ADHD.	   	   6-­‐OHDA	   lesions	  lead	   to	   degeneration	   of	   dopaminergic	   neurons,	   a	   clinical	   profile	   similar	   to	  Parkinson’s	   disease	   (reviewed	   in	   Poewe	   and	   Mahlknecht,	   2009).	   	   The	   ADHD-­‐like	  characteristics	  of	   this	  model	  are	   transient	   (Pappas	  et	  al.,	  1980),	  and	  adult	  animals	  are	   perhaps	   best	   used	   as	   a	   Parkinson’s	   disease	   model	   (Tieu,	   2011;	   Blandini	   and	  Armentero,	  2012;	  Blesa	  et	  al.,	  2012).	  	  Prenatal	  Nicotine	  	   Current	   studies	   are	  not	   clear	   if	   cigarette	   smoking	  during	  pregnancy	   causes	  cognitive	   impairments	   such	   as	   ADHD.	   	   Many	   studies	   find	   a	   significant	   effect	   of	  cigarette	   smoking	   (Milberger	   et	   al.,	   1996,	   1998;	   Ernst	   et	   al.,	   2001;	   Fried	   and	  Watkinson,	   2001),	   but	   some	   see	   no	   such	   effect	   (Thapar	   et	   al.,	   2009;	   Obel	   et	   al.,	  2011).	   	   While	   cigarette	   smoke	   contains	   many	   chemical	   compounds,	   evidence	  suggests	  that	  the	  effect	  of	  nicotine	  on	  the	  developing	  brain	  causes	  future	  behavioral	  problems	  (Slotkin	  et	  al.,	  1987;	  Navarro	  et	  al.,	  1989).	   	  Recent	  research	  in	  both	  mice	  (Zhu	  et	  al.,	  2012)	  and	  rats	   (Schneider	  et	  al.,	  2012)	   finds	   that	  prenatal	  exposure	   to	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nicotine	   does,	   in	   fact,	   result	   in	   ADHD-­‐like	   locomotor	   hyperactivity,	   and	   MPH	  ameliorates	  that	  hyperactivity	  in	  mice	  (Zhu	  et	  al.,	  2012).	  Nicotine-­‐exposed	  rats	  also	  showed	   impulsive	   responses	   on	   the	   5-­‐choice	   serial	   reaction	   time	   task,	   indicating	  that	  nicotine	  also	  affects	  inhibitory	  control.	  Polychlorinated	  Biphenyls	  	   A	   substantial	   body	   of	   evidence	   suggests	   that	   exposure	   to	   polychlorinated	  biphenyls	  (PCBs)	   is	  associated	  with	  development	  of	  ADHD	  in	  humans	  (Sagiv	  et	  al.,	  2010,	  2012;	  reviewed	  in	  Eubig	  et	  al.,	  2010).	  	  Studies	  in	  rats	  have	  demonstrated	  that	  early	   postnatal	   exposure	   to	   sub-­‐toxic	   levels	   of	   PCBs	   leads	   to	   hyperactive	   and	  impulsive	  behavior	  similar	  to	  that	  observed	  in	  SHRs	  (Holene	  et	  al.,	  1998).	   	  Further	  studies	  examined	  changes	  in	  gene	  expression	  following	  PCB	  exposure	  and	  identified	  a	  number	  of	  potential	  target	  genes	  underlying	  the	  ADHD-­‐like	  behavioral	  induced	  by	  PCBs	  (DasBanerjee	  et	  al.,	  2008;	  Sazonova	  et	  al.,	  2011).	   	  Such	  findings	  reiterate	  the	  concept	  that	  environment	  has	  a	  direct	  impact	  on	  gene	  expression	  and	  function	  and	  that	  the	  combination	  of	  genes	  and	  environment	  contribute	  to	  disease	  phenotypes.	  Bisphenol	  A	  	   Early	  postnatal	  exposure	  to	  the	  endocrine	  disruptor	  and	  environmental	  txin	  bisphenol	  A	  (BPA)	  has	  been	  suggested	  as	  a	  model	  for	  ADHD	  since	  BPA-­‐treated	  rats	  dose-­‐dependently	   develop	   locomotor	   hyperactivity,	   particularly	   during	   the	   dark	  phase	   of	   the	   light/dark	   cycle	   (Masuo	   et	   al.,	   2004).	   	   Subsequent	   studies	   confirmed	  that	  BPA	  exposure	  does	  indeed	  cause	  locomotor	  hyperactivity	  (Kiguchi	  et	  al.,	  2007,	  2008),	   but	   that	   the	   hyperactivity	   is	   not	   improved	   by	   treatment	   with	  methylphenidate.	   	  In	  fact,	  BPA-­‐treated	  mice	  displayed	  dose-­‐dependent	  increases	  in	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MPH-­‐induced	   locomotor	   activity.	   More	   recently,	   Zhou	   and	   colleagues	   report	   that	  early	   postnatal	   BPA	   treatment	   leads	   to	   functional	   alterations	   in	   the	   basolateral	  amygdala	   (BLA)	   (Zhou	   et	   al.,	   2011).	   	   It	   appeared	   that	   BPA	   treatment	   causes	  disinhibition	   of	   GABA	   signaling	   and	   enhancement	   of	   dopaminergic	   signaling,	   but	  that	   application	  of	  D1	   receptor	   or	  NMDA	   receptor	   antagonist	   or	  GABA-­‐A	   receptor	  agonist	   in	  the	  BLA	  improve	  hyperactive	  and	  inattentive	  symptoms.	   	  Although	  such	  signaling	   changes	   are	   not	   typically	   considered	   for	   ADHD,	   they	   may	   provide	  interesting	  avenues	  for	  future	  study.	  BrdU	  	   5-­‐bromo-­‐2’-­‐deoxyuridine	  (BrdU)	   is	  a	  nucleotide	  analog	   that	   is	   incorporated	  into	   DNA	   during	   cell	   division	   and	   is	   known	   to	   affect	   neurogenesis	   and	   cellular	  differentiation	   (Biggers	  et	  al.,	  1987;	  Kolb	  et	  al.,	  1999;	  Kuwagata	  et	  al.,	  2001).	  Rats	  exposed	   prenatally	   to	   BrdU	   are	   similar	   to	   6-­‐OHDA	   lesioned	   animals	   (Avale	   et	   al.,	  2004b)	   in	   that	   they	   display	   locomotor	   hyperactivity,	   decreased	   DA	   levels,	   and	  increased	   5-­‐HT	   levels	   (Kuwagata	   et	   al.,	   2004).	   Such	   changes	   in	   the	   DA	   and	   5-­‐HT	  systems	   led	   to	   the	   suggestion	   of	   BrdU-­‐treated	   rats	   as	   an	   ADHD	   model.	   Further	  research	   observed	   no	   changes	   in	  DAT	   density	   in	   BrdU-­‐treated	   rats	   and	   that	   their	  locomotor	  hyperactivity	  was	  increased	  by	  methylphenidate	  treatment	  (Muneoka	  et	  al.,	   2006;	   Orito	   et	   al.,	   2009).	   	   Similar	   to	   DAT	   KO	  mice	   (Gainetdinov	   et	   al.	   1999),	  however,	   the	   selective	   serotonin	   reuptake	   inhibitor	   paroxetine	  did	   ameliorate	   the	  hyperactivity	   of	   BrdU-­‐treated	   rats	   (Orito	   et	   al.,	   2009).	   	   These	   findings	   suggest	  changes	   in	   serotonergic	   signaling	   may	   be	   an	   adaptive	   response	   to	   reduced	  dopaminergic	  signaling.	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Neonatal	  Hypoxia	  	   Previous	   studies	  have	  suggested	   that	   children	  born	  prematurely	   commonly	  go	   on	   to	   develop	   ADHD	   (Szatmari	   et	   al.,	   1990;	   Botting	   et	   al.,	   1997;	   Bhutta	   et	   al.,	  2002),	   and	   recent	   evidence	   found	   an	   association	   between	   ischemic-­‐hypoxic	  conditions	  at	  birth	  and	  ADHD,	  particularly	  in	  preterm	  births	  (Getahun	  et	  al.,	  2013b).	  	  Efforts	   to	   understand	   the	   impact	   of	   premature	   birth	   and	   hypoxic	   conditions	   on	  brain	  development	  in	  rats	  have	  demonstrated	  that	  acute	  neonatal	  hypoxia	  leads	  to	  locomotor	  hyperactivity	  (Speiser	  et	  al.,	  1983;	  Oorschot	  et	  al.,	  2007)	  but	  the	  impact	  on	   attention	   remains	   unclear	   (Decker	   et	   al.,	   2003;	   Oorschot	   et	   al.,	   2007).	  	  Interestingly,	   rats	   with	   neonatal	   hypoxic	   injuries	   display	   an	   upregulation	   of	   D1	  receptor	  and	  vesicular	  monoamine	  transporter	  (VMAT),	  suggesting	  downregulated	  DA	  signaling,	  but	  normal	  levels	  of	  DAT	  and	  TH	  (Decker	  et	  al.,	  2003).	  	  These	  findings	  suggest	   that	   neonatal	   hypoxia	   induces	   neurochemical	   and	   behavioral	   changes	  consistent	  with	  ADHD,	  but	  further	  studies	  are	  needed	  to	  identify	  the	  precise	  lesion	  that	  yields	  such	  alterations.	  	  Prenatal	  Ethanol	  	   Several	   studies	   have	   recognized	   the	   similarity	   in	   behavior	   of	   children	  diagnosed	  with	  fetal	  alcohol	  syndrome	  and	  ADHD	  (Nanson	  and	  Hiscock,	  1990;	  Coles	  et	   al.,	   1997;	   O’Malley	   and	   Nanson,	   2002).	   	   Prenatal	   exposure	   to	   ethanol	   also	  produces	  ADHD-­‐like	   characteristics	   in	   rats	   –	   locomotor	   hyperactivity,	   impulsivity,	  and	   attention	   are	   all	   negatively	   affected	   by	   ethanol	   in	   a	   dose-­‐dependent	   fashion	  (Hausknecht	  et	  al.,	  2005;	  Kim	  et	  al.,	  2013).	  	  Furthermore,	  prenatal	  ethanol	  exposure	  alters	  the	  development	  of	  electrical	  activity	  in	  DA	  neurons	  of	  the	  VTA	  (Choong	  and	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Shen,	  2004).	  	  It	  remains	  unclear,	  though,	  if	  prenatal	  ethanol	  exposure	  contributes	  to	  ADHD,	   or	   if	   ADHD	   symptoms	   are	  merely	   a	   component	   of	   a	   larger	   ethanol-­‐related	  clinical	  syndrome.	  X-­‐Ray	  	   A	  single	  study	  has	  examined	  the	  effects	  of	  early	  postnatal	  x-­‐ray	  exposure	  on	  ADHD-­‐like	   phenotypes	   in	   rats	   (Highfield	   et	   al.,	   1998).	   	   Hippocampal	   irradiation	  resulted	   in	   significant	   cell	   death	   in	   the	   hippocampus	   and	   produced	   deficits	   in	  patterned	   single	   alternation,	   a	   form	   of	   memory-­‐based	   learning.	   	   Interestingly,	  treatment	   with	   amphetamine	   improved	   performance	   on	   the	   learning	   task.	  	  Regardless,	   it	   is	  difficult	   to	  separate	  a	   learning	  deficit	  due	  to	  hippocampal	  damage	  from	  poor	  task	  performance	  due	  to	  inattention.	  	  As	  such,	  the	  x-­‐irradiated	  rat	  is	  only	  of	  minor	  importance	  for	  furthering	  the	  understanding	  of	  ADHD.	  Chronic	  DAT	  Inhibition	  	   Sub-­‐chronic	   treatment	   with	   the	   potent	   DAT	   inhibitor	   GBR	   12909	   and	  subsequent	   withdrawal	   has	   been	   suggested	   as	   a	   model	   for	   ADHD	   (Hewitt	   et	   al.,	  2005,	  2009).	  This	  model	   is	  based	  on	  the	  rebound	  hypothesis	  –	  DAT	  inhibition	  will	  initially	  reduce	  DAT	  activity,	  but	  upon	  withdrawal	  DAT	  expression	  will	  rebound	  and	  be	   over-­‐expressed.	   	   After	   short-­‐term	  GBR	  12909	   treatment,	   rats	  maintain	   a	   small	  but	   significant	   elevation	   in	   locomotor	   activity	   and	  poor	  performance	  on	   an	  object	  discrimination	  task,	  a	  result	  attributed	  to	  inattention.	  	  While	  this	  model	  is	  based	  on	  alteration	   of	  DAT	   function,	   the	   behavioral	   phenotypes	   observed	   are	   transient	   and	  may	  limit	  the	  utility	  of	  this	  model	  system.	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Social	  Isolation	  	   Social	   isolation	   has	   been	   associated	   with	   subsequent	   development	   of	  locomotor	   hyperactivity	   (Wilkinson	   et	   al.,	   1994;	   Võikar	   et	   al.,	   2005),	   anxiety	  (Hellemans	  et	  al.,	  2004;	  Wei	  et	  al.,	  2007),	  aggression	  (Miczek	  and	  O’Donnell,	  1978;	  Wongwitdecha	  and	  Marsden,	  1996;	   Ibi	   et	   al.,	   2008),	   learning	  and	  memory	  deficits	  (Lu	   et	   al.,	   2003;	   Ibi	   et	   al.,	   2008),	   and	   impairment	   of	   prepulse	   inhibition	   of	   the	  acoustic	  startle	  response	  (Wilkinson	  et	  al.,	  1994;	  Day-­‐Wilson	  et	  al.,	  2006).	  Socially	  isolated	  rats	  treated	  with	  methylphenidate	  showed	  reduced	  anxiety-­‐like	  behaviors,	  but	   no	   change	   in	   aggression	   (Koike	   et	   al.,	   2009).	   	   Further	   study	   revealed	   an	  apparent	   attention	   deficit,	   as	   socially	   isolated	   rats	   performed	   poorly	   on	   a	   water	  finding	  test	  (a	  test	  of	  latent	  learning)	  (Ouchi	  et	  al.,	  2013).	  	  Interestingly,	  some	  of	  the	  behavioral	   deficits	   were	   improved	   by	   treatment	   with	   the	   selective	   serotonin	  reuptake	   inhibitor	   fluoxetine	   or	   antipsychotic	   clozapine	   (Koike	   et	   al.,	   2009).	   	   The	  diverse	   repertoire	   of	   behavioral	   deficiencies	   and	   response	   to	   a	   variety	   of	   drugs	  suggests	   that	   social	   isolation	   may	   be	   a	   model	   for	   a	   very	   complex	   psychiatric	  syndrome	   and	   could	   prove	   useful	   for	   studies	   relevant	   to	   schizophrenia	   or	  depression	  in	  addition	  to	  ADHD.	  Maternal	  Separation	  	   Separation	  of	  infant	  rats	  from	  their	  mothers	  during	  the	  first	  two	  weeks	  of	  life	  has	   been	   used	   to	   study	   the	   effects	   of	   early	   life	   stress	   because	   newborn	   rats	   are	  entirely	   dependent	   on	   the	  mother	   at	   this	   age	   (Janus,	   1987).	   	  Maternal	   separation	  (MS)	   has	   been	   suggested	   as	   a	   model	   of	   ADHD	   based	   on	   subsequent	   locomotor	  hyperactivity	  (von	  Hoersten	  et	  al.,	  1993;	  Arnold	  and	  Siviy,	  2002;	  Braun	  et	  al.,	  2003;	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Colorado	   et	   al.,	   2006;	   Kwak	   et	   al.,	   2009),	   however	   several	   studies	   have	   observed	  either	   no	   change	   or	   a	   decrease	   in	   locomotor	   behavior	   following	  MS	   (Janus,	   1987;	  Stanton	   et	   al.,	   1992;	   Rhees	   et	   al.,	   2001;	   Shalev	   and	   Kafkafi,	   2002;	   Matthews	   and	  Robbins,	   2003).	   Such	   conflicting	   findings	   raise	   questions	   regarding	   the	   validity	   of	  MS	  rats	  as	  an	  ADHD	  model.	  	   Recent	  studies	  have	  utilized	  maternal	  separation	  and	  early	  weaning	  (MSEW)	  in	  mice	  to	  model	  early	  life	  neglect	  and	  abuse	  (ENA)	  (George	  et	  al.,	  2010;	  Duque	  et	  al.,	  2012),	  a	  complex	  syndrome	  that	  can	  manifest	   later	   in	   life	  as	  ADHD	  (Ouyang	  et	  al.,	  2008)	  as	  well	  as	  anxiety,	  depression,	  and	  substance	  abuse	  (reviewed	  in	  Heim	  et	  al.,	  2010).	   	   Such	   mice	   do	   display	   locomotor	   hyperactivity,	   increased	   anxiety,	  depressive-­‐like	   symptoms	   (George	   et	   al.,	   2010),	   and	   subtle	   deficits	   related	   to	  attention	  (Carlyle	  et	  al.,	  2012).	  	  While	  perhaps	  not	  an	  ideal	  model	  for	  ADHD,	  MSEW	  mice	   may	   be	   a	   useful	   tool	   for	   studying	   environmental/experiential	   influences	   on	  complex	  behaviors.	  	   Interestingly,	   efforts	   have	   been	   made	   to	   study	   the	   effects	   of	   maternal	  separation	   on	   SHRs.	   	   Using	   this	   compound	   model,	   Womersley	   and	   colleagues	  demonstrated	   that	   MS	   did	   not	   alter	   SHR	   behavior	   (i.e.	   MS	   does	   not	   increase	  locomotor	  behavior	  or	  induce	  anxiety)	  (Womersley	  et	  al.,	  2011).	   	  However,	  MS	  did	  alter	   DAT	   function	   in	   SHRs;	   the	   time	   to	   clear	   DA	   was	   increased	   in	   maternally	  separated	  SHRs,	  an	  effect	  attributed	  to	  a	  decrease	  in	  either	  DAT	  surface	  expression	  or	  affinity	   for	  DA.	   	  Further	  study	  using	  the	  MS	  SHR	  model	  revealed	  neurochemical	  changes	  in	  GABA-­‐A	  receptor-­‐mediated	  modulation	  of	  norepinephrine	  release	  in	  the	  hippocampus	  (Sterley	  et	  al.,	  2013).	  	  However,	  the	  behavior	  of	  MS	  SHRs	  is	  unaffected	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(Womersley	  et	  al.,	  2011),	  leading	  to	  the	  hypothesis	  that	  additional	  adaptive	  changes	  likely	  occur	  in	  response	  to	  MS	  (Sterley	  et	  al.,	  2013),	  thus	  further	  highlighting	  the	  fact	  that	  environmental	  inputs	  can	  interact	  with	  genetic	  factors	  in	  some	  manifestations	  of	  ADHD.	  Habenula	  Disruption	  	   The	  habenula	   consists	  of	   a	  pair	  of	  nuclei	  –	   lateral	   (LHb)	  and	  medial	   (MHb)	  habenula	   –	   that	   receive	   inputs	   primarily	   from	   limbic	   structures	   and	   serve	   to	  regulate	   the	   activity	   of	   monoaminergic	   neurons	   in	   several	   midbrain	   nuclei	  (Hikosaka,	   2010).	   Pharmacological	   inactivation	   of	   the	   lateral	   habenula	   has	   been	  shown	   to	   increase	   DA	   release	   in	   the	   prefrontal	   cortex	   and	   nucleus	   accumbens	  (Lecourtier	   et	   al.,	   2008),	   suggesting	   that	   the	   LHb	   is	   inhibiting	   dopaminergic	  neurotransmission.	   	   Rats	   that	   received	   either	   chemical	   (Lee	   and	   Goto,	   2011)	   or	  genetic	   (Kobayashi	   et	   al.,	   2013)	   lesions	   of	   the	   habenula	   resulted	   in	   locomotor	  hyperactivity,	   impulsivity,	   and	   inattention	   (Lee	   and	   Goto,	   2011;	   Kobayashi	   et	   al.,	  2013).	   	   Furthermore,	   low	   dose	   AMPH	   treatment	   attenuated	   hyperactive	   and	  impulsive	   traits	   in	   juvenile	   rats,	   and	   dopamine	   D3	   receptor	   and	   DAT	   expression	  were	  reduced	  in	  juvenile	  rats	  (Lee	  and	  Goto,	  2011).	  	  Taken	  together,	  these	  findings	  suggest	   that	   lesion	  of	   the	  habenula	  disrupts	  dopaminergic	   signaling	  and	  results	   in	  ADHD-­‐like	   behaviors.	   	   Habenular	   dysfunction	   has	   been	   associated	   with	  schizophrenia	   (Sandyk,	   1992;	   Caputo	   et	   al.,	   1998;	   Shepard	   et	   al.,	   2006),	   but	  may	  prove	  to	  be	  an	  interesting	  target	  for	  future	  studies	  related	  to	  ADHD.	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Specific	  Aims	  	   The	   work	   presented	   herein	   seeks	   to	   generate	   and	   characterize	   a	   new	  construct-­‐valid	  mouse	  model	  for	  ADHD,	  the	  knock-­‐in	  mouse	  expressing	  the	  ADHD-­‐associated	   DAT	   coding	   variant	   Val559.	   	   To	   achieve	   these	   goals,	   I	   pursued	   the	  following	  aims:	  1) Generate	  the	  DAT	  Val559	  knock-­‐in	  mouse.	  2) Characterize	   biochemical	   features	   of	   DAT	   Val559	   and	   validate	   that	   in	   vitro	  findings	  regarding	  DAT	  Val559	  (Mazei-­‐Robison	  et	  al.,	  2008)	  are	  maintained	  in	  the	  mouse	  model.	  3) Characterize	  baseline	  behavioral	  profile	  of	  DAT	  Val559	  mice.	  4) Test	   behavioral	   effects	   of	   amphetamine,	   a	   psychostimulant	   medication	  commonly	  used	  in	  the	  treatment	  of	  ADHD.	  5) Examine	  DAT	  Val559	  function	  via	  in	  vivo	  and	  ex	  vivo	  preparations.	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CHAPTER	  II	  	  GENERATION	  AND	  INITIAL	  CHARACTERIZATION	  
	  
Introduction	  	   Increasing	   evidence	   supports	   the	   concept	   that	   risk	   for	   neuropsychiatric	  disorders	   is	   derived	   from	   a	   complex	   interplay	   of	   genetic	   variation	   and	  environmental	  factors	  (Nigg	  et	  al.,	  2010;	  Wermter	  et	  al.,	  2010).	  	  Although	  difficult	  to	  identify,	   rare	   variants	   may	   be	   of	   larger	   effect	   than	   common	   variants,	   and,	   when	  localized	   to	   functionally	   annotated	   regions	   of	   the	   genome,	   such	   as	   protein	   coding	  sequences,	  afford	  the	  generation	  of	  animal	  models	  that	  may	  be	  used	  for	  mechanistic	  studies	   (Boerio	   et	   al.,	   2010;	   Hassouna	   et	   al.,	   2012;	   Veenstra-­‐VanderWeele	   et	   al.,	  2012).	   	   In	   addition,	   as	   described	   in	   Chapter	   1,	   ADHD	   is	   the	   most	   common	  neuropsychiatric	  disorder	  diagnosed	  in	  children,	  and	  a	  preponderance	  of	  evidence	  associates	   altered	   DA	   signaling,	   in	   general,	   and	   the	   dopamine	   transporter,	  specifically,	   to	   the	   disorder.	   Therefore,	   we	   hypothesized	   that	   the	   ADHD	   patient	  population	  may	  be	  enriched	  for	  rare,	  highly	  penetrant	  coding	  variants.	  	  To	  that	  end,	  we	  screened	   the	  DAT	  coding	  sequence	  and	  splice	   junctions	  of	  ADHD	  probands	   for	  rare,	  non-­‐synonymous	  variation	  absent	  from	  control	  samples	  (Mazei-­‐Robison	  et	  al.,	  2005)	  and	  identified	  DAT	  A559V	  in	  a	  pair	  of	  brothers	  diagnosed	  with	  ADHD	  (note:	  the	  genetic	  variant	  is	  referred	  to	  as	  A559V	  hDAT,	  however	  the	  mutant	  DAT	  protein	  is	   named	  based	  on	   the	   amino	   acid	   at	   position	  559;	  Ala559	   refers	   to	  WT	  DAT	  and	  Val559	   refers	   to	   the	  mutant	   DAT	   encoded	   by	   the	  mutant	   A559V	  DAT	   gene).	   DAT	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Val559	  exhibits	  a	  unique	  alteration	  of	  function,	  basal	  DA	  efflux	  (Mazei-­‐Robison	  et	  al.,	  2008).	   	  We	  speculate	  that	  DAT	  Val559	  may	  contribute	  to	  risk	  for	  ADHD,	  as	  well	  as	  suggest	  a	  more	  general	  mechanism	  by	  which	  altered	  DA	  signaling	  and	  the	  resulting	  compensatory	  changes	  contribute	  to	  the	  disorder.	  	   Since	   in	   vitro	   studies	   of	   DAT	   Val559	   have	   obvious	   limitations	   regarding	  applicability	   to	  an	   intact	  nervous	  system,	  we	  engineered	  knock-­‐in	  mice	   to	  express	  DAT	   Val559	   in	   order	   to	   better	   study	   the	   biochemical	   and	   behavioral	   effects	   this	  variant	  in	  vivo.	  	  This	  chapter	  will	  describe	  the	  generation	  of	  the	  DAT	  Val559	  knock-­‐in	   mouse	   and	   initial	   characterization	   of	   its	   viability	   and	   basic	   sensorimotor	  functions	  (note:	  experiments	  were	  performed	  in	  both	  hetero-­‐	  and	  homozygous	  DAT	  Val559	  animals;	  hetero-­‐	  or	  homozygosity	  will	  be	  noted	  for	  all	  results).	  
Methods	  
Production	  of	  DAT	  Val559	  Knock-­‐In	  Mice	  Transgenic	   mice	   were	   produced	   using	   a	   linearized	   DNA	   construct	   derived	  from	  the	  genomic	  DNA	  sequence	  of	  the	  129S6/SvEvTac	  mouse	  strain	  to	  match	  the	  strain	  background	  of	   the	  mouse	  stem	  cells	   (TL-­‐1)	   that	  are	  used	   for	  gene	   targeting	  experiments.	  	  The	  targeting	  construct	  contains	  5’	  and	  3’	  homologous	  arms	  from	  the	  
Slc6a3	  gene,	  derived	  from	  129S6	  mouse	  genomic	  DNA,	  with	  a	  mutation	  in	  the	  5’	  arm	  to	   encode	   a	   valine	   at	   amino	   acid	   position	   559	   introduced	   by	   oligonucleotide-­‐mediated	   site-­‐directed	   mutagenesis	   (Stratagene	   Quik-­‐Change	   Mutagenesis	   Kit,	  Agilent	  Technologies,	   Santa	  Clara,	  CA).	   	  The	   targeting	  construct	  also	   included	  self-­‐excising	  Cre	  recombinase	  and	  neomycin	  resistance	  (NeoR)	  cassettes	  in	  the	  3’	  intron	  and	   a	   thymidine	   kinase	   cassette	   for	   negative	   selection.	   The	  DAT	  Val559	   targeting	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construct	  was	  electroporated	  into	  TL-­‐1	  embryonic	  stem	  cells	   in	  the	  ES/Transgenic	  Core	   Facility	   operated	   by	   the	   Vanderbilt	   University	   Center	   for	   Stem	   Cell	   Biology.	  Successful	  homologous	  recombination	  was	  confirmed	  by	  Southern	  blotting	  for	  both	  5’	  (576	  stem	  cell	  clones	  screened;	  12	  positive	  for	  5’	  probe	  (2.08%))	  and	  3’	  probes	  (6	  stem	   cell	   clones	   containing	   the	   5’	   end	   of	   the	   construct	   screened;	   2	   positive	   for	   3’	  probe	  (0.34%	  of	  all	  stem	  cell	  clones).	  The	  presence	  of	  the	  Val559	  substitution	  was	  subsequently	  confirmed	  on	  both	  strands	  via	  Sanger	  sequencing	  (1	  clone	  positive	  for	  5’	   and	   3’	   probes	   via	   Southern	   blotting	   and	   presence	   of	   Val559	   substitution	   by	  sequencing	  (0.17%	  of	  all	  stem	  cell	  clones).	  C57BL/6J	  blastocysts	  were	  injected	  with	  successfully	  targeted	  stem	  cells	  and	  then	   implanted	   into	   pseudo-­‐pregnant	   females.	   	   The	   resulting	   chimeric	   offspring	  were	  mated	  with	  WT	  C57BL/6J	  mice	   to	   test	   for	  germline	   transmission	  of	   the	  DAT	  Val559	  allele.	   	  Thereafter,	  genotypes	  of	  all	  mice	  were	  determined	  by	  PCR	  (forward	  primer:	  CAG	  CAT	  GGA	  AAA	  AAT	  CCA	  TGA	  A;	  reverse	  primer:	  AGC	  TAT	  ATT	  CAC	  CAT	  CAA	  AAG	  G;	  490	  base	  pair	  (BP)	  product	  =	  WT,	  561	  bp	  product	  =	  homo,	  490	  and	  561	  bp	   products	   =	   het).	   	   The	   difference	   in	   PCR	   product	   size	   between	  WT	   and	   Val559	  DAT	  arises	  from	  71	  bp	  remaining	  in	  DAT	  intronic	  sequence	  after	  the	  excision	  of	  the	  Cre	  and	  NeoR	  cassettes.	  A	  single	  male	  derived	   from	  the	   testcross	  was	   then	  mated	  with	  a	  WT	  129S6	  female	  to	  generate	  the	  initial	  colony	  for	  breeding,	  resulting	  in	  a	  hybrid	  background	  strain	  consisting	  of	  25%	  C57BL/6J	  and	  75%	  129S6	  genomic	  character.	  	  All	  animals	  used	  for	  subsequent	  studies	  were	  derived	  from	  heterozygous	  breedings	  at	  this	  and	  subsequent	  generations.	  	  Mice	  were	  maintained	  under	  standard	  housing	  conditions	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on	  a	  12-­‐hour	   light/dark	   cycle	   (lights	  off	  1800-­‐0600	   for	  breeding	   colony;	   lights	  off	  0200-­‐1400	   for	   behavior	   colony)	   with	   food	   (irradiated	   LabDiet	   5L0D	   chow	   (PMI	  Nutrition	  International,	  St.	  Louis,	  MO))	  and	  water	  available	  ad	  libitum.	   	   In	  order	  to	  assess	   growth	   and	   development,	   male	   mice	   of	   all	   three	   genotypes	   were	   weighed	  weekly	  from	  3-­‐12	  weeks	  of	  age.	  
Irwin	  Screen	  Basic	   sensorimotor	   function	   and	   reflexes	   of	   DAT	   Val559	   hetero-­‐	   and	  homozygous	  mice	  were	  examined	  using	  a	  modified	  version	  of	  the	  Irwin	  test	  battery	  (Irwin,	  1968).	   	  Mice	  were	  recorded	  over	  2	  consecutive	  days	  during	  the	  light	  phase	  (1600-­‐2000).	   General	   physical	   condition	   (presence	   of	   whiskers,	   quality	   of	   fur	  	  (general	   coat	   condition,	   bald	   patches,	   piloerection),	   limb	   tone,	   body	   tone)	   for	  individual	  mice	  was	  observed	  in	  a	  clean	  cage	  containing	  corncob	  bedding.	  	   Motor	  abilities	  and	  reflexes	  were	  assayed	  as	  follows:	  Trunk	  curl:	  each	  mouse	  was	   lifted	   12-­‐18	   inches	   by	   the	   base	   of	   the	   tail	   and	   the	   presence	   of	   nose-­‐to-­‐tail	  curling	  of	  the	  body	  assessed.	  Forepaw	  reaching:	  each	  mouse	  was	  lifted	  by	  the	  base	  of	  the	   tail	   and	  moved	   horizontally	   towards	   a	   metal	   wire	   food	   bin/cage	   insert.	   	   The	  degree	  to	  which	  the	  mouse	  extended	  its	  forepaws	  as	  it	  approached	  the	  wire	  food	  bin	  was	  scored	  (no	  reaching	  =	  0,	  reaching	  upon	  nose	  contact	  =	  1,	  reaching	  upon	  whisker	  contact	   =	   2,	   reaching	   before	   whisker	   contact	   (18-­‐20	   mm)	   =	   3,	   early,	   vigorous	  reaching	  (>	  25	  mm)	  =	  4).	  Inverted	  screen:	  Two	  to	  four	  mice	  were	  placed	  on	  a	  metal	  grid	  screen	  (10	  x	  14	  cm)	  into	  individual	  compartments.	   	  After	  placement,	  the	  mice	  were	  given	  time	  to	  establish	  a	  grip	  on	  the	  screen	  before	  it	  was	  inverted	  60	  cm	  above	  a	   clean	   plastic	   cage	   containing	   fresh	   corncob	   bedding.	   	   The	   latency	   to	   fall	   was	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recorded	   for	   up	   to	   1	   minute,	   at	   which	   point	   the	   mice	   were	   removed	   from	   the	  apparatus	   and	   returned	   to	   the	   home	   cage.	   Positional	   passivity:	   Each	   mouse	   was	  subjected	   to	   sequential	   handling	   and	   the	   reaction	   to	   handling	   (e.g.	   struggle	   to	  escape)	   assessed.	   	   Mice	   were	   first	   restrained	   by	   the	   tail	   (score	   =	   0),	   then	   gently	  restrained	  by	  the	  neck	  (score	  =	  1),	  restrained	  by	  the	  nape	  of	  the	  neck	  (scruffed)	  and	  held	  supine	  (score	  =	  2),	  and	  finally	  restrained	  by	  the	  hind	  legs	  (score	  =	  3).	  	  Data	  are	  represented	  as	  the	  number	  of	  mice	  showing	  any	  positional	  passivity.	  Rotarod:	  Motor	  coordination	   and	   balance	   were	   assessed	   using	   an	   accelerating	   rotarod	   apparatus	  (Ugo	  Basile,	  Comerio	  VA,	  Italy).	  	  Mice	  were	  placed	  on	  the	  rotating	  cylinder	  (3	  cm	  in	  diameter)	  and	  confined	  to	  a	  segment	  of	  the	  cylinder	  (approximately	  6	  cm	  wide)	  by	  gray	  plastic	  dividers.	   	  The	   rotational	   speed	  of	   the	   cylinder	   increased	   from	  5	   to	  40	  rpm	   over	   the	   5-­‐minute	   testing	   period.	   	   The	   latency	   at	   which	   mice	   fell	   off	   of	   the	  rotating	  cylinder	  was	  measured.	  	  Each	  mouse	  was	  given	  a	  trial	  on	  the	  rotarod	  before	  performance	  was	  assessed.	  Grip	  strength:	  Grip	  strength	  was	  measured	  using	  a	  force	  gauge	  attached	  to	  a	  small	  metal	  grate	  (8	  x	  8	  cm).	   	  Each	  mouse	  was	  allowed	  to	  grip	  the	  metal	  grate	  with	  its	  forepaws,	  then	  gently	  pulled	  backwards	  by	  the	  base	  of	  the	  tail	  until	  it	  released	  the	  grate.	  	  Grip	  strength	  was	  recorded	  with	  a	  digital	  gauge	  that	  returned	  the	  maximum	  force	  during	  each	  trial.	   	  The	  average	  grip	  strength,	  given	  in	  Newtons,	   is	   the	   average	   of	   three	   trials.	   Righting	   reflex:	   Mice	   were	   inverted	   to	   a	  supine	  position	  in	  the	  research’s	  hand.	  	  The	  mouse	  was	  then	  released	  and	  the	  ability	  of	  the	  mouse	  to	  right	  itself	  was	  assessed.	  	  Air	  righting	  reflex:	  Mice	  were	  inverted	  to	  a	  supine	   position	   in	   the	   researcher’s	   hand	   while	   being	   held	   approximately	   30	   cm	  above	  a	  cage	  containing	  8-­‐10	  cm	  of	  clean	  corncob	  bedding.	  	  The	  mouse	  was	  released	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and	  allowed	  to	  drop	  into	  the	  cage	  and	  bedding	  below.	   	  The	  ability	  of	  the	  mouse	  to	  right	  itself	  while	  falling	  was	  assessed.	   	  Ear	  twitch:	  Mice	  were	  gently	  restrained	  and	  the	  auditory	  meatus	  gently	  touched	  with	  the	  tip	  of	  a	  size	  6.1	  Touch	  Test	  (Von	  Frey)	  Sensory	   Evaluator	   (Stoelting,	  Wood	   Dale,	   IL).	   	   The	   presence	   of	   a	   reaction	   (active	  retraction	  and/or	  flick	  of	  the	  ear)	  was	  assessed.	  Petting	  escape:	  Mice	  were	  stroked	  down	   the	   length	   of	   the	   body,	   starting	   with	   a	   light	   touch	   and	   gradually	   increased	  pressure	  as	   the	   researcher	  approached	   the	  mouse’s	   tail.	   	  The	  escape	   reaction	  was	  assessed	  as	  follows:	  no	  response	  (score	  =	  0),	  mild	  (escape	  from	  moderate	  pressure,	  score	   =	   1),	  moderate	   (escape	   from	   light	   pressure,	   score	   =	   2),	   or	   vigorous	   (escape	  from	  approach,	   score	  =	  3).	  Data	  are	  presented	  as	   the	  number	  of	  mice	   showing	  an	  escape	   response.	   	   Data	   for	   all	   measures	   of	   sensorimotor	   function	   were	   analyzed	  using	  a	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  
Backcrossing	  to	  C57	  Background	  	   Since	  the	  primary	  DAT	  Val559	  colony	  is	  maintained	  on	  a	  hybrid	  background,	  we	  opted	  to	  backcross	  to	  a	  pure	  C57BL/6J	  background.	   	   In	  order	  to	  accelerate	  the	  generation	  of	   congenic	   C57BL/6J-­‐DAT	  Vall559	  mice,	  we	  utilized	   the	   commercially	  available	   MAX-­‐BAX®	   speed	   congenic	   service	   (Charles	   River	   Laboratories	  International,	   Inc.,	   Wilmington,	   MA)	   (for	   a	   review	   of	   the	   basic	   speed	   congenic	  process,	  see	  Wong,	  2002).	  Briefly,	  heterozygous	  hybrid	  DAT	  Val559	  male	  mice	  were	  bred	  with	  WT	  C57BL/6J	  females.	  	  Offspring	  were	  genotyped	  and	  DNA	  samples	  from	  those	  carrying	  the	  DAT	  Val559	  allele	  were	  subjected	  to	  screening	  on	  a	  microarray-­‐based	  microsatellite	  panel.	  	  This	  microsatellite	  marker	  panel	  contains	  DNAs	  that	  are	  polymorphic	  between	  the	  129S6	  and	  C57BL/6J	  strains.	  Using	  a	  fluorescence-­‐based	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genotyping	  assay,	  the	  genome	  is	  analyzed	  to	  determine	  which	  of	  the	  mice	  screened	  possesses	   the	   most	   markers	   associated	   with	   the	   target	   (C57BL/6J)	   strain.	   	   The	  mouse	  with	  the	  highest	  percentage	  of	  C57BL/6J	  genome	  was	  selected	  for	  breeding	  with	  a	  WT	  C57BL/6J	  and	  the	  microsatellite	  analysis	  repeated.	  	  DAT	  Val559	  mutant	  mice	  were	  backcrossed	  onto	  the	  C57BL6/J	  background	  for	  4	  generations.	  
Results	  
Successful	  Generation	  of	  DAT	  Val559	  Mice	  To	  express	  the	  DAT	  Val559	  variant	  from	  the	  endogenous	  mouse	  Slc6a3	  locus,	  we	   performed	   homologous	   recombination	   with	   a	   construct	   bearing	   an	   altered	  codon	  encoding	  the	  Val	  substitution	  in	  exon	  13,	  as	  well	  as	  self-­‐excising	  loxP-­‐flanked	  Cre	  recombinase	  and	  neomycin	  resistance	  (NeoR)	  cassettes	  in	  the	  3’	  intron	  (Fig.	  6).	  Chimeric	   animals	   positive	   for	   integration	   of	   the	   targeting	   construct	   (Fig.	   7)	   were	  crossed	  with	   a	  WT	   C57BL/6J	  mouse	   to	   test	   for	   germline	   transmission.	   A	   founder	  animal	   positive	   for	   germline	   transmission	   of	   the	  Val559	   variant	   and	  Neo	   excision	  (Fig.	  8)	  was	  selected	  and	  bred	  as	  described	  in	  Methods.	  
Evaluation	  of	  Growth	  and	  Sensorimotor	  Function	  of	  DAT	  Val559	  Mice	  	   Before	   proceeding	   with	   full	   characterization	   of	   DAT	   Val559	   mice,	   we	  assessed	  growth	  and	  development	  and	  basic	  sensorimotor	   function.	  Whereas	  DAT	  KO	  mice	  show	  reduced	  weight	  gain	  and	  survival	  (Giros	  et	  al.,	  1996),	  neither	  hetero-­‐	  nor	  homozygous	  DAT	  Val559	  mice	  displayed	  growth	  abnormalities	   relative	   to	  WT	  littermates	  (Fig.	  9).	  	  Furthermore,	  general	  sensorimotor	  assessment	  of	  male	  mice	  at	  7	  weeks	  of	  age	  revealed	  no	  genotype	  differences	  in	  general	  health,	  reflexes,	  or	  basic	  motor	  function	  (Table	  3).	  Although	  we	  observe	  normal	  growth	  of	  DAT	  Val559	  mice,	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  Figure	  6.	  Targeting	  strategy	  to	  generate	  DAT	  Val559	  knock-­‐in	  mice.	  Structure	  of	  the	  DAT	   gene	   (top),	   DAT	   Val559	   targeting	   construct	   (middle),	   and	   successfully	  recombined	  DAT	  gene	  (bottom).	   	  Coding	  exons	  are	  displayed	  as	  white	  boxes,	  non-­‐coding	  exonic	  sequence	  appears	  as	  a	  gray	  box.	  	  Following	  successful	  recombination,	  the	   Cre	   recombinase	   and	   neomycin	   resistance	   cassette	   are	   excised	   from	   the	   DAT	  gene.	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  Figure	  7.	  Southern	  blot	  analysis	   to	  screen	   for	  genomic	   integration	  of	   the	   targeting	  construct.	  	  Probes	  for	  the	  (A)	  5’	  and	  (B)	  3’	  ends	  of	  the	  targeting	  construct	  bind	  to	  a	  larger	  band	  for	  the	  WT	  allele	  and	  a	  smaller	  band	  for	  the	  DAT	  Val559	  allele	  following	  the	  appropriate	  restriction	  enzyme	  digest	  (EcoRI	  for	  5’	  probe;	  EcoRV	  for	  3’	  probe).	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  Figure	   8.	   Genotype	   determination	   of	   DAT	   Val559	   mice.	   	   Following	   successful	  recombination	  and	  excision	  of	  Cre	  recombinase	  and	  neomycin	  resistance	  cassettes,	  genotypes	  of	   all	  mice	   can	  be	  determined	  by	  PCR.	   	  The	  presence	  of	   a	  490	  bp	  band	  indicates	  a	  WT	  DAT	  allele,	  a	  561	  bp	  band	  indicates	  a	  DAT	  Val559	  homozygote,	  and	  the	  presence	  of	  both	  490	  and	  561	  bp	  bands	  indicates	  a	  DAT	  Val559	  heterozygote.	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  Figure	  9.	   Growth	  of	  DAT	  Val559	  mice	   after	  weaning	   (3-­‐12	  weeks)	   does	  not	   differ	  among	  genotypes.	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  Table	   3.	   Sensorimotor	   evaluation	   of	   DAT	   Val559	   mice.	   DAT	   Val559	   hetero-­‐	   and	  homozygous	   mice	   display	   no	   deficiencies	   in	   measures	   of	   general	   health,	   motor	  capability,	   or	   reflexes	   (each	   test	   analyzed	   by	   one-­‐way	   ANOVA,	   P	   =	   n.s.	   for	   all	  measures).	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we	  detected	  a	   small	  but	   significant	   reduction	   in	   the	  number	  of	  DAT	  Val559	  males	  present	  in	  the	  post-­‐weaning	  population	  (Table	  4)	  (chi-­‐square	  test:	  male:	  P	  =	  0.006;	  female:	  P	  =	  0.80;	  overall:	  P	  =	  0.006).	  
Generation	  of	  Congenic	  DAT	  Val559	  Mice	  on	  C57BL/6J	  Background	  	   As	   described	   in	   the	   methods,	   animals	   used	   for	   the	   experiments	   described	  herein	  were	  maintained	  on	  a	  hybrid	  background.	  	  We	  used	  a	  commercially	  available	  marker-­‐assisted	  selection	  protocol	  (“speed	  congenic”)	   to	  express	  DAT	  Val559	  on	  a	  pure	   C57BL/6J	   background.	   	   After	   only	   four	   generations	   of	   backcrossing	   to	   the	  C57BL/6J	   target	   strain,	  we	  successfully	  generated	  DAT	  Val559	  heterozygotes	  with	  99%	  C57BL/6J	  genomic	  character	  (Table	  5).	  	  These	  animals	  were	  then	  bred	  in	  order	  to	  establish	  the	  C57BL/6J	  DAT	  Val559	  mouse	  colony.	  
Discussion	  	   Rare	  genetic	  variation	   is	   increasingly	   recognized	  as	   source	   for	   insights	   into	  the	  etiology	  of	  complex	  disorders	  (Horschitz	  et	  al.,	  2005;	  Kauwe	  et	  al.,	  2008;	  Quast	  et	  al.,	  2012;	  Takata	  et	  al.,	  2013).	  	  Oftentimes,	  such	  variation	  is	  limited	  to	  a	  single,	  and	  sometimes	   small	   pedigree,	   compelling	   the	   demonstration	   of	   functional	  perturbations	  in	  vitro	  and	  in	  vivo	  to	  make	  reasonable	  conclusions	  regarding	  possible	  disease	  associations.	  	  	  Having	  analyzed	  the	  biochemical	  features	  of	  the	  DAT	  Val559	  variant	   in	   vitro	   (Mazei-­‐Robison	   et	   al.,	   2008),	   we	   pursued	   construction	   of	   a	   DAT	  Val559	  knock-­‐in	  mouse	  model	  to	  permit	  in	  vivo	  analyses	  of	  the	  functional	  impact	  of	  the	  DAT	  Val559	  variant.	  	  	   After	   successful	   generation	   of	   the	   DAT	   Val559	   mice,	   we	   established	  heterozygous	   breeders	   and	   evaluated	   growth	   and	   development	   of	   offspring	   as	   a	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  Table	  4.	  Expected	  and	  observed	  allele	  frequencies	  of	  DAT	  Val559.	  The	  DAT	  Val559	  allele	   is	   significantly	   under-­‐represented	   in	   the	   total	   population	   of	   post-­‐weaning	  mice	   (**	   =	  P	   <	   0.01,	   chi-­‐square	   test),	   driven	   primarily	   by	   a	   reduction	   in	   the	  male	  mice	   possessing	   the	   DAT	   Val559	   allele	   (***	   =	   P	   =	   0.001,	   chi-­‐square	   test).	   	   Males	  obtained	  from	  446	  litters,	  females	  obtained	  from	  367	  litters	  (for	  some	  litters,	  males	  were	   utilized	   for	   behavioral	   experiments,	   but	   females	   were	   not	   needed	   and,	  therefore,	  never	  genotyped).	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  Table	   5.	   Expected	   and	   observed	   C57BL/6J	   (C57)	   genomic	   content	   throughout	  backcross	   from	  hybrid	  129S6/C57	  background	   to	   congenic	  C57BL/6J	  background.	  	  At	  each	  generation,	  DAT	  Val559	  heterozygous	  mice	  were	  crossed	  with	  WT	  C57	  mice.	  	  C57	   genomic	   character	   of	   each	   generation	   was	   determined	   via	   Charles	   River	  Laboratories	  MAX-­‐BAX®	   speed	   congenic	   service.	   For	   each	   generation,	   the	  mouse	  with	   the	   highest	   percentage	   of	   C57	   genomic	   character	   was	   bred	   to	   generate	   the	  subsequent	  generation.	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function	  of	  genotype	  to	  ensure	  that	  perturbations	  in	  DA	  signaling	  resulting	  from	  the	  presence	   of	   DAT	   Val559	   did	   not	   affect	   mouse	   viability.	   	   Whereas	   DAT	   KO	   mice	  display	   retarded	   growth	   and	   reduced	   survival	   (Giros	   et	   al.,	   1996),	   we	   found	   that	  DAT	  Val559	  mice	  develop	  normally	  without	  any	  gross	  morphological	  abnormalities.	  	  We	   have	   also	   obtained	   brain	   sections	   from	   these	   mice	   from	   Neuroscience	  Associated	   (Knoxville,	   TN),	   and	   preliminary	   gross	   inspection	   shows	   no	   obvious	  alterations	  to	  brain	  structure.	  Furthermore,	  since	  DA	  signaling	  is	  a	  key	  modulator	  of	  motor	   function,	  we	   assayed	   basic	  motor	   function	   and	   reflexes	   in	   the	   DAT	   Val559	  mice.	  	  No	  deficits	  in	  reflexes,	  sensory	  function,	  or	  motor	  function	  were	  observed.	  	   Interestingly,	  we	  did	  observe	  a	  small	  but	  significant	  reduction	  in	  the	  number	  of	  male	  progeny	  expressing	  DAT	  Val559,	  suggesting	  a	  contribution	  of	  DAT	  function	  to	   neurodevelopmental	   processes.	   The	   reason	   for	   the	   male	   bias	   evident	   in	   this	  reduced	  recovery	  of	  DAT	  Val559	  mice	  is	  unclear	  at	  present;	  it	  is	  reminiscent	  of	  the	  as-­‐yet	   unexplained	   male	   predominance	   of	   ADHD,	   and	   could	   derive	   from	  perturbations	   of	   common	   pathways.	   	   	   For	   instance,	  we	   do	   know	   that	   DAT	  mRNA	  expression	  is	  evident	  in	  the	  mouse	  CNS	  by	  E13.5	  (Allen	  Institute	  for	  Brain	  Science)	  and	   the	   rat	   CNS	   by	   E14-­‐15	   (Fujita	   et	   al.,	   1993;	   Perrone-­‐Capano	   et	   al.,	   1994),	   and	  robustly	   expressed	   by	   E70	   in	   the	   rhesus	   monkey	   (Fang	   and	   Rønnekliev,	   1999).	  Other	   studies	   have	   shown	   the	  presence	   of	  DA	   and	  DA	   receptors	   in	   the	  periphery,	  including	  both	   rodent	   (Kim	  et	  al.,	   1997)	  and	  human	   (Elwan	  et	  al.,	   2003)	  placenta,	  possibly	   related	   to	   a	   role	   for	   D2-­‐like	   receptors	   in	   regulating	   secretion	   of	   human	  placental	   lactogen	   (hPL),	   a	   growth	   factor	   that	   modulates	   the	   mother’s	   metabolic	  state	  and	  helps	  to	  establish	  the	  energy	  supply	  for	  the	  developing	  fetus	  (Saxena	  et	  al.,	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1969;	   Spellacy,	   1969;	   Petit	   et	   al.,	   1990).	   	   DAT	   is	   also	   expressed	   by	   neural	   crest-­‐derived	  neurons	  in	  the	  gut	  (Li	  et	  al.,	  2004).	  	  Further	  studies	  that	  restrict	  the	  spatial	  and	   temporal	  expression	  of	   the	  DAT	  Val559	  variant	  are	  needed	  to	   infer	  when	  and	  where	   the	   precise	   role	   of	   the	   mutant	   protein	   in	   developmental	   processes.	   	   In	  addition,	   although	   the	   gross	   brain	   structure	   of	   DAT	   Val559	   mice	   is	   normal,	  Stanwood	  and	  colleagues	  have	  shown	  that	  pharmacological	  (Stanwood	  et	  al.,	  2001)	  or	  genetic	  (Stanwood	  et	  al.,	  2005)	  manipulation	  of	  DA	  signaling	  during	  development	  leads	   to	  permanent	   alterations	   in	   cortical	   architecture	  and	   function.	   Such	   findings	  encourage	   a	   more	   refined	   analysis	   of	   cortical	   structure	   of	   DAT	   Val559	   mice	  throughout	  development	  and	  into	  adulthood.	  	   As	  addressed	  in	  Methods,	  the	  DAT	  Val559	  mice	  were	  maintained	  and	  studied	  on	  a	  hybrid	  129S6/C57BL/6J	  background.	  	  Over	  the	  course	  of	  my	  studies,	  however,	  I	  successfully	   backcrossed	   DAT	   Val559	   to	   congenicity	   on	   a	   C57BL/6J	   background	  strain	  via	  speed	  congenic	  techniques.	  	  Interestingly,	  the	  background	  strain	  on	  which	  mutant	  mice	  are	  maintained	  can	  have	  sizable	  effects	  on	  both	  behavior	  and	  response	  to	  pharmacological	  manipulation	  (Loos	  et	  al.,	  2010;	  Kerr	  et	  al.,	  2013;	  O’Neill	  and	  Gu,	  2013).	   	   Further	   studies	   are	   needed	   to	   identify	   other	   genetic	   factors	   that	   vary	   by	  background	  strain	  that	  may	  contribute	  to	  the	  phenotypes	  observed	  in	  DAT	  Val559	  mice.	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CHAPTER	  III	  	  	  BIOCHEMICAL	  CHARACTERIZATION	  
	  
Introduction	  	   Prior	   to	   initiating	   our	   biochemical	   studies	   of	   the	   DAT	   Val559	   model,	   we	  developed	  several	  hypotheses	  based	  on	  the	  in	  vitro	  behavior	  of	  the	  allele.	  As	  noted	  in	  Chapter	  1,	   characterization	  of	  DAT	  Val559	   in	  a	  heterologous	  expression	  system	  demonstrated	  that	  the	  mutant	  transporter	  expressed	  in	  HEK-­‐293	  cells	  at	  the	  same	  level	  as	  WT	  DAT	  and	  demonstrated	  normal	  DA	  transport	  kinetics	  (Mazei-­‐Robison	  et	  al.,	   2008).	   	  However,	  DAT	  Val559	   supported	   a	   spontaneous	  outward	   	  DA	   “leak”,	   a	  process	   referred	   to	   as	   anomalous	   DA	   efflux	   (ADE).	   Accordingly,	   and	   assuming	   no	  unexpected	   impact	   of	   the	   addition	   of	   a	   loxP	   site	   in	   intron	   13,	   we	   expected	   DAT	  Val559	  to	  express	  at	  WT	  levels	  in	  our	  knock-­‐in	  mouse	  model	  in	  vivo	  and	  to	  maintain	  normal	  DA	  transport	  kinetics.	  	   Both	  DAT	  KO	  and	  knock-­‐down	  (KD)	  mice	  have	  elevated	  extracellular	  DA	  due	  to	  their	   inability	  to	  recapture	  released	  DA	  (Jones	  et	  al.,	  1998;	  Zhuang	  et	  al.,	  2001),	  and	   likely	   rely	  more	   on	   newly	   synthesized	  DA	   to	  maintain	  DA	   signaling	   than	  WT	  animals.	   	   In	   DAT	   KO	   animals,	   the	   activity	   of	   TH	   is	   doubled	   relative	   to	  WT	  mice,	  though	  TH	  protein	  levels	  fall	  to	  ~10%	  of	  WT	  levels	  (Jones	  et	  al.,	  1998).	  	  Although	  we	  expected	  elevated	  extracellular	  DA	   in	  DAT	  Val559	  mice	  due	   to	  ADE	   (addressed	   in	  Chapter	   5),	   we	   did	   not	   anticipate	   changes	   in	   total	   tissue	   levels	   of	   DA	   (or	   DA	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metabolites)	   or	   in	   TH	   expression	   because	   DA	   reuptake	   and	   vesicular	   packaging	  should	  be	  intact.	  	   Further	   predictions	   regarding	   the	   impact	   of	   DAT	   Val559	   expression	   on	  biochemical	  measures	  of	  the	  mouse	  brain	  are	  not	  based	  on	  in	  vitro	  observations,	  per	  se,	  but	  arise	  from	  predictions	  of	  compensations	  for	  the	  ADE	  exhibited	  by	  the	  mutant	  transporter.	   For	   example,	   potential	   compensatory	   changes	   could	   occur	   in	   DA	  receptor	  expression	  or	  function.	   	  DAT	  KO	  mice,	  for	  example,	  show	  reduced	  D1	  and	  D2	  receptor	  mRNA	  expression	  in	  both	  dopaminergic	  cell	  bodies	  in	  the	  midbrain	  and	  terminal	  fields	  of	  the	  striatum	  (Giros	  et	  al.,	  1996;	  Fauchey	  et	  al.,	  2000a,	  b),	  as	  well	  as	  reduced	  D2	  receptor	  protein	   in	   the	  striatum	  (Jones	  et	  al.,	  1999).	  Such	  changes	  are	  believed	  to	  arise	  from	  the	  excess	  DA	  signaling	  that	  occurs	  as	  a	  result	  of	  the	  inability	  to	  clear	  DA	  out	  of	  the	  synapse	  or	  away	  from	  somatodendritic	  autoreceptors	  that	  act	  to	   constrain	   DA	   signaling	   (Giros	   et	   al.,	   1996).	   Since	   the	   DAT	   Val559	   mice	   are	  expected	   to	  be	  at	   least	  mildly	  hyperdopaminergic	  as	  a	   result	  of	  ADE,	  we	  may	  also	  see	  downregulation	  of	  receptor	  expression.	   	  Such	  alteration	  of	  receptor	  expression	  could	   be	   interpreted	   as	   an	   adaptive	   change	   intended	   to	   dampen	   aberrant	   DA	  signaling	  and	  balance	  the	  increased	  dopaminergic	  tone	  derived	  from	  ADE.	  
Methods	  
Immunoblotting	  Brains	  were	  harvested	   from	  mice	   following	  rapid	  decapitation.	  Brains	  were	  immediately	  placed	  on	  an	  ice-­‐cold	  metal	  platform	  and	  the	  frontal	  cortex,	  midbrain,	  and	   striatum	   quickly	   dissected.	   Dissected	   tissue	   was	   placed	   into	   3	   mL	   of	  homogenization	  buffer	  (130	  mM	  NaCl,	  1.3	  mM	  KCl,	  2.2	  mM	  CaCl2,	  1.2	  mM	  MgSO4,	  1.2	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mM	  KH2PO4,	   10	  mM	  HEPES	   (pH	  7.4),	   10	  mM	  glucose,	   100	   uM	  pargyline,	   ascorbic	  acid,	  10	  uM	  tropolone,	  0.32	  M	  sucrose)	  and	  homogenized	  using	  a	  Potter-­‐Elvehjem	  homogenizer	   (Wheaton,	   Millville,	   NJ).	   Protein	   concentrations	   of	   all	   samples	   were	  determined	  by	  a	  bicinchoninic	  acid	   (BCA)	  protein	  assay	   (Thermo	  Fisher	  Scientific,	  Rockford,	  IL).	  Equal	  amounts	  of	  protein	  were	  incubated	  with	  Laemmli	  sample	  buffer	  for	  1	  hr	  at	   room	  temperature	  and	  analyzed	  using	  SDS-­‐PAGE	  and	  western	  blotting.	  DAT	   protein	  was	   visualized	   on	   samples	   blotted	   to	   Immobilon-­‐P	   PVDF	  membrane	  (EMD	   Millipore	   Corporation,	   Billerica,	   MA)	   using	   a	   rat	   anti-­‐hDAT	   antibody	  (MAB369,	  1:2500	  dilution;	  Millipore,	  Billerica,	  MA).	  Tyrosine	  hydroxylase	  (TH)	  was	  visualized	   using	   a	   rabbit	   anti-­‐TH	   antibody	   (SAB4300675,	   1:1000	   dilution;	   Sigma-­‐Aldrich,	  St.	  Louis,	  MO),	  and	  β-­‐actin	  visualized	  using	  a	  mouse	  anti-­‐β-­‐actin	  antibody	  (A5316,	   1:2000	   dilution;	   Sigma-­‐Aldrich,	   St.	   Louis,	   MO)	   as	   a	   loading	   control.	  Appropriate	   HRP-­‐conjugated,	   secondary	   antibodies	   were	   obtained	   from	   Jackson	  ImmunoResearch	  Laboratories,	   Inc.	  (West	  Grove,	  PA).	  Secondary	  antibody	  labeling	  was	  detected	  using	  Western	  Lightning	  Plus	  ECL	  (Perkin	  Elmer,	  Waltham,	  MA)	  and	  exposure	  to	  Hyblot	  CL	  Autoradiography	  Film	  (Denville	  Scientific,	  Inc.,	  Metuchen,	  NJ).	  Multiple	   exposures	   were	   obtained	   to	   insure	   linearity	   of	   band	   detection.	   Western	  blots	  were	  quantified	  using	  NIH	  ImageJ	  software	  and	  data	  analyzed	  using	  one-­‐way	  ANOVA	   with	   Bonferroni’s	   post	   hoc	   test	   for	   multiple	   comparisons,	   with	   P	   <	   0.05	  considered	  significant.	  
Synaptosomal	  DA	  Transport	  Assays	  Brains	  were	  harvested	  from	  mice	  following	  rapid	  decapitation.	  	  Brains	  were	  immediately	   placed	   on	   an	   ice-­‐cold	   metal	   platform	   and	   the	   striatum	   quickly	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dissected.	  Tissue	  samples	  were	  placed	  into	  3	  mL	  of	  homogenization	  buffer	  (130	  mM	  NaCl,	  1.3	  mM	  KCl,	  2.2	  mM	  CaCl2,	  1.2	  mM	  MgSO4,	  1.2	  mM	  KH2PO4,	  10	  mM	  HEPES	  (pH	  7.4),	   10	   mM	   glucose,	   100	   uM	   pargyline,	   ascorbic	   acid,	   10	   uM	   tropolone,	   0.32	   M	  sucrose)	   and	   homogenized	   using	   a	   Potter-­‐Elvehjem	   homogenizer	   (Wheaton,	  Millville,	   NJ).	   Homogenates	   were	   centrifuged	   at	   500	   x	   g	   at	   4°C	   for	   10	   min.	  Supernatants	  were	   removed	   and	   centrifuged	   at	   12000	   x	  g	   at	   4°C	   for	   10	  min.	   The	  resulting	  synaptosome-­‐enriched	  pellets	  were	   then	  resuspended	   in	  2.5	  mL	  of	  assay	  buffer	  (130	  mM	  NaCl,	  1.3	  mM	  KCl,	  2.2	  mM	  CaCl2,	  1.2	  mM	  MgSO4,	  1.2	  mM	  KH2PO4,	  10	  mM	   HEPES	   (pH	   7.4),	   10	   mM	   glucose,	   100	   uM	   pargyline,	   ascorbic	   acid,	   10	   uM	  tropolone)	   and	   protein	   concentrations	   determined	   using	   the	   Coomassie	   Plus	  (Bradford)	   Protein	   Assay	   (Thermo	   Fisher	   Scientific,	   Rockford,	   IL).	   This	   material	  (hereafter	  called	  synaptosomes)	  was	  then	  diluted	  to	  30	  ug	  of	  total	  protein	  per	  100	  uL.	   Synaptosomes	   were	   incubated	   with	   varying	   concentrations	   of	   [3H]-­‐DA	   (46.0	  Ci/mmol;	   Perkin	   Elmer,	  Waltham,	  MA)	   ranging	   from	   50	   nM	   to	   1	   uM	   (50	   nM	  was	  100%	   labeled	   substrate,	  DA	   concentrations	  between	  250	  nM	  and	  1	  uM	  used	  10%	  labeled	   and	   90%	   unlabeled	   DA)	   for	   5	   min.	   at	   37oC.	   To	   determine	   non-­‐specific	  transport,	  parallel	   samples	  were	   incubated	  with	  10	  uM	  cocaine	   for	  10	  min.	  before	  the	   addition	   of	   [3H]-­‐DA.	   Assays	   were	   terminated	   by	   rapid	   filtration	   over	   0.3%	  polyethyleneimine-­‐soaked	  GF/B	  glass	  microfiber	  filters	  (Whatman,	  Clifton,	  NJ)	  and	  washed	  3X	  with	   ice-­‐cold	  Krebs-­‐Ringers-­‐HEPES	  buffer	   (130	  mM	  NaCl,	   1.3	  mM	  KCl,	  2.2	   mM	   CaCl2,	   1.2	   mM	   MgSO4,	   1.2	   mM	   KH2PO4,	   10	   mM	   HEPES	   (pH	   7.4)).	   Filters	  placed	  into	  scintillation	  vials	  with	  7	  mL	  of	  Ecoscint	  H	  (National	  Diagnostics,	  Atlanta,	  GA)	  scintillation	  fluid,	  shaken	  overnight	  at	  room	  temperature,	  and	  then	  radioactivity	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was	   quantified	   using	   a	   TriCarb	   2900TR	   scintillation	   counter	   (Perkin	   Elmer,	  Waltham,	  MA).	  Specific	  [3H]-­‐DA	  transport	  was	  assayed	  in	  triplicate	  for	  all	  samples.	  Data	   were	   analyzed	   using	   one-­‐way	   ANOVA	   with	   Bonferroni’s	   post	   hoc	   test	   for	  multiple	  comparisons.	  
Receptor	  Binding	  Assays	  Frozen	  tissue	  was	  dissected	  and	  frozen	  as	  noted	  above	  then	  placed	  in	  2	  mL	  of	  binding	  buffer	  (50	  mM	  Tris	  (pH	  7.4),	  5	  mM	  MgCl2,	  5	  mM	  KCl,	  1	  mM	  EDTA,	  120	  mM	  NaCl)	   and	   homogenized	   using	   an	   Omni-­‐Tip	   handheld	   homogenizer	   (Omni	  International,	   Kennesaw,	   GA)	   at	   10000-­‐12000	   rpm	   for	   10-­‐15	   secs.	   Homogenates	  were	   then	   centrifuged	   at	   20000	   x	   g	   at	   4°C	   for	   20	   min.	   Membrane	   pellets	   were	  resuspended	  in	  3	  mL	  of	  binding	  buffer	  and	  homogenized	  again	  as	  described	  above.	  Homogenates	  were	  pre-­‐incubated	  at	  37°C	  for	  15	  min	  and	  then	  centrifuged	  at	  20000	  
x	  g	  at	  4°C	  for	  20	  min.	  Membrane	  pellets	  were	  again	  resuspended	  in	  3	  mL	  of	  binding	  buffer	  and	  homogenized	  as	  described	  above.	  Protein	  concentration	  was	  determined	  by	  bicinchoninic	  acid	  (BCA)	  protein	  assay	  (Thermo	  Fisher	  Scientific,	  Rockford,	   IL).	  Samples	   were	   stored	   at	   -­‐80°C	   until	   used	   for	   binding	   assays.	   Membrane	   samples	  were	  then	  thawed	  and	  (100-­‐150	  ug	   for	  cortex,	  150-­‐200	  ug	   for	  midbrain,	  and	  100-­‐150	   ug	   for	   striatum)	   incubated	   in	   a	   final	   reaction	   volume	   of	   1	   mL	   at	   room	  temperature	   for	   75	   min	   in	   the	   presence	   of	   3	   nM	   [3H]-­‐SCH	   23390	   (D1	   receptor	  assays;	  84.3	  Ci/mmol;	  Perkin	  Elmer,	  Waltham,	  MA)	  or	  90	  min	  in	  the	  presence	  of	  3	  nM	  [3H]-­‐raclopride	  (D2	  receptor	  assays;	  76	  Ci/mmol;	  Perkin	  Elmer,	  Waltham,	  MA).	  Binding	  reactions	  were	  terminated	  by	  the	  addition	  of	  8	  mL	  of	  ice-­‐cold	  wash	  buffer	  (50	  mM	  Tris	  (pH	  7.4))	  followed	  by	  rapid	  filtration	  over	  water-­‐moistened	  S&S	  (#5)	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(Schleicher	  and	  Schuell	  Bioscience,	   Inc.,	  Kenne,	  NH)	  or	  Whatman	  GF/B	  (Whatman,	  Clifton,	  NJ)	  glass	  fiber	  filter	  using	  a	  Millipore	  vacuum	  manifold.	  Each	  filter	  was	  then	  washed	   2X	  with	   8	  mL	   of	   ice-­‐cold	  wash	   buffer.	   Filters	  were	   placed	   in	   scintillation	  vials	   and	   10	   mL	   of	   Biosafe	   II	   scintillation	   fluid	   (Research	   Products	   International	  Corp.,	  Mount	  Prospect,	   IL)	  was	  added	   to	  each	  vial.	  Vials	  were	  shaken	  overnight	  at	  room	   temperature,	   and	   then	   radioactivity	   was	   counted	   using	   a	   TriCarb	   2900TR	  scintillation	   counter	   (Perkin	   Elmer,	   Waltham,	   MA).	   Non-­‐specific	   binding	   was	  determined	   using	   parallel	   incubations	   as	   above	   with	   the	   addition	   of	   2	   uM	  butaclamol	   to	   samples	   with	   binding	   values	   from	   these	   samples	   subtracted	   from	  radioligand	  only	  samples	  to	  determine	  specific	  binding.	  All	  samples	  (total	  and	  non-­‐specific	   binding)	   were	   assayed	   in	   triplicate.	   Data	   were	   analyzed	   using	   one-­‐way	  ANOVA	  with	  Bonferroni’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  
Assessment	  of	  Tissue	  Biogenic	  Amines	  Brain	  regions,	  harvested	  and	  dissected	  as	  noted	  above,	  were	   flash-­‐frozen	  in	  liquid	  nitrogen	  and	  stored	  at	   -­‐80°C.	  Frozen	  brain	   tissue	  was	  homogenized	  using	  a	  tissue	  dismembrator	  (Misonix	  XL-­‐2000;	  Qsonica,	  LLC,	  Newtown,	  CT)	  in	  100-­‐750	  uL	  of	   a	   solution	   containing	   100	  mM	  TCA,	   10	  mM	  NaC2H3O2,	   100	   uM	  EDTA,	   5	   ng/mL	  isoproterenol	   (an	   internal	  standard),	  and	  10.5%	  methanol	   (pH	  3.8).	  Samples	  were	  spun	  in	  a	  microcentrifuge	  at	  10000	  x	  g	  for	  20	  min.	  and	  the	  supernatants	  were	  stored	  at	   -­‐80°C	   until	   assayed	   (Cransac	   et	   al.,	   1996).	   Prior	   to	   assay,	   thawed	   supernatants	  were	  centrifuged	  at	  10000	  x	  g	   for	  20	  min.	  before	  being	  analyzed	  by	  HPLC.	  Twenty	  uL	  samples	  of	  each	  sample	  were	  injected	  using	  a	  Waters	  2707	  auto-­‐sampler	  onto	  a	  Phenomenex	   Kintex	   (2.6	   u,	   100	   A)	   C18	   HPLC	   column	   (100	   x	   4.6	   mm).	   Biogenic	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amines	  were	   eluted	  with	   a	  mobile	   phase	   (89.5%	  100	  mM	  TCA,	   10	  mM	  NaC2H3O2,	  100	  uM	  EDTA,	  and	  10.5%	  methanol	   (pH	  3.8))	  delivered	  at	  0.6	  mL/minute	  using	  a	  Waters	   515	   HPLC	   pump.	   Analytes	   were	   detected	   utilizing	   an	   Antec	   Decade	   II	  (oxidation:	  0.4)	  (3	  mm	  GC	  WE,	  HYREF)	  electrochemical	  detector	  operated	  at	  33°C.	  HPLC	  instrument	  control	  and	  data	  acquisition	  was	  managed	  by	  Empower	  software.	  Data	   were	   analyzed	   with	   one-­‐way	   ANOVA	   with	   Bonferroni’s	   post	   hoc	   test	   for	  multiple	  comparisons.	  
Results	  
DAT	  Val559	  Expression	  and	  Transport	  Capacity	  	   Previous	   in	   vitro	   studies	   demonstrated	   that	   DAT	   Ala559	   (WT)	   and	   DAT	  Val559	   express	   equivalently,	   both	   in	   total	   extracts	   and	   cell	   surface	   fractions	  (biotinylation),	  and	  did	  not	  differ	  in	  inward	  DA	  transport	  capacity	  (Mazei-­‐Robison	  et	  al.,	  2008).	  	  Consistent	  with	  these	  findings,	  striatal	  extracts	  from	  DAT	  Val559	  animals	  demonstrate	   normal	   transporter	   protein	   levels	   (Fig.	   10).	   	   Similarly,	   striatal	  synaptosomes	   from	   both	   hetero-­‐	   and	   homozygous	   DAT	   Val559	   animals	   show	  equivalent	   DA	   transport	   kinetics	   as	   compared	   to	   WT	   samples	   (Fig.	   11),	   with	   no	  differences	  in	  DA	  KM	  or	  transport	  VMAX.	  
DAT	  Val559	  Effects	  on	  Neurochemistry	  and	  DA	  System	  Components	  	   Whereas	  DAT	  KO	  mice	  show	  drastically	  reduced	  tissue	  levels	  of	  DA	  (less	  than	  5%	   of	   WT	   levels)	   (Jones	   et	   al.,	   1998),	   DAT	   Val559	   mice	   show	   no	   genotype-­‐dependent	  changes	  in	  total	  levels	  of	  DA,	  DA	  metabolites	  (DOPAC,	  HVA,	  3-­‐MT),	  or	  DA	  turnover	  (DA:DOPAC	  ratio)	  in	  cortex,	  midbrain,	  or	  striatum	  (Fig.	  12).	  Interestingly,	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  Figure	   10.	   DAT	   Val559	   mice	   have	   normal	   striatal	   DAT	   expression	   (n	   =	   6	   per	  genotype;	  P	  >	  0.05,	  one-­‐way	  ANOVA).	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  Figure	   11.	   DAT	   Val559	   in	   striatal	   synaptosomes	   supports	   normal	   DA	   transport	  kinetics	  (n	  =	  5	  WT,	  4	  het,	  7	  homo;	  Vmax+/-­‐	  SEM	  (pmol/min/ug	  protein):	  WT	  =	  1.01	  +/-­‐	  0.215,	  het	  =	  0.8284	  +/-­‐	  0.1822,	  homo	  =	  0.8847	  +/-­‐	  0.1770,	  P	   >	  0.05,	   one-­‐way	  ANOVA;	  Km	  +/-­‐	  SEM:	  WT	  =	  0.1774	  +/-­‐	  0.03839,	  het	  =	  0.08762	  +/-­‐	  0.0261,	  homo	  =	  0.1407	  +/-­‐	  0.04754,	  P	  >	  0.05,	  one-­‐way	  ANOVA).	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Figure	   12.	   Dopaminergic	  neurochemistry	   is	   not	  significantly	   different	   in	   (A)	  cortex,	   (B)	   midbrain,	   or	   (C)	  striatum	   between	   WT	   and	  DAT	  Val559	  mice	  (n	  =	  8	  WT,	  8	  het,	  9	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVA).	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we	  detected	  small	  but	  significant	  changes	  in	  cortical	  and	  striatal	  5-­‐HT	  levels	  without	  concomitant	  changes	  in	  5-­‐HT	  metabolite	  5-­‐HIAA	  or	  5-­‐HT	  turnover	  (Fig.	  13).	  	   Since	  DAT	  KO	  mice	  are	  unable	  to	  recover	  released	  DA,	  they	  rely	  totally	  on	  the	  synthesis	  of	  DA	  to	  maintain	  dopaminergic	  signaling.	  	  Moreover,	  Jones	  and	  colleagues	  demonstrated	   that	  TH	  expression	   in	  DAT	  KO	  mice	   is	   reduced	  by	  96%,	   though	   the	  rate	  of	  DA	  synthesis	  by	  available	  TH	   is	  doubled	  relative	   to	   the	  rate	  of	  synthesis	   in	  WT	  animals	  (Jones	  et	  al.,	  1998).	  	  In	  contrast,	  we	  found	  in	  DAT	  Val559	  animals,	  that	  TH	  total	  protein	  levels	  are	  equivalent	  to	  WT	  levels	  (Fig.	  14).	   	  Finally,	  DAT	  KO	  mice	  show	  reductions	  in	  D1	  and	  D2	  receptor	  mRNA	  expression	  in	  striatum	  (Giros	  et	  al.,	  1996;	  Fauchey	  et	  al.,	  2000a,	  b)	  and	  reduced	  D2	  receptor	  levels	  in	  midbrain	  (Jones	  et	  al.,	  1999).	  	  In	  contrast,	  we	  observed	  no	  change	  in	  D1	  or	  D2	  receptors	  in	  the	  cortex,	  midbrain,	  or	  striatum	  of	  DAT	  Val559	  hetero-­‐	  or	  homozygotes	  (Fig.	  15).	  
Discussion	  	   All	  of	  the	  findings	  reported	  in	  this	  chapter	  derived	  from	  direct	  evaluation	  of	  DAT	  Val559	  are	  consistent	  with	  previous	  in	  vitro	  studies	  of	  the	  mutant	  protein.	  DAT	  Val559	  total	  expression	  and	  transport	  function	  in	  mouse	  striatum	  are	  equivalent	  to	  those	  of	  the	  WT	  protein.	  Whereas	  the	  loss	  of	  DA	  reuptake	  in	  DAT	  KO	  mice	  results	  in	  reduced	  tissue	  DA	  and	  TH	  protein	  levels	  (Giros	  et	  al.,	  1996;	  Jones	  et	  al.,	  1998),	  the	  normal	   inward	  DA	   reuptake	  of	  DAT	  Val559	  mice,	   along	  with	  normal	   levels	   of	  TH,	  appears	  to	  sustain	  normal	  tissue	  DA	  levels.	  It	  is	  also	  possible	  that	  ADE	  occurs	  in	  the	  context	   of	   reduced	  DA	  neuron	  excitability,	   such	   that	   the	   loss	  of	   cytoplasmic	  DA	   is	  offset	   by	   reduced	   vesicular	   release,	   resulting	   in	   normal	   tissue	   DA	   levels.	   	   Thus,	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  Figure	  13.	  Noradrenergic	  and	  serotonergic	  neurochemistry	  of	  WT	  and	  DAT	  Val559	  mice.	  (A)	  Cortical	  serotonin	  (5-­‐HT)	  levels	  are	  significantly	  elevated	  in	  DAT	  Val559	  homozygotes	  (n	  =	  8	  WT,	  8	  het,	  9	  homo;	  *	  =	  P	  <	  0.05,	  one-­‐way	  ANOVA),	  but	  5-­‐HT	  metabolite	  5-­‐HIAA	  levels	  and	  5-­‐HT	  turnover	  (5-­‐HT/5-­‐HIAA	  ratio)	  and	  noradrenaline	  (NE)	  levels	  are	  unchanged	  (P	  >	  0.05,	  one-­‐way	  ANOVA).	  (B)	  Midbrain	  noradrenergic	  and	  serotonergic	  neurochemistry	  is	  not	  changed	  in	  DAT	  Val559	  mice	  (P	  >	  0.05,	  one-­‐way	  ANOVA).	  (C)	  Striatal	  5-­‐HT	  levels	  are	  also	  significantly	  elevated	  in	  DAT	  Val559	  homozygotes	  (*	  =	  P	  <	  0.05,	  one-­‐way	  ANOVA)	  without	  changes	  in	  5-­‐HIAA	  or	  5-­‐HT	  turnover	  (P	  >	  0.05,	  one-­‐way	  ANOVA).
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Figure	  14.	  DAT	  Val559	  mice	  have	  normal	  striatal	  TH	  expression	  (n	  =	  3	  per	  genotype;	  
P	  >	  0.05,	  one-­‐way	  ANOVA).	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Figure	  15.	  Radioligand	  binding	  assays	  reveal	  no	  differences	  in	  (A)	  D1	  receptor	  (n	  =	  3-­‐5	   per	   genotype	   per	   brain	   region;	   [3H]-­‐SCH-­‐23390	   binding,	   cortex	   and	  midbrain	  plotted	  on	  left	  y-­‐axis,	  striatum	  plotted	  on	  right	  y-­‐axis;	  P	  >	  0.05	  for	  each	  brain	  region,	  one-­‐way	   ANOVA)	   or	   (B)	   D2	   receptor	   (n	   =	   3-­‐5	   per	   genotype	   per	   brain	   region;	  [3H]raclopride	  binding,	  cortex	  and	  midbrain	  plotted	  on	  left	  y-­‐axis,	  striatum	  plotted	  on	  right	  y-­‐axis;	  P	  >	  0.05	  for	  each	  brain	  region,	  one-­‐way	  ANOVA).	  
	  	   93	  
further	   studies	   are	   needed	   to	   examine	   basal	   and	   stimulated	   excitability	   of	   DA	  neurons	  in	  the	  DAT	  Val559	  mouse	  model.	  	   The	  observed	  changes	  in	  serotonin	  levels	  in	  the	  striatum	  and	  cortex	  are	  also	  quite	  interesting.	  	  Caron’s	  research	  group	  reported	  in	  DAT	  KO	  mice	  that	  locomotor	  hyperactivity	  was	   attenuated	  by	   treatment	  with	   selective	   5-­‐HT	   reuptake	   inhibitor	  (SSRI)	   treatment	   (Gainetdinov	   et	   al.,	   1999)	   even	   though	   locomotor	   activity	   of	  WT	  animals	  was	   unaffected,	   and	   that	   cocaine	   self-­‐administration	   remained	   intact	   and	  was	  mediated	  by	  cocaine	  binding	  to	  SERT	  (Rocha	  et	  al.,	  1998).	  	  In	  addition,	  DAT	  KO	  mice	  have	   elevated	  5-­‐HT	   levels	   in	   the	   frontal	   cortex	   and	  hippocampus	   (Fox	   et	   al.,	  2013),	   suggesting	   that	   5-­‐HT	   signaling	   undergoes	   compensatory	   changes	   in	   the	  context	  of	  hyperdopaminergia.	  	  On	  the	  other	  hand,	  following	  loss	  of	  DA	  signaling	  by	  6-­‐OHDA	   lesions,	   Avale	   and	   coworkers	   found	   increased	   5-­‐HT	   axon	   sprouting	   and	  elevated	  striatal	  5-­‐HT	  levels	  (Avale	  et	  al.,	  2004b),	  suggesting	  that	  5-­‐HT	  signaling	  can	  also	   compensate	   for	   a	   hypodopaminergic	   state.	   Investigation	   of	   specific	   5-­‐HT	  receptor-­‐mediated	   modulation	   of	   DA	   signaling	   revealed	   that	   5-­‐HT2A	   and	   5-­‐HT2C	  receptors	   exert	   excitatory	   and	   inhibitory	   control	   of	   DA	   signaling,	   respectively	   (Di	  Matteo	  et	  al.,	  2002;	  Porras	  et	  al.,	  2002;	  reviewed	  in	  Esposito	  et	  al.,	  2008),	  offering	  a	  mechanism	   by	   which	   5-­‐HT	   signaling	   can	   respond	   to	   both	   hypo-­‐	   and	  hyperdopaminergic	  states.	  	  In	  the	  context	  of	  DAT	  Val559,	  we	  expect	  ADE	  to	  cause	  a	  mildly	  hyperdopaminergic	   state.	  The	  observed	   increases	   in	   cortical	   and	   striatal	  5-­‐HT,	   therefore,	   may	   be	   indicative	   of	   compensatory	   changes	   in	   5-­‐HT	   signaling	   to	  account	  for	  the	  altered	  dopaminergic	  tone	  due	  to	  DAT	  Val559.	  	  Further	  exploration	  of	   serotonergic	   function,	   in	  general,	   and	  5-­‐HT	  receptor	  expression	  and	   function	   in	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the	  cortex	  and	  striatum,	  specifically,	  is	  needed	  to	  better	  elucidate	  the	  impact	  of	  DAT	  Val559.	  	   In	   contrast	   to	   DAT	   KO	   mice,	   we	   showed	   that	   DA	   receptor	   density	   is	  unchanged	   in	  DAT	  Val559	  mice.	  DAT	  KO	  animals	  show	  significant	  reduction	   in	  DA	  receptor	  mRNA	  expression	  (Giros	  et	  al.,	  1996)	  and	  D2	  receptor	  protein	  expression	  (Jones	  et	  al.,	  1999).	  	  It	  is	  possible	  that	  the	  increase	  in	  extracellular	  DA	  concentration	  due	  to	  ADE,	  partially	  offset	  by	  normal	  DA	  uptake,	  is	  of	  a	  smaller	  magnitude	  than	  that	  observed	  with	  a	  complete	  loss	  of	  DA	  reuptake	  in	  the	  DAT	  KO	  mice	  and,	  as	  a	  result,	  DA	   receptor	   levels	   may	   not	   change.	   	   Furthermore,	   changes	   in	   D2	   receptor	  expression	   in	   DAT	   KOs	   were	   subsequently	   shown	   to	   reflect	   a	   reduction	   in	  somatodendritic	  D2	  autoreceptor	  function	  (Jones	  et	  al.,	  1999).	  	  Also,	  the	  radioligand	  binding	   data	   presented	   here	   do	   not	   address	   potential	   changes	   in	   DA	   receptor	  localization	   (i.e.	   internalization)	   or	   function	   (i.e.	   desensitization)	   that	   do	   not	  necessarily	   require	   changes	   in	   protein	   levels.	   	   Further	   studies	   are	   warranted	   to	  more	   closely	   examine	   DA	   receptor	   function	   and	   regulation	   in	   the	   context	   of	   DAT	  Val559.	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CHAPTER	  IV	  	  BEHAVIORAL	  CHARACTERIZATION	  
	  	  
Introduction	  	   DA	   signaling	   plays	   an	   important	   role	   in	   a	   variety	   of	   behaviors	   that	   can	   be	  readily	   evaluated	   in	   rodent	  models.	   	   For	   example,	   locomotor	   activity	   in	   the	   open	  field	   is	  very	  sensitive	   to	  extracellular	  DA	   levels.	  Also,	  elevation	  of	  extracellular	  DA	  via	   treatment	   with	   AMPH	   (Dews,	   1953;	   Smith,	   1965)	   or	   cocaine-­‐like	  psychostimulants	  (Heise	  and	  Boff,	  1962;	  Van	  Rossum	  and	  Hurkmans,	  1964;	  Smith,	  1965.)	   produces	   significant	   hyperactivity	   in	   open	   field	   chambers.	   Consistent	  with	  these	  findings,	  DAT	  KO	  and	  KD	  animals	  where	  extracellular	  levels	  of	  DA	  are	  elevated	  5	  and	  2	  fold,	  respectively,	  are	  extremely	  hyperactive	  in	  a	  novel	  environment	  (Giros	  et	   al.,	   1996;	   Zhuang	   et	   al.,	   2001),	   whereas	   DA	   depletion	   by	   reserpine	   treatment	  (Carlsson	  et	  al.,	  1958;	  Utley	  and	  Carlsson,	  1965;	  Almgren	  et	  al.,	  1976;	  Johnels,	  1982),	  extensive	   6-­‐OHDA	   lesion	   (Koob	   et	   al.,	   1981),	   or	   genetic	   ablation	   of	   TH	   (Zhou	   and	  Palmiter,	   1995;	   Nishii	   et	   al.,	   1998)	   produces	   hypokinesis,	   a	   characteristic	   of	  Parkinson’s	  disease.	  	  Assuming	  that	  DAT	  Val559	  mice	  have	  elevated	  extracellular	  DA	  levels	   due	   to	   ADE,	   we	   anticipated	   that	   these	   mice	   could	   be	   spontaneously	  hyperactive	  as	  compared	  to	  WT	  littermates.	  	   As	  reviewed	  in	  Chapter	  1,	   in	  vitro	  data	  have	  shown	  that	  DAT	  Val559	  has	  an	  abnormal	   response	   to	  AMPH,	   such	   that	  AMPH	  blocks	  ADE	  as	  opposed	   to	   inducing	  DA	  release	  (Mazei-­‐Robison	  et	  al.,	  2008),	  acting	  more	  like	  a	  competitive	  substrate	  or	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inhibitor.	  	  In	  the	  DAT	  Val559	  mice,	  therefore,	  AMPH	  is	  expected	  to	  lead	  to	  a	  certain	  degree	  of	  locomotor	  activation,	  as	  AMPH	  will	  prevent	  reuptake	  of	  released	  DA	  (in	  a	  mechanism	   similar	   to	   cocaine	   (Izenwasser	   et	   al.,	   1993)	   or	   methylphenidate	  (Schweri,	   1990;	  Héron	   et	   al.,	   1994;	  Wall	   et	   al.,	   1995).	  However,	   in	   the	   absence	   of	  AMPH-­‐evoked,	  nonvesicular	  DA	  release,	  this	  locomotor	  activation	  is	  expected	  to	  be	  of	  a	  smaller	  magnitude	  than	  that	  seen	  in	  WT	  mice.	  	   It	   is	   important	   to	   note	   that	   both	   of	   the	   children	   identified	   with	   the	   DAT	  Val559	   each	   possessed	   only	   one	   mutant	   allele	   (Mazei-­‐Robison	   et	   al.,	   2005).	   	   We	  expect,	  therefore,	  that	  DAT	  Val559	  acts	  dominantly	  and	  can	  exert	  its	  effects	  despite	  the	  presence	  of	  a	  WT	  DAT	  allele.	  	  Accordingly,	  we	  may	  also	  see	  blunted	  responses	  to	  AMPH	  in	  DAT	  Val559	  heterozyogtes.	  	  If	  DAT	  Val559	  is	  acting	  in	  a	  dominant	  manner,	  then	  we	   anticipate	   that	   hetero-­‐	   and	  homozygotes	  will	   display	   similar	   phenotypes,	  rather	  than	  intermediate,	  gene-­‐dosage	  dependent	  differences	  among	  genotypes.	  	   The	  impact	  of	  DAT	  Val559	  on	  other	  behavioral	  readouts	  is	  difficult	  to	  predict.	  In	   addition	   to	   locomotor	   hyperactivity,	   DAT	   KO	   mice	   display	   stereotyped	  movements	   such	   as	   head	  weaving	   (Wong	   et	   al.,	   2012;	   Fox	   et	   al.,	   2013).	   	   It	   is	   not	  unreasonable,	  then,	  that	  DAT	  Val559	  mice	  could	  also	  exhibit	  stereotyped	  behaviors,	  though	  the	  extent	  may	  be	  dictated	  by	  the	  size	  of	  the	  elevations	  in	  extracellular	  DA	  and/or	  how	   they	  are	  achieved.	   In	   this	   this	   chapter,	   I	  present	  a	   characterization	  of	  locomotor	   phenotypes	   using	   the	   DAT	   Val559	   mice,	   as	   well	   as	   their	   response	   to	  treatment	  with	  AMPH.	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Methods	  
Open	  field	  Locomotor	  Assay	  All	  locomotor	  behavior	  was	  assessed	  using	  male	  mice,	  aged	  5-­‐9	  weeks,	  with	  7-­‐10	   days	   of	   acclimation	   to	   a	   reverse	   light/dark	   cycle	   between	   3-­‐5	  weeks	   of	   age,	  during	   the	   animal’s	   active	   (dark	   phase	   of	   light/dark	   cycle)	   period.	   Locomotor	  activity	   in	   the	   open	   field	   was	   measured	   using	   27	   x	   27	   x	   20.5	   chambers	   (Med	  Associates,	  St.	  Albans,	  VT)	  placed	  within	  light-­‐	  and	  air-­‐controlled,	  sound-­‐attenuating	  boxes	   (64	   x	   45	   x	   42	   cm).	   Locomotion	   was	   detected	   by	   interruption	   of	   infrared	  beams	  by	  the	  body	  of	  the	  mouse	  (16	  photocells	  in	  each	  horizontal	  axis	  located	  1	  cm	  above	  the	  activity	  chamber	  floor,	  as	  well	  as	  16	  photocells	  elevated	  4	  cm	  above	  the	  chamber	   floor	   to	   detect	   rearing	   and	   jumping	   behaviors).	   Data	  were	   collected	   and	  quantified	  by	  Med	  Associates	  Activity	  Monitor	  software.	  	  Mice	  were	  acclimated	  to	  the	  activity	  chambers	  during	  a	  30-­‐minute	  session	  2-­‐3	  days	  before	  data	   recording	  began.	  On	  Day	  1	  of	   the	  experimental	   sequence,	  mice	  were	  weighed	  then	  placed	  into	  activity	  chambers	  and	  activity	  was	  monitored	  for	  30	  min.	   The	   mice	   were	   then	   removed	   from	   the	   activity	   chambers	   and	   received	   a	   5	  mL/kg	  i.p.	  injection	  of	  0.9%	  saline	  (AMPH	  experiments)	  or	  0.02%	  DMSO	  (SKF	  83822	  experiments).	  Mice	  were	  returned	   to	   the	  activity	  chambers	  and	   locomotor	  activity	  was	   recorded	   for	   60	  min.	  No	  manipulations	  were	  performed	  on	  Day	  2.	  On	  Day	  3,	  mice	  were	  weighed	  then	  placed	  into	  activity	  chambers	  and	  activity	  recorded	  for	  30	  minutes.	  Mice	  were	  then	  removed	  from	  the	  activity	  chambers	  and	  injected	  i.p.	  with	  AMPH	  (in	  0.9%	  saline;	  3	  mg/kg,	  5	  mL/kg)	  or	  SKF83822	  (in	  0.02%	  DMSO,	  2	  mg/kg,	  5	  mL/kg).	  Mice	  were	  then	  returned	  to	  the	  chambers	  and	  activity	  recorded	  for	  60	  min.	  
	   98	  
Time	  course	  data	  were	  analyzed	  using	  two-­‐way	  ANOVA	  with	  Sidak’s	  post	  hoc	  test	  for	  multiple	   comparisons,	   and	   cumulative	   measures	   of	   behavior	   (i.e.	   total	   distance	  traveled,	   time	   in	   stereotypy,	   number	   of	   stereotyped	   behaviors,	   time	   rearing,	   and	  number	  of	  rearing	  behaviors)	  during	  the	  entire	  60-­‐minute	  recording	  analyzed	  using	  one-­‐way	  ANOVA	  with	  Tukey’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  
Darting	  Mice	  were	  moved	  from	  group	  housing	  and	  isolated	  in	  clean	  cages	  for	  60-­‐75	  minutes.	   After	   acclimating	   to	   the	   new	   cage,	   darting	   responses	  were	   initiated	   by	   a	  researcher	  reaching	  for	  the	  base	  of	  the	  mouse’s	  tail,	  mimicking	  an	  attempt	  to	  pick	  up	  the	   animal,	  without	  making	   contact.	   Each	  mouse	  was	   approached	   5-­‐7	   times,	  with	  20-­‐30	  seconds	  between	  approaches,	   to	  elicit	   the	  darting	  reaction	  (total	  number	  of	  approaches:	   130	   WT,	   223	   het,	   103	   homo).	   Escape	   reactions	   (“darting”)	   were	  recorded	   and	   then	   videos	   were	   imported	   into	   iMovie	   (Apple,	   Cupertino,	   CA)	   and	  slowed	   to	   10%	  of	   original	   speed.	   The	   beginning	   and	   ending	   video	   frames	   of	   each	  darting	  incident	  were	  noted	  with	  timestamps	  and	  then	  imported	  into	  ImageJ	  (NIH,	  Bethesda,	  MD)	  with	  the	  timestamps	  used	  to	  isolate	  the	  first	  frame	  of	  each	  dart.	  A	  Z-­‐stack	   image	   was	   then	   created	   over	   the	   entire	   darting	   reaction,	   and	   a	   subtracted	  image	  (first	  frame	  subtracted	  from	  Z-­‐stack)	  was	  produced,	  leaving	  a	  negative	  image	  where	  the	  mouse	  moved	  during	  the	  dart.	  A	  freehand	  line	  was	  then	  plotted	  through	  the	  center	  of	  each	  mouse’s	  darting	  path	  and	  the	  distance	  quantified.	  To	  account	  for	  variability	   between	   videos,	   the	   length	   of	   one	   side	   of	   each	   mouse’s	   cage	   was	  measured	  and	  used	  to	  convert	  from	  pixels	  (path	  length	  measurement	  in	  ImageJ)	  to	  centimeters	   (Fig.	   16).	   Speed	   from	   the	   initiation	   of	   the	   darting	   movement	   until	   1	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  Figure	  16.	  Darting	  behavior	  analysis.	  For	  each	  darting	  event,	   the	   first	  video	   frame	  before	  the	  mouse	  starts	  moving	  (A)	  is	  subtracted	  from	  a	  stacked	  image	  of	  the	  dart	  in	  which	  the	  entire	  video	  clip	  is	  compressed	  into	  a	  single	  still	  image	  (B).	  	  The	  resulting	  negative	  image	  (C)	  reveals	  the	  path	  of	  the	  dart	  that	  can	  be	  measured.	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second	  elapsed	   (or	   the	  animal	   stopped	  moving)	  was	   then	   calculated	  based	  on	   the	  distance	   traveled	   and	   duration	   of	   each	   dart.	   Data	   were	   analyzed	   using	   one-­‐way	  ANOVA	   with	   Tukey’s	   multiple	   comparisons	   test	   and	   are	   depicted	   as	   a	   frequency	  distribution	  of	  darting	  speed,	  as	  well	  as	  average	  darting	  speed.	  
Elevated	  Zero	  Maze	  Anxiety	   behaviors	   were	   examined	   using	   an	   elevated	   zero	   maze	   (62.5	   cm	  outer	   diameter,	   5	   cm	   path	   width,	   15	   cm	   wall	   height	   in	   closed	   segments;	   maze	  fabricated	   by	   Vanderbilt	   Kennedy	   Center	   Scientific	   Instrumentation	   Service)	   with	  recordings	  lasting	  for	  5	  min.	  At	  the	  start	  of	  each	  trial,	  mice	  were	  placed	  onto	  an	  open	  portion	  of	  the	  maze,	  adjacent	  to	  and	  facing	  one	  of	  the	  closed	  segments.	  Each	  session	  was	   recorded	   by	   a	   ceiling-­‐mounted	   video	   camera	   connected	   to	   a	   computer	   for	  digital	   video	   acquisition	   and	   analysis	   with	   ANY-­‐maze	   software	   (Stoelting,	   Wood	  Dale,	  IL).	  Data	  analyzed	  include	  the	  percent	  of	  time	  spent	  in	  the	  open	  zone,	  number	  of	  open	  and	  closed	  zones	  entries,	  and	  distance	  traveled	  around	  the	  maze.	  Data	  were	  analyzed	   using	   one-­‐way	   ANOVA	   with	   Bonferroni’s	   post	   hoc	   test	   for	   multiple	  comparisons.	  
	  Acoustic	  Startle	  The	   acoustic	   startle	   response	   was	   assessed	   in	   sound-­‐attenuated	   acoustic	  startle	   chambers	   (Med-­‐Associates,	   St.	   Albans,	   VT).	  Mice	  were	   gently	   restrained	   in	  transparent	  acrylic	  cylinders	  (3.2	  cm	  inner	  diameter;	  Med	  Associates,	  Inc.	  model:	  	  ENV-­‐263A)	  and	  placed	  on	  a	  startle	  platform	  with	  load	  cells	  and	  a	  force	  transducer.	  Mice	  were	  habituated	   to	   the	  chambers	   for	   five	  minutes	  before	   the	  presentation	  of	  the	  first	  acoustic	  startle	  stimulus.	  Each	  mouse	  was	  recorded	  for	  48	  startle	  trials	  (70,	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80,	   90,	   100,	   110,	   or	   120	   dB	   white	   noise	   bursts,	   each	   presented	   8	   times	   in	  pseudorandom	  order).	  The	  startle	   response	   following	  each	  stimulus	  was	  recorded	  and	   analyzed	   by	   Startle	   Reflex	   software	   (MED	   Associates,	   version	   5).	   Data	   were	  analyzed	   using	   two-­‐way	   ANOVA	   with	   Tukey’s	   post	   hoc	   test	   for	   multiple	  comparisons.	  
Results	  
Locomotor	  Response	  to	  a	  Novel	  Environment	  	   DAT	  KO	  mice	  display	  profound	  locomotor	  hyperactivity	  in	  open	  field	  testing	  (Giros	  et	  al.,	  1996;	  Speilewoy	  et	  al.,	  2000).	   In	  open	  field	  assessments	  of	   locomotor	  response	  to	  a	  novel	  environment,	  we	  did	  not	  observe	  locomotor	  hyperactivity,	  but	  rather	  a	  modest,	  but	  significant,	  reduction	  in	  horizontal	  locomotor	  activity	  between	  WT	   and	   DAT	   Val559	   heterozygous	   animals	   (Fig.	   17A).	   	   Interestingly,	   rearing	  behavior	   was	   also	   significantly	   reduced	   in	   DAT	   Val559	   animals	   (Fig.	   17B).	   No	  genotype	  differences	  were	  detected	  in	  time	  spent	  in	  the	  center	  versus	  total	  time	  in	  the	   chamber,	   a	   measure	   of	   anxiety	   (Fig.	   17C).	   In	   addition,	   preliminary	   evidence	  obtained	  using	  home-­‐cage	  recordings	  also	  indicates	  a	  reduction	  in	  rearing	  activity	  in	  DAT	  Val559	  mice	  (see	  Appendix	  3),	  suggesting	  that	  this	  behavioral	  change	  reflects	  a	  trait	   induced	   by	   constitutive	   DAT	   Val559	   expression	   versus	   a	   state	   induced	   by	   a	  novel	  environment	  (or	  their	  interaction).	  
Darting,	  Elevated	  Zero	  Maze,	  and	  Acoustic	  Startle	  	   Although	  we	  observed	  no	  spontaneous	  hyperactivity,	  we	  did	  notice	  early	  on	  in	  our	  handling	  of	  the	  DAT	  Val559	  mice	  that	  when	  researchers	  reached	  to	  transfer	  animals	   between	   cages,	   the	   presence	   of	   a	   DAT	   Val559	   genotype	   could	   be	   fairly	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  Figure	   17.	   DAT	   Val559	   mice	   display	   reduced	   locomotor	   activity	   and	   rearing	  behavior	  in	  a	  novel	  testing	  environment.	  (A)	  Horizontal	   locomotor	  activity	  (n	  =	  28	  WT,	  30	  het,	  25	  homo;	   left:	   time	  course	  of	   locomotor	  behavior,	  P(genotype)	  >	  0.05,	  two-­‐way	  RMANOVA;	  right:	  total	  +/-­‐	  SEM	  distance	  traveled	  in	  30	  minutes	  in	  activity	  chambers,	   overall	   P	   <	   0.05,	   post	   hoc	   tests	   (Tukey’s	   multiple	   comparisons	   test)	  reveals	   *	   =	   P	   <	   0.05	   for	  WT	   vs.	   het,	   P	   =	   0.0764	   (n.s.)	   for	  WT	   vs.	   homo,	   one-­‐way	  ANOVA)	  and	   (B)	   rearing	  activity	   (left:	  number	  of	   rearing	  behaviors	  +/-­‐	  SEM	   in	  30	  minutes	   in	   activity	   chambers,	   overall	   P	   <	   0.001,	   post	   hoc	   tests	   (Tukey’s	   multiple	  comparisons	   test)	   reveals	   ***	   =	  P	   <	   0.001	   for	  WT	  vs.	   het,	   *	   =	  P	   <	   0.05	   for	  WT	  vs.	  homo,	   one-­‐way	   ANOVA;	   right:	   time	   +/-­‐	   SEM	   rearing	   in	   30	   minutes	   in	   activity	  chambers,	   overall	  P	   <	   0.01	   for	  WT	   vs.	   het,	  P	   =	   0.1334	   for	  WT	   vs.	   homo,	   one-­‐way	  ANOVA)	  are	  significantly	  reduced	  in	  DAT	  Val559	  mice	  without	  changes	  in	  (C)	  time	  spent	   in	   the	   center	   versus	   the	   edge	   of	   the	   activity	   chambers	   (percent	   of	   time	   +/-­‐	  SEM	  in	  center	  of	  chambers	  during	  30-­‐minute	  recording,	  P	  >	  0.05,	  one-­‐way	  ANOVA).	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reliably	   assigned	   based	   on	   the	   presence	   of	   a	   more	   robust	   escape	   response,	   a	  behavior	   that	   we	   termed	   “darting”.	   	   After	   rigorous	   quantification	   of	   the	   speed	   of	  each	   escape	   response,	   we	   identified	   a	   significant	   genotype	   effect,	   such	   that	   DAT	  Val559	  mice	  display	  a	   faster	  escape	  reaction	   than	   their	  WT	  counterparts,	  whether	  considered	  as	  a	  distribution	  of	  all	  darting	  speeds	  (Fig.	  18A,	  or	  average	  darting	  speed	  for	  each	  genotype	  (Fig.	  18B).	   	  Furthermore,	   the	   increase	   in	  darting	  speed	   for	  DAT	  Val559	  animals	  is	  specific	  to	  the	  darting	  behavior;	  average	  locomotor	  speed	  during	  recordings	   of	   basal	   open	   field	   activity	   do	   not	   differ	   among	   genotypes	   (Fig.	   18C).	   The	  increased	  darting	  speed	  that	  we	  observed	  in	  DAT	  Val559	  animals	  could	  reflect	   an	   increase	   in	   the	   general	   startle	   response	   and/or	   anxiety.	   	   To	   test	   these	  possibilities	   we	   assessed	   DAT	   Val559	  mice	   and	  WT	   littermates	   for	   their	   acoustic	  startle	  response	  and	  performance	  on	  the	  elevated	  zero	  maze	  (EZM).	   	  We	  observed	  no	   impact	  of	   genotype	  on	   startle	   latency	  or	  peak	   startle	  magnitude	  at	   any	  decibel	  level	   tested	   (Fig.	   19).	   	  We	   also	   found	  no	   genotype-­‐dependent	   effect	   on	   locomotor	  activity	  in	  the	  zero	  maze	  or	  in	  time	  spent	  in	  the	  open	  areas	  of	  the	  maze	  (Fig.	  20).	  
Blunted	  Locomotor	  Activation	  by	  AMPH	  	   In	  control	  experiments,	  DAT	  Val559	  mice	  display	  a	  small	  but	  non-­‐significant	  reduction	   in	   locomotor	  activity	   following	  saline	   injection	   (Fig.	  21A),	   similar	   to	   the	  behavioral	  pattern	  observed	  during	  recording	  of	  basal	  locomotor	  activity	  (Fig.	  17A).	  	  DAT	  Val559	  mice	  are	  less	  active	  during	  the	  first	  30	  minutes	  after	  injection,	  perhaps	  reflecting	   a	   subdued	   response	   to	   injection	   stress,	   as	   activity	   levels	   of	  DAT	  Val559	  mice	  normalize	  to	  WT	  levels	  during	  the	  last	  30	  minutes	  of	  the	  trial.	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  Figure	   18.	   DAT	   Val559	   mice	   display	   significantly	   increased	   darting	   speed	   upon	  imminent	  handling.	  (A)	  Frequency	  distribution	  of	  darting	  speeds.	  (B)	  Mean	  +/-­‐	  SEM	  darting	   speed	   (n	   =	   21	   WT,	   33	   het,	   14	   homo;	   overall	   P	   <	   0.0001,	   post	   hoc	   test	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  ****	  =	  P	  <	  0.0001	  for	  WT	  vs.	  homo	  and	  *	  =	  P	  <	  0.05	  for	  het	  vs.	  homo	  comparisons,	  one-­‐way	  ANOVA))	  is	  significantly	  faster	  for	  DAT	  Val559	  mice,	  but	   (C)	  mean	  +/-­‐	  SEM	   locomotor	   speed	  during	  basal	  open	   field	  recording	  	  is	  not	  different	  among	  genotypes	  (P	  >	  0.05,	  one-­‐way	  ANOVA).	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  Figure	  19.	  Despite	  significantly	  faster	  darting	  responses,	  DAT	  Val559	  mice	  show	  no	  differences	   in	   (A)	   acoustic	   startle	   latency	   or	   (B)	   peak	   startle	   response	   (n	   =	   8	   per	  genotype;	  P	  >	  0.05,	  two-­‐way	  ANOVAs).	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  Figure	  20.	  Despite	  significantly	  faster	  darting	  responses,	  DAT	  Val559	  mice	  show	  no	  differences	  in	  elevated	  zero	  maze	  behavior,	  including	  (A)	  time	  in	  the	  open	  area	  and	  (B)	  distance	  traveled	  on	  the	  maze	  (n	  =	  20	  WT,	  24	  het,	  14	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVAs).	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  In	  vitro	  studies	  of	  AMPH	  action	  on	  DAT	  Val559	  demonstrated	  that	  the	  drug	  acts	   only	   as	   a	   competitive	   substrate,	   inhibiting	   both	   DA	   uptake	   and	   ADE	   (Mazei-­‐Robison	   et	   al.,	   2008),	   as	   opposed	   to	   its	   well-­‐established	   ability	   to	   produce	   DAT-­‐mediated	   DA	   efflux	   (Sulzer	   et	   al.,	   2005).	   Consistent	   with	   these	   previous	   findings,	  DAT	   Val559	   mice	   have	   a	   significantly	   blunted	   (approximately	   50%)	   locomotor	  response	   after	   i.p.	   administration	   of	   3	  mg/kg	  AMPH	   (Fig.	   21B).	   	   Interestingly,	   the	  blunted	  response	  to	  AMPH	  of	  Val559	  mice	  relative	  to	  WT	  animals	  was	  not	  limited	  to	  ambulatory	  behavior;	  AMPH	  also	  elicited	  significantly	  less	  rearing	  behavior	  in	  DAT	  Val559	  mice	  (Fig.	  22A),	  but	  stereotyped	  movements	  were	  equivalent	  between	  WT	  and	  DAT	  Val559	  animals	  (Fig.	  22B).	  D1	   receptors	   have	   been	   shown	   to	   mediate	   the	   locomotor	   hyperactivity	  triggered	   by	   AMPH	   treatment	   in	   vivo	   (O’Neill	   and	   Shaw,	   1999;	   Hall	   et	   al.,	   2009).,	  After	   titrating	   the	   i.p.	   dosage	   (data	   not	   shown)	   of	   the	   D1	   agonist	   SKF	   83822	   (2	  mg/kg)	  to	  elicit	  an	  equivalent	  locomotor	  activation	  as	  3	  mg/kg	  AMPH,	  we	  observed	  no	  genotype	  differences	  in	  the	  locomotor	  response	  (Fig.	  23A).	  DAT	  Val559	  animals	  display	   a	   small	   but	   non-­‐significant	   reduction	   in	   rearing	   behavior	   following	   SKF	  83822	  treatment	  (Fig.	  23B),	  as	  well	  as	  no	  change	  in	  stereotyped	  behavior	  (Fig.	  23C).	  Across	  conditions	  (basal,	  saline-­‐,	  AMPH-­‐,	  or	  SKF	  83822-­‐treated),	  DAT	  Val559	  animals	  display	  reduced	   locomotor	  behavior	  relative	   to	  WT	  mice	  only	  after	  AMPH	  treatment	   (Fig.	   24A).	   In	   contrast,	   rearing	   behavior	   is	   significantly	   reduced	   at	  baseline,	  and	  continues	  to	  trend	  towards	  reduction	  across	  all	  other	  conditions	  (Fig.	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  Figure	   21.	   DAT	   Val559	   mice	   have	   a	   significantly	   blunted	   locomotor	   response	   to	  AMPH.	  (A)	  DAT	  Val559	  mice	  display	  a	  small	  but	  insignificant	  reduction	  in	  locomotor	  activity	  following	  saline	  injection	  (n	  =	  37	  WT,	  21	  het,	  15	  homo;	  left:	  time	  course	  of	  locomotor	   behavior,	  P(genotype)	   >	   0.05,	   two-­‐way	  RMANOVA,	   right:	   total	   +/-­‐	   SEM	  distance	  traveled	  in	  60	  minutes	  after	  saline	  injection,	  P	  >	  0.05,	  one-­‐way	  ANOVA)	  but	  (B)	  an	  approximately	  50%	  reduction	  in	  AMPH-­‐induced	  locomotor	  stimulation	  (n	  =	  9	  WT,	  9	  het,	  6	  homo;	  left:	  time	  course	  of	  AMPH	  response,	  P(genotype)	  <	  0.05,	  post	  hoc	  testing	  (Tukey’s	  multiple	  comparisons	  test)	  reveals	  P	  <	  0.05	  at	  20,	  25,	  40,	  45,	  and	  55	  min	  and	  P	  <	  0.01	  at	  30	  and	  35	  min	  after	  AMPH	  injection	  for	  WT	  vs.	  het	  and	  P	  <	  0.05	  at	   20,	   25,	   30,	   and	   35	   min	   after	   AMPH	   injection	   for	   WT	   vs.	   homo,	   two-­‐way	  RMANOVA;	   right:	   total	   +/-­‐	   SEM	   distance	   traveled	   in	   60	   minutes	   after	   AMPH	  administration,	  *	  =	  overall	  P	  <	  0.05,	  one-­‐way	  ANOVA).	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  Figure	   22.	   DAT	   Val559	   mice	   display	   reduced	   rearing	   behavior	   following	   AMPH	  treatment.	   (A)	   The	   number	   of	   rearing	   behaviors	   and	   time	   spent	   rearing	   are	  significantly	  reduced	  following	  3	  mg/kg	  AMPH	  treatment	  (n	  =	  9	  WT,	  9	  het,	  6	  homo;	  
left:	  number	  of	  rearing	  behaviors	  +/-­‐	  SEM	  in	  60	  minutes	  following	  AMPH,	  overall	  P	  <	  0.05,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveals	  *	  =	  P	  <	  0.05	  for	  WT	  vs.	  het,	  P	  =	  0.0537	  for	  WT	  vs.	  homo,	  one-­‐way	  ANOVA;	  right:	  time	  spent	  rearing	  +/-­‐	  SEM	  after	  AMPH,	  overall	  P	  <	  0.05,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveals	  *	  =	  P	  <	  0.05	  for	  WT	  vs.	  het	  and	  WT	  vs.	  homo	  comparisons,	  one-­‐way	  ANOVA)	  but	  (B)	  stereotyped	  behaviors	  are	  unaffected	  (n	  =	  9	  WT,	  9	  het,	  6	  homo;	  left:	  number	  of	  stereotyped	  behaviors	  +/-­‐	  SEM	  in	  60	  minutes	  following	  AMPH,	  P	  >	  0.05,	  one-­‐way	  ANOVA;	  right:	  time	  in	  stereotypy	  +/-­‐	  SEM	  in	  60	  minutes	  after	  AMPH,	  P	  >	  0.05,	  one-­‐way	  ANOVA).	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  Figure	   23.	   Locomotor	   activity,	   stereotypy,	   and	   rearing	   behavior	   do	   not	   differ	  between	   DAT	   Val559	   mice	   and	   WT	   controls	   after	   treatment	   with	   D1	   receptor	  agonist	   SKF83822.	   (A)	   Locomotor	   activity	   following	   treatment	   with	   2	   mg/kg	  SKF83822	  (D1R	  agonist)	  does	  not	  differ	  between	  DAT	  Val559	  mice	  and	  WT	  controls	  (n	  =	  8	  per	  genotype;	  left:	  time	  course	  of	  SKF83822	  response,	  P(genotype)	  >	  0.05,	  all	  post	  hoc	   comparisons	  P	   >	   0.05,	   two-­‐way	  RMANOVA;	   right:	   total	   +/-­‐	   SEM	  distance	  traveled	   in	   60	   minutes	   following	   SKF83822	   administration,	   P	   >	   0.05,	   one-­‐way	  ANOVA).	  Similarly,	  (B)	  rearing	  behavior	  (left:	  number	  of	  rearing	  behaviors	  +/-­‐	  SEM	  following	  SKF83822	  treatment,	  P	  >	  0.05,	  one-­‐way	  ANOVA;	  right:	  time	  +/-­‐	  SEM	  spent	  rearing	   after	   SKF83822	   administration,	   P	   >	   0.05,	   one-­‐way	   ANOVA)	   and	   (C)	  stereotyped	  behaviors	  (left:	  number	  of	  stereotyped	  movements	  following	  SKF83822	  treatment,	   P	   >	   0.05,	   one-­‐way	   ANOVA;	   right:	   time	   +/-­‐	   SEM	   in	   stereotypy	   after	  SKF83822	   administration,	  P	   >	   0.05,	   one-­‐way	   ANOVA)	   do	   not	   differ	   between	   DAT	  Val559	  mice	  and	  WT	  controls.	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  Figure	  24.	  Locomotor	  and	   rearing	  behavior	   in	   an	  open	   field	  across	  all	   treatments.	  (A)	  Total	  distance	  traveled	  +/-­‐	  SEM,	  (B)	  number	  of	  rearing	  behaviors	  +/-­‐	  SEM,	  and	  (C)	   time	   spent	   rearing	   +/-­‐	   SEM	   during	   60	  minutes	   following	   injection	   of	   nothing	  (basal),	  saline,	  AMPH,	  or	  D1	  agonist	  SKF	  83822.	  
	   112	  
24B,	   C).	   	   Stereotyped	   behavior	   does	   not	   differ	   among	   genotypes	   regardless	   of	  treatment	  condition	  (data	  not	  shown).	  
Discussion	  
	   Because	   ADHD	   is	   a	   childhood	   disorder	   (American	   Psychiatric	   Association,	  1994)	  and	  displays	  a	  consistent	  male	  bias	  (Gaub	  and	  Carlson,	  1997;	  Getahun	  et	  al.,	  2013a),	  we	  focused	  our	  studies	  on	  juvenile/adolescent	  (aged	  5-­‐9	  weeks)	  male	  mice.	  	  All	  experiments	  were	  performed	  during	  the	  dark	  phase	  of	  the	  light-­‐dark	  cycle.	  	  Mice	  are	   generally	   a	   nocturnal	   species,	   becoming	   more	   active	   during	   the	   dark	   phase	  (Cambras	   and	  Díez-­‐Noguera,	   1991;	  Goulding	   et	   al.,	   2008),	   and	   activity	   levels	   vary	  between	  mouse	  background	  strains	  (Goulding	  et	  al.,	  2008;	  Gürkan	  et	  al.,	  2008).	   In	  my	  own	  experience,	  the	  DAT	  Val559	  mice	  were	  considerably	  less	  active	  during	  the	  light	  phase,	  such	  that	  their	   lack	  of	  activity	  made	  basal	  behavioral	  analysis	  difficult.	  For	   ease	   of	   performing	   experiments	   during	   the	   dark	   phase,	   therefore,	  mice	  were	  maintained	   on	   a	   reverse	   light-­‐dark	   cycle.	   	   Mice	   were	   given	   at	   least	   one	   week	   to	  acclimate	  to	  the	  reverse	  light	  cycle,	  as	  light	  cues	  are	  known	  to	  affect	  feeding,	  sleep,	  and	  locomotor	  activity	  (Ikeda	  et	  al.,	  2000),	  and	  5-­‐6	  days	  is	  sufficient	  for	  mice	  to	  re-­‐entrain	  to	  the	  new	  light-­‐dark	  cycle	  (Kopp	  et	  al.,	  1998).	  	   Somewhat	  surprisingly,	  given	  the	  prediction	  of	   in	  vivo	  ADE	  for	  DAT	  Val559,	  no	  basal	  locomotor	  hyperactivity	  was	  observed	  in	  the	  open	  field	  test,	  and,	  in	  fact,	  the	  animals	  were	  slightly	  hypoactive,	  suggesting	  less	  arousal	  by	  the	  novel	  environment.	  The	   lack	  of	  hyperactivity	   relative	   to	  WT	   littermates	  suggests	  either	   that	  1)	  ADE	   is	  not	   occurring	   in	   vivo	   or	   2)	   that	   adaptive	   changes	   in	   response	   to	   ADE	   may	   have	  occurred	   that	   have	   diminished	   environmental	   arousal	   or	   overall	   exploratory	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interest.	   	   In	   support	   of	   the	   latter	   hypothesis,	   DAT	   Val559	   animals	   displayed	  reductions	   in	   rearing	   behavior	   in	   both	   open	   field	   chambers	   and	   in	   home	   cage	  recordings	   (see	   Appendix	   3).	   Arguing	   against	   a	   perturbation	   of	   exploratory	  behavior,	   our	   preliminary	   studies	   using	   the	   novel	   object	   recognition	   paradigm	  reveal	  no	  impact	  of	  the	  DAT	  Val559	  variant	  (see	  Appendix	  3).	  	  At	  a	  molecular	  level,	  the	  observed	  change	  in	  rearing	  behavior	  could	  reflect	  a	  change	  in	  D2R	  function,	  as	  Kelly	   and	   colleagues	   demonstrated	   that	   D2R	   deficient	   mice	   display	   reduced	  locomotor	   activity	   and	   rearing	   behavior	   (Kelly	   et	   al.,	   1998).	   In	   addition,	   D2R	   KO	  mice	   have	  drastically	   reduced	   locomotor	   responses	   upon	   amphetamine	   treatment	  (Kelly	   et	   al.,	   2008;	  Neve	   et	   al.,	   2013),	   a	   finding	   attributed	   primarily	   to	   loss	   of	   the	  postsynaptic	   isoform,	   D2L.	   	   Since	  we	   observed	   no	   change	   in	   D2	   protein	   levels	   in	  striatum	  and	  midbrain,	  we	  suspect	  that	   if	  changes	  in	  D2R	  do	  occur,	  they	  will	  be	  at	  the	  level	  of	  surface	  expression	  or	  functional	  coupling	  to	  signaling	  pathways.	  In	  light	  of	  the	  loss	  of	  AMPH	  sensitivity	  in	  D2R	  KO	  mice,	  downregulation	  of	  D2R	  functionality	  (likely	  desensitization	  arising	  from	  constant	  DA	  stimulation	  due	  to	  ADE)	  provides	  a	  reasonable	   mechanism	   for	   the	   blunted	   rearing	   behavior	   that	   we	   observe	   in	   DAT	  Val559	  mice	  following	  AMPH	  treatment.	   	  Experiments	  to	  determine	  the	  underlying	  mechanism	   of	   the	   reduced	   rearing	   behavior	   observed	   in	   DAT	   Val559	   mice	   are	  certainly	  warranted.	  	   Although	  we	  observed	  no	  hyperactivity	  in	  the	  DAT	  Val559	  mice	  on	  open	  field	  testing	  or	  in	  our	  preliminary	  studies	  with	  home	  cage	  monitoring,	  we	  did	  identify	  a	  novel	  hyperactive	  phenotype	   that	  we	  termed	  “darting”.	   	  We	  noticed	   that	  when	  we	  reached	   to	   transfer	   the	  mice	   between	   cages,	   the	   presence	   of	   a	   DAT	   Val559	   allele	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could	  be	  fairly	  reliably	  determined	  based	  only	  on	  a	  more	  robust	  escape	  reaction.	  As	  we	  found	  no	  genotype	  differences	  in	  tests	  of	  anxiety	  behavior	  or	  startle	  responses,	  we	  believe	  darting	  behavior	   to	  be	  a	  behavioral	  phenotype	   linked	   to	  a	   response	   to	  imminent	  handling.	  Interestingly,	  spontaneous	  darting	  behavior	  has	  been	  reported	  as	   a	   phenotype	   that	   reliably	   differentiates	   C57BL6J	   and	   DBA/2J	   inbred	   mouse	  strains	  (Kafkafi	  et	  al.,	  2003).	   	  Additionally,	  spontaneous	  darting	  behavior	  mediated	  by	  glutamatergic	  corticostriatal	  projections	  (Fonnum	  et	  al.,	  1981)	  has	  been	  reported	  following	   administration	   of	   the	   NMDA	   receptor	   antagonist	   CPP	   (3(2-­‐carboxypiperazin-­‐4-­‐yl)-­‐propyl-­‐l-­‐phosphonic	   acid)	   in	   the	   prefrontal	   cortex	   of	   rats	  (O’Neill	  and	  Liebman,	  1987;	  Crawley	  et	  al.,	  1992).	  Together,	  these	  findings	  raise	  the	  possibility	  that	  alterations	  in	  DA	  signaling	  in	  the	  cortex	  or	  striatum	  of	  DAT	  Val559	  mice	  could	  lead	  to	  alterations	  in	  glutamatergic	  signaling	  that	  contribute	  to	  darting.	  The	  darting	  phenotype	  that	  we	  observed	  may	  derive	  from	  a	  deficit	  in	  cortical	  inhibition	   of	   DA	   release	   (Lodge,	   2011).	   Studies	   in	   humans	   with	   ADHD	   have	  demonstrated	  deficits	  in	  response	  inhibition	  (reviewed	  in	  Aron	  and	  Poldrack,	  2005;	  and	  Barnes	  et	  al.,	  2011)	  that	  has	  been	  explained	  using	  the	  “activation-­‐suppression	  model”	   (van	   den	   Wildenberg	   et	   al.,	   2010).	   According	   to	   this	   model,	   the	   motor	  response	   to	   a	   salient	   but	   irrelevant	   stimulus	   must	   be	   suppressed	   in	   order	   to	  respond	   to	  a	   relevant	  stimulus.	   	   In	   the	  context	  of	   this	  model,	   the	  darting	  behavior	  exhibited	   by	   DAT	   Val559	   mice	   may	   reflect	   an	   inability	   to	   suppress	   an	   escape	  response	   to	   imminent	   handling,	   a	   harmless	   stimulus	   that	   the	   animals	   experience	  regularly	  during	  cage	  transfers.	  Thus	  far,	  we	  have	  been	  unable	  to	  pharmacologically	  manipulate	   the	  darting	  response	  of	  DAT	  Val559	  mice,	   likely	  due	   to	  associations	  of	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approach	   linked	   to	   a	   negative	   stimulus	   that	   overwhelms	   genotype	   differences	   in	  darting	  behavior.	   	  Clearly,	   further	  studies	  are	  needed	  to	  define	  the	  nature	  of	  brain	  circuits	  and	  signaling	  alterations	  that	  drive	  the	  darting	  behavior	  we	  report.	  	   AMPH	   is	  well	   known	   to	   elicit	  DAT-­‐mediated	  DA	   efflux	   (Sulzer	   et	   al.,	   2005)	  and	   induce	   locomotor	   hyperactivity	   (Dews,	   1953;	   Smith,	   1965).	   	   Based	   on	   our	   in	  
vitro	   findings	   with	   DAT	   Val559	   that	   AMPH	   lacks	   DA	   releasing	   properties	   but	  remains	   a	   competitive	   substrate	   (Mazei-­‐Robison	   et	   al.,	   2008),	   we	   predicted	   a	  blunted,	  locomotor	  stimulatory	  effect	  of	  AMPH	  though	  not	  a	  full	  insensitivity	  to	  the	  stimulant.	   Consistent	   with	   the	   in	   vitro	   data,	   DAT	   Val559	   mice	   display	   an	  approximately	   50%	   reduction	   in	   AMPH-­‐induced	   locomotor	   activity.	   Interestingly,	  DAT	   Val559	  mice	   exhibited	   reduced	   rearing	   behavior,	   both	   during	   acclimation	   to	  the	   open	   field,	   after	   saline	   injections,	   and	   after	   AMPH	   injections.	   D1Rs	   have	   been	  implicated	   in	   the	   locomotor	   hyperactivity	   triggered	   by	   AMPH	   in	   vivo	   (O’Neill	   and	  Shaw,	  1999;	  Hall	  et	  al.,	  2009).	  	  Upon	  stimulation	  with	  the	  D1	  agonist	  SKF83822	  at	  a	  dose	   titrated	   to	   achieve	   stimulation	   at	   levels	   seen	   with	   3	   mg/kg	   i.p.	   AMPH,	   we	  observed	   no	   genotype	   differences	   in	   locomotor	   stimulation.	   This	   finding	   suggests	  that	   striatal	  D1	   signaling	   is	   intact	   in	  DAT	  Val559	  mice,	   and	   that	   the	  differences	   in	  locomotor	  response	  between	  WT	  and	  DAT	  Val559	  mice	  observed	  with	  AMPH	  likely	  arise	  from	  presynaptic	  mechanisms	  and/or	  network-­‐level	  plasticities.	  	  	  	   As	  mentioned	   above,	  DAT	  Val559	  mice	  were	   also	   recorded	   in	   a	   home	   cage	  	  monitoring	  (HCM)	  system	  (see	  Appendix	  3).	  	  For	  HCM	  experiments,	  mice	  are	  housed	  individually,	  then	  video-­‐recorded	  over	  the	  course	  of	  several	  days,	  and	  all	  behaviors	  documented	   by	   an	   automated	   system.	   While	   open	   field	   testing	   is	   informative,	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especially	  for	  measuring	  drug	  effects,	  HCM	  analysis	  allows	  for	  detection	  of	  changes	  in	  basal	  behaviors,	  and	  removes	  potential	  confounds	  arising	  from	  the	  novelty	  of	  the	  testing	   apparatus.	   	   HCM	   of	   DAT	   Val559	   mice	   confirms	   the	   reduction	   in	   rearing	  behavior	   observed	   in	   open	   field	   tests,	   and	   may	   prove	   useful	   for	   detecting	  spontaneous	  darting	  behavior.	  	  Interestingly,	  Val559	  hetero-­‐	  and	  homozygotes	  displayed	  remarkably	  similar	  phenotypes	  on	  all	  behaviors	  measured.	  	  Such	  findings	  suggest	  that	  DAT	  Val559	  may	  act	  in	  a	  dominant	  fashion	  in	  the	  heterozygous	  animals,	  such	  that	  one	  mutant	  allele	  drives	   the	  mutant	   phenotype	   despite	   the	   presence	   of	   a	  WT	   allele.	   Several	   studies	  have	  provided	  evidence	  that	  DAT	  forms	  dimers	  (Hastrup	  et	  al.,	  2001;	  Torres	  et	  al.,	  2003;	  Sorkina	  et	  al.,	  2003),	  providing	  a	  possible	  mechanism	  by	  which	  DAT	  Val559	  might	   act	   in	   a	   dominant	   manner.	   	   Further	   studies	   are	   required	   to	   formally	  demonstrate	  DAT	  Val559’s	  dominant	  effect.	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CHAPTER	  V	  	  
IN	  VIVO	  AND	  EX	  VIVO	  CHARACTERIZATION	  
	  
Introduction	  	   As	   discussed	   previously,	   in	   vitro	   characterization	   of	   DAT	   Val559	   revealed	  that	   the	   mutant	   transporter	   exhibits	   normal	   DA	   transport,	   but	   supports	   a	  spontaneous	  outward	  DA	   leak,	   a	  phenomenon	   termed	  anomalous	  DA	  efflux	   (ADE)	  (Mazei-­‐Robison	  et	  al.,	  2008).	   	  Furthermore,	  DAT	  Val559	  displays	  an	   inappropriate	  response	   to	   the	   psychostimulant	   AMPH	   –	   instead	   of	   inducing	   DAT-­‐mediated	   DA	  efflux,	  AMPH	  blocks	  both	  DA	  uptake	  and	  ADE.	  Based	  on	  these	  phenotypes,	  we	  made	  several	  predictions	  and	  performed	  several	   experiments	   regarding	   the	  biochemical	  (Chapter	  3)	  and	  behavioral	  (Chapter	  4)	  ramifications	  of	  the	  DAT	  Val559	  variant.	  	  Despite	  a	  strong	  in	  vitro	  phenotype,	  there	  remains	  a	  possibility	  that	  adaptive	  changes	   can	   occur	   during	   development	   that	   might	   change	   how	   DAT	   Val559	  functions	  in	  vivo.	  	  For	  example,	  compensatory	  changes	  in	  DA	  synthesis,	  vesicle	  pools,	  DAT	  regulation,	  or	  alternative	  inactivation	  mechanisms	  could	  be	  engaged	  to	  nullify	  any	  extracellular	  changes	  in	  DA	  that	  are	  expected	  from	  DAT-­‐mediated	  ADE	  or	  AMPH	  blockade.	  Additionally,	  we	  certainly	  cannot	  disregard	  the	  possibility	  that	  the	  Val559	  allele	  produces	  other	  effects	  on	  DAT	  in	  vivo	  that	  could	  alter	  the	  basal	  efflux	  observed	  
in	  vitro.	  Thus,	  in	  order	  to	  provide	  direct	  evidence	  of	  basal	  DA	  efflux	  and	  an	  altered	  ability	   of	  AMPH	   to	  produce	   transporter-­‐mediated	  DA	  efflux,	  we	  performed	   in	  vivo	  microdialysis	   and	   ex	   vivo	   [3H]-­‐DA	   release	   studies.	   	   These	   techniques	   allow	   for	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measurement	  of	  basal	  and	  evoked	  DAT	  Val559	  function	  in	  native	  tissue,	  and	  provide	  critical	  evidence	  regarding	  the	  ongoing	  potential	  for	  altered	  DAT	  function	  to	  modify	  synaptic	  events.	  
Methods	  
Microdialysis	  Mice	   were	   anesthetized	   with	   isoflurane	   (5%	   for	   induction,	   2%	   for	  maintenance	  during	  surgery)	  and	  placed	  in	  a	  stereotaxic	  frame	  using	  mouse-­‐specific	  ear	  bars	  (Kopf	  Instruments,	  Tujunga,	  CA).	  A	  guide	  cannula	  (CMA7)	  was	  placed	  1	  mm	  above	   the	   dorsal	   striatum	   (-­‐0.86	   AP	   from	   Bregma,	   +/-­‐	   1.6	   mL	   and	   -­‐2.0	   DV	   from	  dura)	   and	   secured	   to	   the	   skull	   using	   glass	   ionomer	   cement	   (Instech	   Solomon,	  Plymouth	  Meeting,	   PA).	   After	   recovery	   from	   surgery	   (18-­‐24	   hours),	   animals	  were	  placed	  in	  individual	  dialysis	  chambers	  (clear	  cylindrical	  enclosure,	  14	  cm	  diameter,	  22	  cm	  high;	   Instech	  Solomon,	  Plymouth	  Meeting,	  PA).	  A	  microdialysis	  probe	  (CMA	  Microdialysis,	   USA)	   with	   an	   active	   length	   of	   2	   mm	   was	   inserted	   into	   the	   guide	  cannula.	   One	   end	   of	   a	   tether	   was	   attached	   to	   the	   headpiece	   and	   the	   other	   end	  attached	   to	   a	   liquid	   swivel	   (Instech	   Solomon,	   Plymouth	   Meeting,	   PA)	   that	   was	  mounted	   on	   a	   counterbalanced	   arm	   above	   the	   dialysis	   chamber.	   The	   probe	   was	  perfused	  with	  artificial	   cerebral	   spinal	   fluid	   (aCSF;	  149	  mM	  NaCl,	  2.8	  mM	  KCl,	  1.2	  mM	  CaCl2,	  1.2	  mM	  MgCl2,	  5.4	  mM	  d-­‐glucose,	  pH	  7.2)	  at	  a	  flow	  rate	  of	  1.0	  uL/minute	  overnight.	   After	   the	   fourth	   baseline	   sample,	   the	   aCSF	   was	   switched	   to	   aCSF	  containing	  0.1	  uM	  D-­‐amphetamine	   for	   the	  remaining	  9	  samples.	  Dialysate	  samples	  were	   stored	   at	   -­‐80°C	   and	   analyzed	   by	   HPLC-­‐EC	   for	   DA	   and	   serotonin	   levels,	   as	  described	   above.	   After	   the	   dialysis	   session,	   animals	  were	   overdosed	  with	   sodium	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pentobarbital,	  brains	  removed	  and	  post-­‐fixed	   in	  4%	  paraformaldehyde	   in	  100	  mM	  phosphate	   buffer,	   sectioned,	   stained	   for	   Nissl	   substance,	   and	   then	   inspected	   for	  acceptable	   probe	   placement.	   Data	   were	   analyzed	   using	   two-­‐way	   ANOVA	   with	  Sidak’s	  post	  hoc	  test	  for	  multiple	  comparisons.	  
DA	  Release	  in	  Striatal	  Slices	  Brains	  were	  harvested	   from	  mice	   following	  rapid	  decapitation.	  Brains	  were	  immediately	   placed	   on	   an	   ice-­‐cold	   metal	   platform	   and	   the	   striatum	   quickly	  dissected.	   Striatal	   slices	  were	   then	   incubated	   for	   30	  min.	  with	  150	  nM	   [3H]-­‐DA	   at	  37oC	  and	  loaded	  into	  the	  perfusion	  chambers	  of	  a	  Brandel	  SF-­‐12	  superfusion	  system	  (Brandel,	  Inc.,	  Gaithersburg,	  MD),	  sandwiched	  between	  GF/B	  glass	  fiber	  filter	  discs	  (Whatman,	  Clifton,	  NJ).	  The	  chambers	  were	  perfused	  at	  a	  flow	  rate	  of	  0.4	  mL/min.	  with	  oxygenated	  Krebs’-­‐Ringer’s-­‐HEPES	  (KRH)	  buffer	  (130	  mM	  NaCl,	  3	  mM	  KCl,	  2.2	  mM	  CaCl2,	  1.2	  mM	  MgSO4,	  1.2	  mM	  KH2PO4,	  10	  mM	  D-­‐glucose,	  10	  mM	  HEPES	  pH	  7.4)	  at	  37°C	  for	  1	  hr	  prior	  to	  the	  start	  of	  the	  experiment	  to	  achieve	  a	  steady	  baseline	  of	  [3H]-­‐DA	  release.	  For	  studies	  of	  K+-­‐	  or	  AMPH-­‐evoked	  [3H]-­‐DA	  release,	  chambers	  were	  perfused	  with	  KRH	  at	  a	  flow	  rate	  of	  0.4	  mL/min	  and	  samples	  were	  collected	  every	  5	  minutes.	   After	   collection	   of	   3	   baseline	   samples,	   perfusate	   was	   switched	   to	   KRH	  buffer	  supplemented	  with	  20	  mM	  KCl	  to	  evoke	  vesicular	  [3H]-­‐DA	  release	  or	  1	  uM	  D-­‐AMPH	   to	   evoke	   non-­‐vesicular	   [3H]-­‐DA	   release	   for	   15	   min	   and	   then	   returned	   to	  perfusion	  with	  KRH	  for	  an	  additional	  15	  min.	  For	  studies	  of	  quinpirole	  modulation	  of	   DA	   release,	   two	   5	   min	   baseline	   KRH	   perfusates	   were	   collected	   and	   then	   the	  perfusion	   buffer	   was	   switched	   to	   KRH	   supplemented	  with	   5	   uM	   quinpirole	   for	   5	  min.	  Then	  the	  perfusate	  was	  switched	  to	  KRH	  containing	  5	  uM	  quinpirole	  and	  1	  uM	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D-­‐AMPH	  and	  samples	  were	  collected	  for	  the	  next	  15	  minutes,	  followed	  by	  a	  return	  to	   perfusion	   for	   15	   minutes	   with	   KRH.	   Five	   mL	   of	   EcoScint	   XR	   scintillation	   fluid	  (National	  Diagnostics,	  Atlanta,	  GA)	  was	  added	  to	  all	  samples	  and	  radioactivity	  was	  counted	  using	  a	  TriCarb	  2900TR	  scintillation	  counter	  (Perkin	  Elmer,	  Waltham,	  MA).	  Data	  for	  [3H]-­‐DA	  released	  are	  presented	  as	  the	  fraction	  of	  the	  total	  [3H]-­‐DA	  loaded	  into	   each	   sample	   (amount	   released	  +	   amount	   remaining	   in	   the	   tissue).	  Data	  were	  analyzed	  using	  either	  one-­‐way	  ANOVA	  with	  Bonferroni’s	  post	  hoc	   test	   for	  multiple	  comparisons	   (for	   total	   [3H]-­‐DA	   release)	   or	   two-­‐way	   ANOVA	  with	   Sidak’s	  post	  hoc	  test	  for	  multiple	  comparisons	  (for	  time	  course	  of	  [3H]-­‐DA	  release).	  
Results	  
In	  vivo	  Microdialysis	  	   In	  order	  to	  determine	  whether	  the	  ADE,	  and	  loss	  of	  AMPH-­‐induced	  DA	  efflux,	  observed	   in	   our	   in	   vitro	   studies	   of	   transfected	   DAT	   Val559	   could	   account	   for	   the	  blunted	   locomotor	   response	   to	   AMPH	   we	   observed	   in	   the	   DAT	   Val559	   mice,	   we	  performed	   in	   vivo	   microdialysis	   studies	   in	   unanesthetized,	   freely	  moving	   animals	  and	   used	   HPLC	   to	   measure	   endogenous	   extracellular	   levels	   of	   DA	   and	   5-­‐HT.	  Although	   basal	   extracellular	   5-­‐HT	   levels	   in	   the	   striata	   of	   WT	   and	   DAT	   Val559	  animals	   exhibited	   no	   significant	   genotype	   effect	   (Fig.	   25A),	   such	   an	   effect	   was	  evident	  for	  extracellular	  DA	  levels	  where	  we	  observed	  an	  ~10-­‐fold	  increased	  in	  DA	  levels	   in	  the	  DAT	  Val559	  homozygotes	  over	  that	  of	  WT	  control	  animals	  (Fig.	  25B).	  	  Although	  variability	  in	  the	  samples	  from	  heterozygous	  DAT	  Val559	  mice	  precluded	  a	   conclusion	   of	   significant	   changes,	   our	  mean	   values	   for	   these	   animals	   were	   also	  much	  higher	  than	  seen	  for	  WT	  animals.	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  Figure	  25.	  DAT	  Val559	  mice	  have	  elevated	  basal	  extracellular	  DA,	  but	  5-­‐HT	  levels	  are	  unaffected.	  (A)	  Basal	  extracellular	  5-­‐HT	  levels	  do	  not	  differ	  between	  genotypes	  (n	  =	  4	  per	  genotype;	  left:	  time	  course	  of	  basal	  5-­‐HT	  release,	  P(genotype)	  >	  0.05,	  two-­‐way	  RMANOVA;	  right:	  mean	  +/-­‐	  SEM	  extracellular	  5-­‐HT	  concentration	  prior	  to	  AMPH	  stimulation,	  P	  >	  0.05,	  one-­‐way	  ANOVA)	  but	  (B)	  basal	  extracellular	  DA	  levels	  are	  significantly	  elevated	  in	  DAT	  Val559	  mice	  (n	  =	  4	  per	  genotype;	  left:	  time	  course	  of	  basal	  DA	  release,	  P(genotype)	  <	  0.01,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  P	  <	  0.05	  at	  20	  min	  for	  WT	  vs.	  het	  and	  P	  <	  0.05	  at	  20,	  40,	  and	  80	  min	  and	  P	  <	  0.01	  at	  60	  min	  for	  WT	  vs.	  homo,	  two-­‐way	  RMANOVA;	  right:	  mean	  +/-­‐	  SEM	  extracellular	  DA	  concentration	  prior	  to	  AMPH	  stimulation,	  *	  =	  P	  <	  0.05,	  one-­‐way	  ANOVA).	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   Next,	  to	  probe	  the	  capacity	  of	  AMPH	  to	  induce	  DA	  efflux	  by	  DA	  terminals,	  we	  infused	  AMPH	  (0.1	  µM)	   into	   the	  striatum	  of	  cannulated	  mice,	  sampling	   to	  monitor	  extracellular	   DA	   levels	   before	   and	   after	   infusion.	   We	   chose	   this	   route	   of	  administration	   as	   systemic	   AMPH	  would	   have	  more	   complex	   effects	   and	   possibly	  cloud	   interpretations	   as	   compared	   to	   direct	   application	   of	   the	   drug	   onto	   DA	  terminals.	   Whereas	   intrastriatal	   administration	   of	   AMPH	   induced	   genotype-­‐independent	   5-­‐HT	   release	   (Fig.	   26A),	   both	   heterozygous	   and	   homozygous	   DAT	  A559V	   animals	   exhibited	   a	   significantly	   lower	   release	   of	   DA	   as	   compared	   to	  WT	  littermates.	   Indeed,	   DAT	   Val559	   heterozygous	   and	   homozygous	   animals	   released	  ~10	  times	  less	  DA	  than	  WT	  controls	  (Fig.	  26B).	  	  
Ex	  vivo	  [3H]-­‐DA	  Release	  from	  Striatal	  Slices	  	   AMPH-­‐evoked	  DA	   release	   in	  vivo	   occurs	   in	   the	   context	   of	  DA	  neuron	   firing	  that	   could	  differ	  between	  genotypes.	   	  To	  determine	  whether	  DA	   terminals	  of	  DAT	  Val559	   animals	   exhibit	   a	   diminished	   capacity	   for	   AMPH-­‐evoked	   DA	   release	  independent	  of	  afferent	  activity	  (i.e.	  regardless	  of	  neuron	  activity,	  DAT	  Val559	  does	  not	  respond	  to	  AMPH),	  we	  monitored	  the	  release	  of	  preloaded	  [3H]-­‐DA	  from	  striatal	  slices	  ex	  vivo.	  Striatal	  slices	  from	  WT	  and	  DAT	  Val559V	  animals	  loaded	  with	  [3H]DA	  to	   the	   same	   extent	   	   (Fig.	   27A).	   	   Next,	   using	   WT	   slices,	   we	   established	   an	   AMPH	  concentration	  (1	  uM)	  that	  generated	  an	  intermediate	  capacity	  for	  DA	  release,	  such	  that	  neither	  ceiling	  nor	   floor	  effects	  would	  obscure	  genotype	  effects.	   	  As	  predicted	  by	   heterologous	   expression	   and	   in	   vivo	   microdialysis	   studies,	   DAT	   Val559	   slices	  demonstrated	  a	  significantly	  reduced	  capacity	  for	  evoked	  DA	  efflux	  as	  compared	  to	  slices	  from	  WT	  controls	  (Fig.	  27B).	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  Figure	  26.	  DAT	  Val559	  mice	  display	  significantly	  blunted	  AMPH-­‐evoked	  DA	  release,	  but	  5-­‐HT	  release	  is	  unaffected.	  Upon	  AMPH	  stimulation,	  (A)	  evoked	  5-­‐HT	  does	  not	  differ	  between	  genotypes	  (n	  =	  4	  per	  genotype;	  left:	  time	  course	  of	  evoked	  5-­‐HT	  release,	  expressed	  as	  fold	  change	  above	  baseline	  +/-­‐	  SEM,	  P(genotype)	  >	  0.05,	  two-­‐way	  RMANOVA;	  right:	  mean	  +/-­‐	  SEM	  integrated	  fold	  change	  of	  5-­‐HT	  relative	  to	  baseline,	  P	  >	  0.05,	  one-­‐way	  ANOVA),	  	  but	  (D)	  AMPH-­‐evoked	  DA	  is	  reduced	  ~10-­‐fold	  in	  DAT	  Val559	  mice	  (n	  =	  4	  per	  genotype;	  left:	  time	  course	  of	  evoked	  DA	  release,	  expressed	  as	  fold	  change	  above	  baseline	  +/-­‐	  SEM,	  P(genotype)	  <	  0.05,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  P	  <	  0.05	  at	  180	  min,	  P	  <	  0.01	  at	  100	  and	  160	  min,	  and	  P	  <	  0.0001	  at	  120	  and	  140	  min	  for	  WT	  vs.	  het	  and	  P	  <	  0.05	  at	  100,	  200,	  and	  220	  min,	  P	  <	  0.01	  at	  160	  and	  180	  min,	  and	  P	  <	  0.0001	  at	  120	  and	  140	  min	  for	  WT	  vs.	  homo,	  two-­‐way	  RMANOVA;	  right:	  mean	  +/-­‐	  SEM	  integrated	  fold	  change	  of	  DA	  relative	  to	  baseline,	  overall	  P	  <	  0.05,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  *	  =	  P	  <	  0.05	  for	  WT	  vs.	  het	  and	  WT	  vs.	  homo,	  one-­‐way	  ANOVA).	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  Figure	  27.	  Striatal	  slices	  from	  DAT	  Val559	  animals	  show	  blunted	  [3H]-­‐DA	  release.	  (A)	  Striatal	  slices	  from	  WT	  and	  DAT	  Val559	  mice	  accumulate	  similar	  levels	  of	  [3H]-­‐DA	  (n	  =	  11	  WT,	  10	  het,	  11	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVA),	  but	  upon	  application	  of	  1	  uM	  AMPH	  (B)	  DAT	  Val550	  tissue	  releases	  significantly	  less	  [3H]-­‐DA	  than	  WT	  tissue	  (n	  =	  11	  WT,	  10	  het,	  11	  homo;	  left:	  time	  course	  of	  AMPH-­‐evoked	  [3H]-­‐DA	  release,	  expressed	  as	  percentage	  of	  available	  DA	  released	  +/-­‐	  SEM,	  P(genotype)	  <	  0.001,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  P	  <	  0.05	  at	  20	  and	  45	  min,	  P	  <	  0.01	  at	  25	  and	  40	  min,	  and	  P	  <	  0.001	  at	  30	  and	  35	  min	  for	  WT	  vs.	  het,	  and	  P	  <	  0.01	  at	  40	  and	  45	  min,	  P	  <	  0.01	  at	  20	  min,	  and	  P	  <	  0.001	  at	  25,	  30,	  and	  35	  min,	  two-­‐way	  RMANOVA;	  right:	  total	  percentage	  +/-­‐	  SEM	  of	  AMPH-­‐evoked	  [3H]-­‐DA	  released,	  overall	  P	  <	  0.001,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveal	  **	  =	  P	  <	  0.01	  for	  WT	  vs.	  het	  and	  ***	  =	  P	  <	  0.001	  for	  WT	  vs.	  homo	  comparisons,	  one-­‐way	  ANOVA).	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Discussion	  	   Two	  key	  in	  vitro	  phenotypes	  of	  the	  DAT	  Val559	  variant	  are	  ADE	  and	  a	  loss	  of	  AMPH-­‐induced	  DA	  release	  (Mazei-­‐Robison	  et	  al.,	  2008).	   	  Our	  findings	  of	  significant	  elevations	  of	  basal	   extracellular	  DA	   levels	   in	   the	   striatum	  of	  DAT	  Val559	  knock-­‐in	  mice	  provide	   supportive	   evidence	  of	  ADE	   in	  vivo.	  However,	  AMPH’s	   effects	   in	  vivo	  are	   less	  straightforward.	   	   In	  a	  heterologous	  expression	  system,	  AMPH	  blocks	  DAT-­‐mediated	   uptake	   and	   efflux,	   but	   in	  vivo,	   AMPH	  does	   not	   block	   efflux,	   and	   actually	  elicits	  some	  DA	  release.	  It	  is	  unlikely	  that	  DAT	  Val559	  fails	  to	  recognize	  AMPH,	  as	  in	  
vitro	   studies	  demonstrated	  equivalent	   inhibitory	  potency	   in	  blocking	  DA	  transport	  through	  WT	   or	   DAT	   Val559	   transporters	   (Mazei-­‐Robison	   et	   al.,	   2008).	   It	   remains	  unclear	   if	   some	   AMPH	   is	   finding	   a	  way	   into	   dopaminergic	   terminals	   despite	   DAT	  Val559’s	   inability	   to	   transport	   it.	   A	   two-­‐mechanism	   model	   for	   AMPH	   entry	   into	  neurons	   has	   been	   proposed	   (Liang	   and	   Rutledge,	   1982);	   at	   low	   concentrations,	  AMPH	   is	   transported	   as	   a	   DAT	   substrate	   and	   may	   be	   responsible	   for	   increased	  locomotor	  activity,	  but	  at	  higher	  concentrations,	  AMPH	  can	  passively	  diffuse	  across	  plasma	  membranes	  and	  induce	  DA	  release	  (Zaczek	  et	  al.,	  1991a,	  b).	  	  Assuming	  that	  DAT	   Val559	   does	   not	   transport	   AMPH	   in	   vivo,	   some	   AMPH	   may	   still	   enter	  dopaminergic	  neurons	  by	  passive	  diffusion,	  at	  which	  point	  AMPH’s	  ability	  to	  induce	  DA	  release	  is	  still	  intact.	  	   Alternatively,	   presynaptic	   compensations	   could	   explain	   the	   observed	  response	   to	  AMPH.	   	  DAT	  KO	  mice	  display	   an	   approximately	   90%	   reduction	   in	  D2	  autoreceptor	   function	   (Jones	   et	   al.,	   1999),	   a	   finding	   attributed	   to	   receptor	  downregulation	   resulting	   from	   constant	   DA	   exposure.	   	   DAT	   Val559	  mice	   are	   also	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hyperdopaminergic	   due	   to	   ADE,	   thus	   autoreceptors	   are	   likely	   downregulated.	  Furthermore,	   in	   D2R	   KO	  mice,	   the	   locomotor	   response	   to	   cocaine	   is	   significantly	  reduced	   relative	   to	  WT	  mice,	   an	   effect	   mediated	   in	   large	   part	   by	   presynaptic	   D2	  autoreceptors,	  as	  D2L	  (postsynaptic	  D2R)	  KO	  mice	  show	  only	  a	  slight	  reduction	  in	  the	   locomotor	   response	   to	   cocaine	   (Welter	   et	   al.,	   2007).	   	   If	   D2	   autoreceptors	   are	  downregulated	  in	  DAT	  Val559	  mice	  and	  AMPH	  is	  acting	  only	  as	  a	  DAT	  inhibitor	  (like	  cocaine),	   then	  we	  would	  expect	  a	  blunted	  response	  to	  AMPH.	  In	  addition,	  we	  have	  not	   yet	   tested	   the	   impact	   of	   a	   DAT	   inhibitor	   such	   as	   methylphenidate	   via	  microdialysis.	   	   Such	  experiments	  are	  necessary	   to	  demonstrate	   that	  AMPH	  acts	  as	  only	  as	  a	  DAT	  blocker	  for	  DAT	  Val559.	  At	  this	  point,	  however,	  we	  cannot	  rule	  out	  the	  possibility	  that	  elevated	  tonic	  firing	  rates	  of	  DA	  neurons	   in	  DAT	  Val559	  mice	  could	  account,	   to	   some	  degree,	   for	  the	  elevated	  basal	  extracellular	  DA	  levels.	  Somatodendritic	  and	  presynaptic	  D2	  DA	  receptors	  exert	  powerful	  negative	  feedback	  control	  over	  DA	  neuron	  firing	  (Lacey	  et	  al.,	   1987;	   Beckstead	   et	   al.,	   2007)	   and	   vesicular	  DA	   release	   (Anzalone	   et	   al.,	   2012;	  Zhang	   and	   Sulzer,	   2012),	   respectively.	   	   Autoinhibitory	   mechanisms	   would	   be	  expected	   to	  oppose	   local	  or	   circuit-­‐level	   compensations	   that	   could	  drive	  excessive	  firing	   and	   release	   of	   DA.	   However,	   under	   sustained	   receptor	   activation,	   as	   occurs	  with	   chronic	   DAT	   blockade,	   D2	   DA	   receptor-­‐mediated	   inhibition	   of	   firing	   and	  release	   can	   be	   desensitized	   (Jones	   et	   al.,	   1996;	   Katz	   et	   al.,	   2010).	   	   DAT	   Val559-­‐mediated	  ADE	  could	  result	  in	  a	  similar	  state	  of	  chronic	  receptor	  activation,	  receptor	  desensitization,	  and	  a	  failure	  to	  exert	  autoinhibitory	  control	  over	  DA	  neuron	  firing	  and	  excitation-­‐secretion	  coupling.	  	  Although	  we	  detected	  no	  changes	  in	  the	  levels	  of	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D2	   receptors	   in	   the	   midbrain	   or	   striatum	   (see	   Chapter	   3),	   radioligand	   binding	  assays	  as	  performed	  in	  our	  studies	  do	  not	  provide	  information	  on	  receptor	  surface	  levels	  or	  receptor	  coupling	  to	  effectors.	  Thus,	  further	  studies	  are	  needed	  to	  examine	  whether	  DA	  autoreceptors	  retain	  their	  signaling	  capacity	  in	  the	  face	  of	  constitutive	  elevation	   of	   extracellular	   DA	   and	   to	   compare	   resting	   and	   modulated	   DA	   neuron	  firing	  rates	  in	  vivo.	  	  	   In	  addition	  to	  tonically	  elevated	  extracellular	  DA	  in	  the	  striatum	  of	  DAT	  Val559	  mice,	  we	  also	  observed	  a	  diminished	  capacity	  for	  AMPH-­‐evoked	  DA	  release	  in	  striatal	  slices	  ex	  vivo	  and	  in	  the	  striatum	  in	  vivo.	  The	  blunted	  ability	  of	  AMPH	  to	  induce	  DA	  release	  in	  striatal	  slices	  also	  supports	  the	  presence	  of	  presynaptic	  changes	  independent	  of	  any	  possible	  changes	  in	  DA	  neuron	  excitability	  since	  AMPH-­‐induced	  DA	  release	  is	  not	  dependent	  on	  impulse	  flow.	  	  The	  more	  substantial	  loss	  of	  AMPH’s	  ability	  to	  induce	  DA	  release	  in	  vivo	  versus	  ex	  vivo	  in	  brain	  slices	  may	  be	  due	  to	  the	  engagement	  of	  other	  signaling	  pathways	  that	  facilitate	  AMPH	  induced	  DA	  release	  in	  vivo.	  Alternatively,	  the	  greater	  AMPH	  effect	  in	  vivo	  may	  arise	  from	  a	  measurement	  of	  release	  in	  this	  context	  from	  endogenous	  DA	  stores,	  whereas	  our	  ex	  
vivo	  studies	  measure	  the	  release	  of	  preloaded,	  radiolabeled	  DA.	  AMPH	  treatments	  lead	  to	  liberation	  of	  endogenous	  DA	  from	  vesicle	  stores,	  providing	  high	  cytoplasmic	  levels	  that	  serve	  as	  a	  substrate	  for	  DAT-­‐mediated	  export.	  Pre-­‐labeling	  of	  DA	  terminals	  with	  [3H]-­‐DA	  is	  known	  to	  largely	  load	  a	  small	  population	  of	  rapidly	  recycling,	  readily-­‐releasable	  vesicles	  (Herdon	  et	  al.,	  1985;	  Covey	  et	  al.,	  2013),	  as	  opposed	  to	  the	  loading	  of	  reserve	  pool	  vesicles	  that	  are	  already	  filled	  with	  unlabeled	  DA.	  Although	  it	  is	  assumed	  that	  radiolabeled	  neurotransmitter	  is	  liberated	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equivalently	  by	  AMPH	  from	  these	  pools,	  but	  if	  this	  is	  not	  the	  case,	  differences	  between	  the	  slice	  and	  dialysis	  measures	  could	  arise.	  Additionally,	  there	  may	  simply	  be	  ceiling	  effects	  on	  the	  amount	  of	  radiolabeled	  neurotransmitter	  that	  can	  be	  released	  due	  to	  a	  continual	  loss	  of	  neurotransmitters	  from	  the	  slices	  that	  is	  not	  resupplied	  by	  synthesis,	  unlike	  endogenous	  stores.	  As	  our	  studies	  progress,	  incorporation	  of	  such	  distinctions	  between	  vesicle	  pools	  will	  likely	  be	  necessary,	  and	  informative,	  in	  understanding	  the	  full	  impact	  of	  the	  DAT	  Val559	  variant	  on	  DA	  signaling.	  Further	  studies	  are	  needed	  to	  examine	  the	  effects	  of	  AMPH	  on	  endogenous	  vs.	  prelabeled	  DA	  release	  both	  in	  vitro	  and	  in	  vivo.	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CHAPTER	  VI	  	  SUMMARY	  AND	  FUTURE	  DIRECTIONS	  	  	   DA	   signaling	   is	   critically	   important	   for	   several	   behaviors	   including	   motor	  function,	   reward	   and	   motivation,	   and	   working	   memory	   and	   executive	   function	  (Barnes	   et	   al.,	   2011;	   Mitaki	   et	   al.,	   2013).	   Several	   neuropsychiatric	   disorders,	  including	   drug	   abuse	   and	   addiction	   (Kalivas	   and	   Volkow,	   2005),	   bipolar	   disorder	  (Manji	   and	   Lenox,	   2000;	   Jones	   and	   Craddock,	   2001),	   schizophrenia	   (Ross	   et	   al.,	  2006;	  Eyles	  et	  al.,	  2012),	  Parkinson’s	  disease	  (Temlett,	  1996),	  and	  ADHD	  (Faraone	  and	  Biederman,	  1998;	  Mazei-­‐Robison	  and	  Blakely,	  2005)	  all	   involve	  dopaminergic	  dysfunction.	   	  A	  key	  regulator	  of	  maintenance	  of	  dopamine	  signaling	   in	  the	  brain	   is	  DAT.	  The	  DAT	  KO	  mouse	  was	  initially	  proposed	  as	  a	  model	  for	  ADHD	  due	  to	  its	  early	  hyperkinetic	   phenotype	   (Giros	   et	   al.,	   1996),	   however	   humans	   with	   homozygous	  loss-­‐of-­‐function	   mutations	   in	   the	   DAT	   gene	   develop	   a	   complex	   motor	   disorder	  described	   as	   infantile	  parkinsonism-­‐dystonia	   (Kurian	   et	   al.,	   2009,	   2011).	   	   Prior	   to	  the	  Blakely	   lab’s	   efforts	   to	   study	  DAT	  variation	   in	  ADHD,	   there	  was	  no	  direct	   link	  between	  DAT	  dysfunction	  and	  disease.	  	   DAT	   is	   the	   primary	   site	   of	   action	   for	   the	   most	   commonly	   prescribed	  therapeutic	   agents	   used	   the	   treat	   ADHD,	   suggesting	   that	   it	   likely	   has	   a	   role	   in	  ADHD’s	   underlying	   pathophysiology.	   Several	   DAT	   coding	   variants	   had	   been	  reported	   in	   large-­‐scale	  genetic	   screens	   (Grünhage	  et	  al.,	  2000;	  Vandenbergh	  et	  al.,	  2000),	  however	  it	  was	  clear	  that	  common	  coding	  polymorphisms	  in	  DAT	  that	  could	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confer	  risk	  for	  ADHD	  were	  unlikely	  to	  exist.	  	  However,	  pursuing	  the	  hypothesis	  that	  ADHD	  subjects	  represented	  a	  clinical	  population	  enriched	  for	  DAT	  variation,	  efforts	  to	  identify	  rare,	  highly	  penetrant	  DAT	  variants	  were	  pursued	  (Mazei-­‐Robison	  et	  al.	  2005;	  Mergy	  MA	  and	  Blakely	  RD,	  unpublished	  findings	  (see	  Appendix	  1)).	  	   Using	   a	   high-­‐throughput	   single	   nucleotide	   polymorphism	   (SNP)	   discovery	  system,	  our	  lab	  identified	  four	  DAT	  variants	  –	  Val24Met,	  Leu167Phe,	  Ala559Val,	  and	  Arg615Cys	  –	  in	  ADHD	  subjects.	  	  Of	  particular	  interest	  was	  Ala559Val,	  as	  it	  had	  been	  previously	   reported	   in	  a	   subject	  diagnosed	  with	  bipolar	  disorder	   (Grünhage	  et	  al.,	  2000),	  then	  re-­‐discovered	  in	  two	  brothers	  with	  ADHD	  (Mazei-­‐Robison	  et	  al.,	  2005).	  ADHD	  and	  bipolar	  disorder	  are	  highly	  comorbid	  (Bernardi	  et	  al.,	  2010;	  Karaahmet	  et	  al.,	  2013;Pataki	  and	  Carlson,	  2013),	  suggesting	  that	  DAT	  Val559	  may	  contribute	  to	  both	   disorders.	   Furthermore,	   the	   small	   pedigree	   known	   for	   DAT	   Val559	   reveals	  transmission	  to	  the	  two	  affected	  boys	  from	  the	  mother	  and	  maternal	  grandmother.	  Unfortunately,	   no	   other	  males	   could	   be	   identified	   as	   carriers	   of	   the	   variant.	   	   The	  female	   carriers	   did	   not	   meet	   diagnostic	   criteria	   for	   ADHD,	   however	   the	   mother	  reported	   a	  mild	   learning	   disability	   and	   the	   grandmother	   rated	   above	   average	   for	  impulsivity/emotional	   lability	   traits	   on	   the	   Conner’s	   Adult	   ADHD	   rating	   scale	  (CAARS-­‐S:L)	  (Mazei-­‐Robison	  et	  al.,	  2008).	  	   In	  vitro	   characterization	   revealed	   that	  DAT	  Val559	   supports	   anomalous	  DA	  efflux	   (ADE)	   that	   can	  be	  blocked	  by	   cocaine,	  methylphenidate,	   and	  AMPH	   (Mazei-­‐Robison	   et	   al.,	   2008).	   	   Subsequent	   work	   demonstrated	   that	   ADE	   is	   supported	   by	  tonic	   D2	   receptor	   signaling	   in	   a	   CaMKII-­‐dependent	   mechanism	   (Bowton	   et	   al.,	  2010).	   	  CaMKII	  interacts	  with	  the	  DAT	  C-­‐terminus	  and	  is	  thought	  to	  phosphorylate	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N-­‐terminal	   serine	   residues	   that	   are	   required	   for	   AMPH-­‐induced	   DA	   efflux	  (Khoshbouei	   et	   al.,	   2004;	   Fog	   et	   al.,	   2006).	   	   DAT	   Val559	   has	   been	   show	   to	   be	  hyperphosphorylated	   relative	   to	  WT	   DAT	   (Sakrikar,	   2012),	   and	   it	   was	   suggested	  that	   the	  mutation	   in	   DAT	   Val559	   pushes	   DAT	   into	   an	   efflux-­‐willing	   conformation	  that	  occur	  after	  AMPH	  treatment.	  	   In	   light	  of	  the	  functional	  perturbations	  associated	  with	  DAT	  Val559	   in	  vitro,	  we	  generated	  the	  DAT	  Val559	  knock-­‐in	  mouse	  in	  order	  to	  study	  the	  biochemical	  and	  behavioral	  effects	  of	  this	  variant	  in	  vivo.	  Using	  traditional	  transgenesis	  methods,	  we	  successfully	   created	   the	   DAT	   Val559	  mouse.	   	   These	  mice	   display	   normal	   growth,	  development,	  and	  basic	  sensorimotor	  function,	  suggesting	  that	  our	  manipulation	  of	  the	   DAT	   gene	   and	   the	   presence	   of	   the	   Val559	   mutation	   are	   well	   tolerated.	  	  Interestingly,	   we	   observed	   a	   small	   but	   significant	   under-­‐representation	   of	   the	  Val559	   allele,	   particularly	   in	   male	   mice.	   	   This	   suggests	   that	   DAT	   function	   has	   a	  neurodevelopmental	  role.	  The	  male	  bias	  of	  the	  DAT	  Val559	  under-­‐representation	  is	  also	   interesting	   in	   light	   of	   the	  male	   predominance	   of	   ADHD,	   suggesting	   a	   role	   for	  DAT	  in	  a	  common	  pathway	  between	  ADHD	  and	  neurodevelopment.	  	  In	  order	  to	  fully	  understand	  how	  DAT	  Val559	   expression	  during	  development	   imparts	   long-­‐lasting	  effects	  on	  behavior,	  future	  efforts	  may	  involve	  creation	  of	  a	  conditional	  DAT	  Val559	  knock-­‐in	  mouse	  in	  which	  the	  temporal	  expression	  of	  DAT	  Val559	  can	  be	  controlled.	  	  Alternatively,	  we	  could	  use	  a	  viral	  approach	  in	  adult	  animals	  to	  examine	  the	  effects	  of	  DAT	  Val559	  in	  the	  adult	  animal.	  	   To	   date,	   DAT	   Val559	  mice	   are	  maintained	   on	   a	   hybrid	   background	   that	   is	  ~75%	   129S6	   and	   ~25%	   C57BL/6.	   	   Backcross	   to	   a	   congenic	   C57	   line	   has	   been	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completed	   and	   certainly	   warrants	   further	   study.	   	   Pure	   inbred	   strains	   provide	   a	  stable	  genetic	  background,	  and	  C57BL/6	  mice	  are	  particularly	  useful	  for	  behavioral	  and	   pharmacological	   analysis	   (reviewed	   in	   Puglisi-­‐Allegra	   and	   Cabib,	   1997;	   and	  Cabib	   et	   al.,	   2002).	   	   Furthermore,	   some	   phenotypes	   are	   affected	   by	   strain	  background.	   	   O’Neill	   and	   Gu	   reported	   that	   the	   amphetamine	   response	   of	   mice	  expressing	  a	  cocaine-­‐insensitive	  DAT	  was	  altered	  upon	  completion	  of	  backcrossing	  to	  a	  pure	  C57BL/6	  background	  (O’Neill	  and	  Gu,	  2013).	  Kerr	  and	  colleagues	  report	  similar	   findings	   in	   the	   Gly56Ala	   SERT	   knock-­‐in	   mouse	   model	   of	   autism;	   when	  backcrossed	   to	   the	  C57	  strain,	   several	  phenotypes	   including	  hyperserotonemia,	  5-­‐HT	   receptor	   sensitivity,	   and	   repetitive	   behaviors	   were	   lost	   (Kerr	   et	   al.,	   2013).	  	  Studies	  of	  DAT	  Val559	  on	  a	  pure	  C57BL/6	  background	  may	  confirm	  the	   impact	  of	  DAT	  Val559	  (i.e.	  phenotypes	  will	  not	  change),	  or	  indicate	  that	  other	  genetic	  factors	  (i.e.	  modifier	  genes,	  epigenetic	  regulation,	  etc.)	  may	  be	  contributing	  to	  the	  observed	  phenotypes.	  	   In	   vitro	   studies	   demonstrated	   that	   WT	   DAT	   and	   DAT	   Val559	   express	  equivalently	  (total	  and	  surface)	  and	  did	  not	  differ	  in	  their	  DA	  transport	  capabilities.	  Consistent	   with	   these	   findings,	   DAT	   Val559	   and	  WT	  mice	   express	   equal	   levels	   of	  DAT	  protein	  and,	   in	  striatal	  synaptosomes,	  show	  equivalent	  DA	  transport	  kinetics.	  	  Further	   studies	   involving	   cell-­‐surface	   biotinylation	   in	   brain	   slices	   are	   needed	   to	  confirm	  that	  surface	  levels	  of	  DAT	  Val559	  are	  normal,	  as	  well.	  	   We	  also	  examined	  DA	  receptor	   levels.	   	  Due	   to	   the	  high	  degree	  of	  homology	  between	  DA	  receptor	  subtypes,	  antibodies	   that	  differentiate	  receptor	  subtypes	  are	  not	  consistent	  and	  may	  not	  accurately	  reflect	  receptor	  expression	  levels.	  	  Therefore,	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we	  performed	   radioligand	   binding	   studies	   on	  membranes	   prepared	   from	  WT	   and	  DAT	   Val559	   mice.	   	   Unfortunately,	   pharmacological	   agents	   only	   discriminate	  between	  D1-­‐like	  and	  D2-­‐like	  DA	  receptors,	  but	  that,	  at	  least,	  separates	  receptors	  by	  functional	  class.	  	  Binding	  studies	  reveal	  no	  differences	  in	  receptor	  density	  between	  WT	   and	  DAT	  Val559	   animals	   in	   cortex,	  midbrain,	   or	   striatum.	   	   	   Receptor	   density,	  however,	  may	  be	  misleading:	  receptor	  function	  and	  expression	  can	  be	  uncoupled,	  so	  further	  studies	  are	  needed	  to	  assay	  receptor	  function.	  	   In	   addition	   to	   studying	   receptor	   function	   directly,	   it	   is	   also	   worthwhile	   to	  examine	  signaling	  pathways	  downstream	  of	  DA	  receptor	  activation.	  As	  reviewed	  in	  Chapter	  1,	  DA	  receptors	  signal	  through	  several	  pathways,	  including	  DARPP-­‐32	  and	  GSK3β.	   	   If	   DA	   receptor	   signaling	   is	   altered	   in	   response	   to	   DAT	   Val559-­‐mediated	  ADE,	  then	  downstream	  pathways	  may	  be	  differentially	  activated	  to	  compensate	  for	  the	   DA	   receptor	   dysregulation.	   	   On	   the	   other	   hand,	   DA	   receptor	   function	  may	   be	  altered	  and,	  as	  a	  result,	  downstream	  signaling	  may	  be	  dysregulated,	  as	  well,	  and	  the	  impact	   of	   DAT	   Val559	   ADE	   can	   spread	   far	   beyond	   the	   dopaminergic	   synapse.	  Studies	   are	   currently	  underway	   to	  probe	   the	   impact	  of	  DAT	  Val559	  on	  DARPP-­‐32	  phosphorylation	  (GL	  Davis,	  personal	  communication).	  	   Alteration	  of	  striatal	  and	  cortical	  serotonin	  was,	  perhaps,	  the	  most	  surprising	  biochemical	   alteration	   observed	   in	   DAT	   Val559	   mice,	   thus	   far.	   We	   observed	  significant	   increases	   in	   tissue	   5-­‐HT	   levels,	   suggesting	   that	   5-­‐HT	   circuits	   are	  compensating	  for	  dysfunctional	  DA	  circuits.	   	  Serotonergic	  adaptation	  to	  altered	  DA	  signaling	   is	   not	   unprecedented	   –	   DAT	   KO	  mice	   respond	   to	   psychostimulants	   in	   a	  SERT-­‐dependent	  manner	   (Gainetdinov	   et	   al.,	   1999)	   and	   loss	   of	  DA	  neurons	   via	   6-­‐
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OHDA	   lesion	   induces	   serotonergic	   axon	   sprouting	   (Avale	   et	   al.,	   2004b).	   	   The	   two	  primary	  5-­‐HT	  receptors	  that	  impinge	  upon	  DA	  circuits	  are	  5-­‐HT2A	  (excitatory)	  and	  5-­‐HT2C	  (inhibitory)	  (Di	  Matteo	  et	  al.,	  2002;	  Porras	  et	  al.,	  20202;	  reviewed	  in	  Esposito	  et	  al.,	  2008).	  Future	  efforts	  should	  explore	  changes	  in	  5-­‐HT	  receptor	  expression	  and	  5-­‐HT	  receptor-­‐dependent	  behaviors.	  For	  instance,	  the	  5-­‐HT2A	  agonist	  DOI	  induces	  a	  robust	   head	   twitch	   response	   (HTR)	   and	   is	   a	   straightforward	   behavioral	   assay	   for	  5HT2A	  receptor	  activation	  (Halberstadt	  and	  Geyer,	  2013).	  	   Behavioral	  characterization	  of	  DAT	  Val559	  mice	  revealed	  a	  surprising	  small	  but	  significant	  reduction	   in	  basal	   locomotor	  activity.	   In	  addition,	  DAT	  Val559	  mice	  had	   a	   significantly	   blunted	   response	   to	   the	   psychostimulant	   AMPH,	   but	   the	  locomotor	  response	  to	  the	  D1	  agonist	  SKF	  83822	  was	  intact.	   	  Based	  on	  the	   in	  vitro	  finding	   that	  AMPH	  acts	   to	  block	   transport	  and	  efflux	   through	  DAT	  Val559	   (Mazei-­‐Robison	  et	  al.,	  2008),	   the	  observed	   locomotor	  behaviors	  are	  remarkably	  similar	  to	  those	   of	   D2R	   KO	   mice.	   In	   D2R	   KO	   mice,	   basal	   locomotor	   activity	   is	   significantly	  reduced,	   as	   is	   locomotor	   activity	   following	   treatment	   with	   cocaine	   (Welter	   et	   al.,	  2007).	   	   The	   locomotor	   response	   to	   cocaine,	   however,	   was	   restored	   when	   only	  postsynaptic	  D2Rs	  were	  knocked	  out,	   indicating	   that	  presynaptic	  D2	  autoreceptor	  function	   is	   responsible	   for	   cocaine-­‐induce	  hyperlocomotion.	   	   In	  DAT	  Val559	  mice,	  ADE	  means	  that	  D2	  autoreceptors	  are	  chronically	  exposed	  to	  DA	  and,	  therefore,	  may	  be	   desensitized.	   	   Thus,	   even	   though	   D2Rs	   have	   not	   been	   experimentally	  manipulated	   in	   DAT	   Val559	   mice,	   they	   may	   be	   functionally	   “knocked	   out”	   and	  AMPH’s	  induction	  of	  locomotor	  activity	  is	  severely	  blunted.	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   It	   is	   important	   to	  note	   that	  we	  have	  not	  yet	   tested	   the	  behavioral	  effects	  of	  DAT	   inhibitors	   such	   as	   cocaine	   or	  methylphenidate	   on	   DAT	   Val559	  mice.	   	   In	   the	  event	   that	   the	   locomotor	   response	   to	   methylphenidate	   or	   cocaine	   resembles	   the	  response	   to	   AMPH,	   such	   findings	   would	   provide	   evidence	   that	   AMPH	   is	   merely	  blocking	  DAT	   and	   support	   the	   hypothesis	   that	  D2	   autoreceptors	   are	   desensitized.	  	  These	  behavioral	  experiments	  would	  dovetail	  nicely	  with	  biochemical	  assays	  of	  DA	  receptor	  function,	  as	  well.	  	  	  	   Despite	  no	  spontaneous	  hyperactivity,	  we	  noticed	  early	  on	  in	  our	  handling	  of	  DAT	  Val559	  animals	  that	  the	  DAT	  Val559	  genotype	  could	  be	  fairly	  reliably	  assigned	  based	  on	  the	  presence	  of	  a	  robust	  escape	  response	  to	  imminent	  handling,	  a	  behavior	  that	  we	  termed	  “darting”.	  	  Analysis	  of	  darting	  speed	  revealed	  that	  DAT	  Val559	  mice	  display	  faster	  darting	  speeds	  than	  their	  WT	  counterparts.	   	  We	  also	  considered	  that	  darting	   may	   be	   a	   locomotor	   manifestation	   of	   a	   startle	   response	   or	   an	   anxiety	  response.	   	  Acoustic	  startle	  testing	  revealed	  no	  difference	  in	  startle	  response	  at	  any	  decibel	   level	   test.	   Testing	   on	   the	   elevated	   zero	   maze	   revealed	   no	   anxiety-­‐like	  behavior.	  	  It	  appears	  that	  darting	  is	  a	  phenotype	  unique	  to	  DAT	  Val559	  mice.	  	  In	  an	  attempt	  to	  ameliorate	  the	  darting	  response,	  I	  injected	  mice	  with	  AMPH.	  	  The	   results	   were	   uninterpretable,	   however,	   as	   injection	   with	   saline	   affected	   the	  distribution	   of	   darting	   speeds	   among	   genotypes.	   	   It	   appears	   that	   a	   stressor	  more	  substantial	  than	  handling	  (i.e.	  an	  injection)	  may	  affect	  darting	  behavior.	  	  In	  order	  to	  test	   the	   effects	   of	  AMPH	  on	  darting	  behavior,	  AMPH	  will	   need	   to	  be	   administered	  orally	  (i.e.	  mixed	  into	  a	  highly	  palatable	  food	  substance	  such	  as	  peanut	  butter	  or	  a	  chocolate	  drink	   such	   as	  Ensure).	   	   This	   finding	   also	   raises	   the	  possibility	   that	  DAT	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Val559	  mice	  are	  more	  sensitive	   to	  stress	   than	   their	  WT	  counterparts;	   testing	  DAT	  Val559	  mice	   in	   acute	   and	   chronic	   stress	   paradigms	  may	   provide	   a	   fruitful	   line	   of	  research.	  It	   is	  worth	  noting	  that	  all	  behavior	  experiments	  were	  performed	  in	  juvenile	  male	  mice.	  Despite	   the	  under-­‐representation	  of	  DAT	  Val559	  alleles	  predominantly	  in	   male	   mice,	   as	   well	   as	   the	   consistently	   documented	   3:1	   male	   bias	   in	   ADHD	  diagnosis	   (Gaub	   and	   Carlson,	   1997;	   Getahun	   et	   al.,	   2013a),	   the	  DAT	  Val559	   allele	  was	  transmitted	  from	  the	  maternal	  grandmother	  (impulsive	  symptoms)	  and	  mother	  (learning	   disability,	   but	   no	   ADHD	   symptoms)	   to	   the	   ADHD	   subjects	   where	   the	  variant	  was	  identified	  (Mazei-­‐Robison	  et	  al.,	  2008).	  Future	  studies	  may	  focus	  on	  the	  effect	   of	   DAT	   Val559	   in	   female	   mice.	   	   If	   DAT	   Val559	   maintains	   its	   biochemical	  characteristics	   in	   females	   (preliminary	   data	   suggests	   that	   it	   does),	   but	   behavior	  differs	   between	   males	   and	   females,	   then	   DAT	   Val559	   mice	   may	   allow	   for	  identification	  of	  female-­‐specific	  factors	  that	  confer	  protection	  from	  ADHD.	  In	  order	  to	  directly	  test	  for	  ADE	  and	  loss	  of	  AMPH-­‐induced	  efflux	  that	  were	  observed	   in	   vitro,	   we	   performed	   in	   vivo	   microdialysis	   studies	   in	   unanesthetized,	  freely	  moving	  animals	  and	  HPLC	  to	  measure	  endogenous	  levels	  of	  extracellular	  DA	  and	   5-­‐HT.	   	   We	   observed	   no	   difference	   in	   basal	   5-­‐HT	   levels,	   but	   basal	   DA	   was	  elevated	  ~10-­‐fold	  in	  DAT	  Val559	  homozygous	  mice.	  	  We	  then	  applied	  AMPH	  directly	  to	   the	   striatum	   and	   measured	   AMPH-­‐induced	   changes	   in	   DA	   and	   5-­‐HT	   levels.	  	  AMPH-­‐induced	  5-­‐HT	  release	  was	  similar	  for	  all	  genotypes,	  but	  DA	  release	  was	  ~10-­‐fold	   less	   in	  DAT	  Val559	  homozygotes	   than	   in	  WT	   animals.	   	   Taken	   together,	   these	  data	  indicate	  that	  DAT	  Val559	  functions	  in	  vivo	  as	  it	  did	  in	  vitro.	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We	   also	   examined	   [3H]-­‐DA	   release	   in	   an	   ex	   vivo	   slice	   preparation.	   Striatal	  slices	   were	   pre-­‐loaded	   with	   [3H]-­‐DA,	   and	   we	   then	   measured	   AMPH-­‐induced	   DA	  release.	  	  Since	  in	  vivo	  DA	  release	  occurs	  in	  the	  context	  of	  neuron	  firing	  that	  could	  be	  different	  among	  genotypes,	  the	  de-­‐afferented	  ex	  vivo	  slice	  preparation	  allows	  us	  to	  assay	   AMPH-­‐induced	   DA	   release	   as	   an	   inherent	   property	   of	   DAT	   Val559.	   	   In	   this	  paradigm,	  we	   observe	   equal	   [3H]-­‐DA	   loading	   into	   slices,	   but	   significantly	   reduced	  AMPH-­‐induced	  release.	  	   Microdialysis	  and	  slice	  release	  studies	  are	  still	  ongoing,	  as	   these	  paradigms	  allow	   us	   to	   probe	   the	   contributions	   of	   vesicular	   and	   non-­‐vesicular	   DA	   release,	   as	  well	   as	   possible	   alterations	   in	   distribution	   of	   vesicle	   pools.	   	   Current	   efforts	   are	  focused	   on	   assaying	   vesicular	   release	   using	   either	   K+	   or	   4-­‐aminopyridine	   (4-­‐AP)	  stimulation	   (R	   Gowrishankar	   and	   PJ	   Gresch,	   personal	   communications).	   These	  experiments	   will	   offer	   insight	   regarding	   the	   possible	   redistribution	   of	   DA	   among	  vesicle	  pools	  in	  DAT	  Val559	  mice.	  	   Since	  we	  have	  evidence	  that	  DAT	  Val559	  supports	  ADE	  in	  vivo	  and	  behavioral	  and	  pharmacological	  evidence	   that	  DA	  signaling	   is	  disrupted	  as	  a	  result,	  we	  might	  predict	  that	  larger	  networks	  of	  genes	  are	  affected	  as	  a	  result	  of	  DAT	  Val559.	  	  Thus,	  transcriptome	   analysis	   would	   be	   a	   worthwhile	   pursuit,	   as	   it	   would	   provide	   an	  unbiased	   assessment	   of	   gene	   expression	   changes	   that	   accompany	   DAT	   Val559	  expression.	   	   Such	   studies	  may	   identify	  new	  genes	  or	  gene	  networks	  beyond	   those	  involved	  with	  DA	  signaling	  that	  contribute	  more	  broadly	  to	  risk	  for	  ADHD.	  	   In	   addition	   to	   the	   experiments	   suggested	   above,	   several	   other	   studies	   are	  also	   underway.	   	   In	   collaboration	   with	   Dr.	   Danny	  Winder’s	   lab,	   DAT	   Val559	   mice	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have	  been	  crossed	  with	  TH-­‐EGFP	  reporter	  mice.	  	  The	  resulting	  animals	  express	  DAT	  Val559	   and	   EGFP	   in	   dopaminergic	   neurons,	   thus	   allowing	   for	   visualization	   of	   DA	  neurons	   to	   be	   used	   for	   electrophysiological	   characterization.	   Preliminary	   data	  suggest	  that	  DAT	  Val559	  mice	  have	  a	  reduced	  (hyperpolarized)	  resting	  membrane	  potential	  relative	  to	  WT	  mice,	  a	  finding	  that	  could	  be	  attributed	  to	  tonic	  D2-­‐induced	  hyperpolarization	  (M	  Fettig,	  personal	  communication).	  	   Further	   electrophysiological	   characterization	   is	   necessary	   to	   examine	  alterations	  to	  patterns	  of	  DA	  signaling.	  	  Dopaminergic	  neurons	  typically	  display	  two	  activity	   patterns	   –	   tonic	   signaling,	   characterized	   by	   spontaneous,	   irregular,	   single	  spike	  events,	  and	  phasic	  signaling,	  which	  is	  depolarization-­‐dependent	  and	  displays	  a	  burst-­‐firing	  activity	  pattern	  (Grace	  and	  Bunney,	  1983).	  	  Tonic	  firing	  is	  established	  by	  an	   intrinsic	   pacemaker	   mechanism	   that	   is	   dependent	   on	   a	   hyperpolarization-­‐activated	   cation	   conductance	   (Grace	   and	   Bunney,	   1984b).	   In	   contrast,	   phasic	   or	  burst	   firing	   is	   depolarization-­‐dependent,	   and	   initiated	   by	   incoming	   cortical	   and	  brainstem	   afferents	   (Grace	   and	   Bunney,	   1984a;	   Charara	   et	   al.,	   1996;	   Lodge	   and	  Grace,	   2006a,	   b).	   	   Studies	   have	   demonstrated	   that	   phasic	   DA	   neuron	   activity	  requires	  NMDA	  receptors,	  as	  NMDA	  receptor	  antagonism	  inhibits	  DA	  neuron	  firing	  (Chergui	  et	  al.,	  1993).	  	  In	  light	  of	  ADE,	  DA	  neurons	  may	  alter	  their	  firing	  patterns	  to	  account	   for	   the	   constant	  presence	  of	  DA	   in	   the	   synapse.	   	  Assessment	  of	   tonic	   and	  phasic	  DA	  neuron	  activity	  in	  DAT	  Val559	  mice	  will	  add	  to	  our	  understanding	  of	  the	  full	  impact	  of	  DAT	  Val559	  on	  neuron	  function.	  	   Thus	  far,	  behavioral	  characterization	  has	  focused	  on	  locomotor	  behavior	  and	  AMPH	  response.	  	  However,	  impulsivity	  and	  attention	  are	  distinct	  realms	  of	  behavior	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that	   have	   not	   yet	   been	   explored.	   	   In	   collaboration	   with	   Dr.	   Martin	   Sarter	   at	   the	  University	  of	  Michigan,	  mice	  will	  be	   tested	  on	  attention	  tasks	  such	  as	   the	  5-­‐choice	  serial	  reaction	  time	  task	  (reviewed	  in	  Robbins,	  2002),	  and	  impulsivity	  tasks	  such	  as	  the	  stop	  signal	  or	  go/no-­‐go	  task	  (reviewed	  in	  Eagle	  et	  al.,	  2008).	  	   It	   is	   also	   necessary	   to	   remain	   careful	   not	   to	   overstate	   the	   impact	   of	   our	  findings	  surrounding	  DAT	  Val559	  mice.	   	  The	  DAT	  KO	  mouse	   is	  a	   fitting	  example	  –	  DAT	  KO	  mice	  were	  originally	  proposed	  as	  a	  model	  for	  ADHD	  as	  they	  are	  extremely	  hyperactive	  (Giros	  et	  al.,	  1996).	  	  However,	  DAT	  KO	  mice	  mirror	  the	  human	  loss-­‐of-­‐function	   syndrome	   (dopamine	   transporter	   deficiency	   syndrome	   (DTDS))	   almost	  exactly	   (Kurian	   et	   al.,	   2009,	   2011).	   	   For	   instance,	   DAT	   KO	   mice	   display	   early	  hyperkinesis	  (that	  looks	  similar	  to	  ADHD),	  but	  later	  become	  immobile	  and	  dystonic.	  	  Furthermore,	  DAT	  KO	  mice	  fail	  to	  develop	  normally	  and	  show	  significantly	  reduced	  survival,	  reminiscent	  of	  the	  failure	  to	  thrive	  observed	  in	  patients	  with	  IPD.	   	  In	  fact,	  Caron’s	   research	  group	  has	   recently	   acknowledged	   that	   the	  DAT	  KO	  mouse	   is	  not	  the	  most	  appropriate	  model	  for	  ADHD,	  and	  are	  perhaps	  most	  useful	  for	  studying	  IPD	  (MG	  Caron,	  personal	  communication).	  	  The	  DAT	  KO	  is	  merely	  an	  example,	  however,	  it	   serves	   as	   a	   useful	   reminder	   to	   keep	   an	   open	   mind	   regarding	   the	   disease-­‐applicability	  of	  our	  findings.	  	   In	   conclusion,	   we	   have	   successfully	   modeled	   a	   rare,	   highly	   penetrant	   DAT	  coding	   variant	   derived	   from	   human	   ADHD	   subjects.	   DAT	   Val559	   mice	   display	  several	   phenotypes	   predicted	   by	   previous	   in	   vitro	   characterization	   of	   the	  mutant	  transporter,	  including	  spontaneous,	  basal	  DA	  efflux	  and	  altered	  response	  to	  AMPH.	  	  This	   new	   model	   has	   also	   allowed	   us	   to	   begin	   characterizing	   the	   impact	   of	   DAT	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Val559	   on	   animal	   behavior.	   	   DAT	   Val559	   mice	   show	   reduced	   AMPH-­‐induced	  locomotor	   stimulation,	   as	   well	   as	   an	   as	   yet	   unexplained	   hyper-­‐reactive	   darting	  phenotype.	  	  Our	  findings	  also	  point	  towards	  alterations	  in	  DA	  signaling,	  most	  likely	  dysregulation	  of	  D2	  autoreceptor	  signaling.	  	  The	  DAT	  Val559	  mouse	  represents	  the	  first	   construct-­‐valid	  mouse	  model	   for	   ADHD	   and	   has	   promise	   as	   a	   useful	   tool	   for	  studying	  dopaminergic	  dysfunction	  relevant	  to	  ADHD.	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APPENDICES	  	   In	  addition	  to	  the	  data	  presented	  in	  Chapters	  2-­‐5,	  which	  has	  been	  submitted	  for	  publication,	  I	  have	  pursued	  several	  other	  studies.	  	  Although	  these	  findings	  are	  not	  published,	  they	  have	  informed	  previous	  and	  ongoing	  efforts.	  	  
Appendix	  1:	  Identification	  of	  New	  DAT	  Coding	  Variants	  	  
Appendix	  2:	  In	  Vitro	  Characterization	  of	  V24M	  hDAT	  	  
Appendix	  3:	  Preliminary	  Behavior	  Experiments	  on	  DAT	  Val559	  Mice	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APPENDIX	  1	  	  IDENTIFICATION	  OF	  NEW	  DAT	  CODING	  VARIANTS	  	  	   Past	  efforts	  in	  the	  Blakely	  lab	  have	  involved	  screening	  of	  the	  coding	  sequence	  and	  exon-­‐adjacent	  regions	  of	  human	  subjects	  diagnosed	  with	  ADHD	  (Mazei-­‐Robison	  et	   al.,	   2005).	   	   In	   a	   continuation	   of	   those	   efforts,	   we	   continued	   screening	   human	  subjects	  diagnosed	  with	  either	  ADHD	  or	  bipolar	  disorder.	  
ADHD	  and	  Bipolar	  Disorder	  Screening	  	   Our	   collaborators,	   Dr.	   Irwin	   Waldman	   at	   Emory	   University	   and	   Dr.	   John	  Kelsoe	  at	  University	  of	  California,	  San	  Diego,	  provided	  us	  with	  collections	  of	  genomic	  DNA	   samples	   from	   192	   ADHD	   (Waldman)	   and	   418	   bipolar	   disorder	   (Kelsoe)	  probands.	   	   Using	   the	  methods	   described	   previously	   (Mazei-­‐Robison	   et	   al.,	   2005),	  and	  with	  the	  aid	  of	  a	  postdoctoral	  fellow	  in	  the	  lab,	  Dr.	  Leah	  Miller,	  I	  screened	  the	  14	  coding	  exons	  of	  the	  DAT	  gene.	  	  The	  results	  of	  these	  efforts	  are	  summarized	  in	  Tables	  6	  and	  7.	  	   It	   is	   important	   to	   note	   that	   our	   initial	   screening	   step	  merely	   identifies	   the	  presence	  of	  a	  single	  nucleotide	  polymorphism	  (SNP),	  and	  the	  identity	  of	  the	  SNP	  is	  subsequently	  determined	  by	   sequencing.	   	  Therefore,	  we	  detect	   synonymous	   (non-­‐coding)	  variants	  as	  well.	  	   As	  the	  tables	  indicate,	  the	  frequency	  of	  most	  of	  these	  SNPs	  is	  quite	  low	  (less	  than	  1%).	  	  As	  these	  are	  non-­‐coding	  SNPs,	  it	  is	  unlikely	  that	  these	  rare,	  synonymous	  mutations	   contribute	   to	   any	   great	   degree	   to	   disease	   risk.	   	   However,	   several	   non-­‐
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  Table	   6.	   Summary	   of	   SNPs	   in	   DAT	   coding	   region	   identified	   in	   192	   probands	  diagnosed	  with	  ADHD.	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  Table	   7.	   Summary	   of	   SNPs	   in	   DAT	   coding	   region	   identified	   in	   418	   probands	  diagnosed	  with	  bipolar	  disorder.	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coding	  variants	  occur	  at	  a	  much	  higher	  frequency	  and	  differ	  between	  the	  ADHD	  and	  bipolar	   subject	   populations.	   	   To	   date,	   however,	   there	   is	   no	   indication	   that	   these	  variants	  contribute	  lead	  to	  any	  perturbation	  in	  DAT	  expression	  or	  function.	  One	  new	  coding	   SNP,	   Val24Met,	   was	   identified	   in	   this	   screen	   as	   well.	   Further	   information	  regarding	  Val24Met	  hDAT	  follows.	  
Identification	  of	  Val24Met	  hDAT	  	   One	   new	   coding	   variant	   was	   identified	   and	   confirmed	   during	   screening	   of	  ADHD	  probands.	   	  This	  particular	  SNP	  generated	  a	  new	  restriction	  fragment	   length	  polymorphism	   (RFLP)	   that	   allowed	   for	   the	   creation	   of	   a	   small,	   one-­‐generation	  pedigree	   (Fig.	   28).	   I	   demonstrated	   that	   Val24Met	   is	   an	   inherited	  mutation,	   being	  transmitted	   by	   the	   father.	   Further	   clinical	   information	   regarding	   the	   ADHD-­‐like	  characteristics	  of	  the	  father	  was	  unavailable.	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Figure	  28.	  V24M	  DAT	  is	  transmitted	   from	   the	  father	   to	   the	   affected	  subject.	   (A)	   V24M	  introduces	   a	   new	  restriction	   enzyme	   site	  into	   exon	   2.	   RFLP	  analysis	   reveals	   the	  presence	   of	   the	   novel	  restriction	   site,	   and	  therefore	   the	   presence	  of	   V24M	   hDAT,	   in	   the	  affected	   proband	   and	  his	   father,	   but	   not	   in	  his	   mother	   or	  unaffected	   sibling.	  	  RFLP	   analysis	   allows	  for	   the	   generation	   of	   a	  small	   pedigree	   (B)	  demonstrating	   this	  transmission	  pattern.	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APPENDIX	  2	  	  
IN	  VITRO	  CHARACTERIZATION	  OF	  V24M	  HDAT	  	  	   Having	   identified	   a	   novel	   coding	   variant,	   V24M,	   in	   an	   ADHD	   proband	  (Appendix	   1),	   efforts	   turned	   to	   characterizing	   the	   functional	   implications	   of	   the	  mutation.	   	   Initial	   characterization	   of	   V24M	   hDAT	   transfected	   in	   cultured	   cells	  revealed	   that	   total	   and	   surface	   protein	   expression	   (assayed	   via	   cell-­‐surface	  biotinylation	   and	   subsequent	   immunoblotting)	   were	   unaffected	   by	   the	   mutation	  (Fig.	   29A).	   	   Furthermore,	   DA	   transport	   was	   equivalent	   in	   the	   mutant	   (Fig.	   29B).	  	  These	  findings	  suggested	  that	  V24M	  is	  a	  tolerated	  mutation	  and	  does	  not	  affect	  DAT	  function.	  
SIFT	  Analysis	  and	  Systematic	  Mutation	  of	  Val24	  	   The	   N-­‐terminal	   tail	   of	   DAT	   contains	   several	   phosphorylation	   sites	   that	  regulate	   transporter	   function.	   	   It	   is	   also	   the	   site	   of	   interaction	   between	   DAT	   and	  several	   other	   proteins	   (reviewed	   in	   Chapter	   1).	   	   Although	   V24M	   appears	   to	   have	  little	   impact	  on	  DAT	   function,	   I	  wanted	   to	  explore	   the	   significance	  of	  Val24	   for	  N-­‐terminal	  functionality.	  	   In	   order	   to	   inform	  my	  experimental	   design,	   I	   used	   the	   computer	   algorithm	  SIFT	   (Sorting	   Intolerant	  From	  Tolerant)	   to	  predict	   the	   effect	   of	   various	  mutations	  (Ng	   and	   Henikoff,	   2001,	   2006;	   Kumar	   et	   al.,	   2009).	   	   Briefly,	   SIFT	   performs	   an	  iterative	  BLAST	  search	  for	  all	  protein	  sequences	  homologous	  to	  the	  target	  protein,	  DAT.	   	   Based	   on	   the	   frequency	   of	   variation	   at	   specific	   amino	   acid	   locations	   in
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  Figure	   29.	   V24M	   displays	   normal	   (A)	   total	   and	   surface	   protein	   expression	   (n	   =	   3	  independent	  experiments;	  P	  >	  0.05,	  two-­‐tailed	  t-­‐test)	  and	  (B)	  transport	  kinetics	  (n	  =	  3	  independent	  experiments;	  P	  >	  0.05,	  two-­‐way	  RMANOVA).	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homologous	   proteins,	   SIFT	   calculates	   the	   probability	   that	   a	   given	   amino	   acid	  substitution	   will	   have	   a	   deleterious	   effect	   on	   protein	   function.	   	   SIFT	   analysis	  predicted	   that	   amino	   acid	   position	   24	   could	   accommodate	   any	   amino	   acid	  substitution	  except	  for	  tryptophan.	  	   Although	  most	   residues	  were	   predicted	   to	   be	   tolerable,	   I	   proceeded	   to	   use	  site-­‐directed	  mutagenesis	  to	  introduce	  non-­‐conservative	  mutations	  into	  amino	  acid	  position	  24.	   	   I	   generated	  a	   series	  of	  V24	  mutants	  by	  mutating	   the	  native	  valine	   to	  cysteine,	  aspartate,	  phenylalanine,	   lysine,	   threonine,	  and	   tryptophan.	  DA	   transport	  in	  all	  of	  the	  mutants	  except	  for	  V24C	  and	  V24K	  was	  significantly	  elevated	  relative	  to	  WT	  hDAT,	  with	  V24W	  showing	   the	  greatest	   increase	   in	  DA	   transport	   (Fig.	  30).	   	   It	  seems	   that	   SIFT’s	   prediction	   of	   “deleterious”	   effect	   on	   protein	   function	   is	  misleading;	  V24W	  hDAT	  appears	  to	  have	  increased	  transport	  function.	  
Effect	  of	  V24	  Variation	  on	  DAT	  Regulation	  
	   After	  demonstrating	  that	  mutation	  of	  Val24	  increases	  transport,	  I	  wanted	  to	  see	  if	  DAT	  regulation	  was	  affected.	  	  In	  cultured	  cells,	  treatment	  with	  AMPH	  or	  PMA	  induces	  DAT	  internalization	  and,	  as	  a	  result,	  reduced	  transport	  function.	  	  I	  tested	  the	  effects	  of	  AMPH	  and	  PMA	  on	  DA	   transport	   in	  DAT	  Val24	  mutants	   transfected	  and	  expressed	  in	  cultured	  cells.	  	  Upon	  AMPH	  treatment,	  all	  V24	  variants	  except	  for	  V24D	  were	  significantly	  down-­‐regulated,	  similar	  to	  WT	  DAT	  (Fig.	  31A).	  It	   is	  thought	  that	  DAT	  regulation	  by	  AMPH	  requires	  PKC	  activity	  (Kantor	  and	  Gnegy,	  1998;	  Saunders	  et	   al..	   2000).	   	   Interestingly,	   aspartate	   substitutions	   are	   frequently	   used	   to	   mimic	  phosphorylation.	   	   My	   findings	   support	   the	   notion	   that	   addition	   of	   the	   phosphate	  group	  at	  the	  N-­‐terminal	  tail	  is	  required	  for	  DAT	  internalization.	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   Since	  AMPH-­‐induced	  internalization	  of	  the	  V24	  hDATs	  is	  mostly	  intact,	  I	  was	  surprised	  to	  find	  that	  PKC	  activation	  by	  PMA	  did	  not	  induce	  downregulation,	  except	  for	   V24C	   (Fig.	   31B).	   	   This	   finding	   suggests	   that	   Val24	  may	   be	   important	   for	   PMA	  activation	  of	  PKC,	  as	   replacement	  of	  V24	  abolishes	  PKC-­‐mediated	  downregulation.	  	  It	   must	   be	   noted	   that	   AMPH	   and	   PMA	   exert	   their	   effects	   primarily	   through	   DAT	  internalization;	  reduction	  of	  DA	  transport	  is	  merely	  a	  proxy	  for	  DAT	  internalization.	  	  Further	  studies	  that	  directly	  look	  at	  DAT	  trafficking	  (i.e.	  biotinylation	  studies),	  may	  offer	  more	  insight	  as	  to	  the	  effects	  of	  mutation	  of	  Val24.	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  Figure	  30.	  V24	  mutants	  display	  significantly	  elevated	  DA	  transport	  relative	   to	  WT.	  (A)	  Saturation	  analysis	   reveals	  altered	   transport	  kinetics,	   and	   (B)	  all	  V24	  mutants	  except	   for	  V24C	  and	  V24K	   transport	   significantly	  more	  DA	   than	  WT	  DAT	  (n	  =	  3-­‐4	  independent	  experiments	  per	  V24	  mutant;	  overall	  P	  <	  0.05,	  post	  hoc	  tests	  (Tukey’s	  multiple	  comparisons	  test)	  reveals	  *	  =	  P	  <	  0.05,	  ***	  =	  P	  <	  0.001,	  and	  ****	  =	  P	  <	  0.0001	  for	  V24	  mutant	  vs.	  WT	  DAT	  comparison;	  one-­‐way	  ANOVA).	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  Figure	  31.	  Regulation	  of	  V24	  DAT	  mutants	  by	  AMPH	  and	  PMA.	  	  (A)	  All	  DATs	  except	  for	   V24D	   are	   appropriately	   downregulated	   by	   AMPH	   treatment	   (n	   =	   3-­‐4	  independent	   experiments	   per	   V24	  mutant;	   overall	  P	   >	   0.05,	   post-­‐hoc	   tests	   reveal	  that	  *	  =	  P	  <	  0.05	  for	  WT	  vs.	  V24D	  comparison;	  two-­‐way	  ANOVA).	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APPENDIX	  3	  	  PRELIMINARY	  BEHAVIOR	  EXPERIMENTS	  ON	  DAT	  VAL559	  MICE	  	  	  	   Throughout	   the	   course	   of	   behavioral	   characterization	   of	   the	   DAT	   Val559	  mice,	   I	   preformed	   preliminary	   experiments	   on	   a	   number	   of	   different	   paradigms,	  then	  conducted	  more	  thorough	  experiments	  on	  those	  that	  were	  most	  relevant.	  This	  appendix	  will	  present	  those	  preliminary	  behavior	  findings.	  
Cliff	  Avoidance	  Reaction	  	   Impulsivity	   is	   a	   key	   feature	   of	   ADHD,	   and	   has	   been	   defined	   as	   a	   lack	   of	  behavioral	   inhibition.	   In	   animal	   testing	   paradigms,	   premature,	   mistimed,	   and/or	  difficult	   to	   suppress	   behaviors	   are	   considered	   to	   reflect	   impulsivity	   (Dalley	   et	   al.,	  2008;	   Eagle	   and	   Baunez,	   2010).	   	   A	   simple	   test	   of	   impulsivity	   involves	   placing	   a	  mouse	   atop	   a	   raised	   platform	   and	   assessing	   how	   mice	   explore	   the	   edge	   of	   the	  platform	   (Yamashita	   et	   al.,	   2013).	   	   Mice	   typically	   balance	   their	   exploratory	  tendencies	  with	  a	  desire	  to	  remain	  safe	  and	  therefore	  avoid	  the	  edge	  of	  the	  elevated	  platform.	   	   This	   edge	   avoidance	   behavior	   has	   been	   termed	   the	   cliff	   avoidance	  reaction.	   I	  performed	  this	  assay	  with	  DAT	  Val559	  mice	  to	  test	   for	  obvious	  signs	  of	  impulsivity	  and	  observed	  no	  differences	   in	   latency	   to	   fall	   (Fig.	  32A)	  or	   the	   rate	  of	  head	  dips	  over	  the	  edge	  of	  the	  cliff	  (Fig.	  32B),	  suggesting	  that	  DAT	  Val559	  mice	  do	  not	  impulsively	  explore	  the	  edge	  of	  the	  cliff.	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  Figure	  32.	  DAT	  Val559	  mice	  do	  not	  differ	  from	  WT	  controls	  in	  either	  (A)	  latency	  to	  fall	  +/-­‐	  SEM	  (n	  =	  13	  WT,	  7	  het,	  14	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVA)	  or	  (B)	  number	  of	  head	  dips	  per	  10	  seconds	  +/-­‐	  SEM	  (n	  =	  15	  WT,	  16	  het,	  16	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVA)	  in	  the	  cliff	  avoidance	  test.	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Novel	  Object	  Recognition	  	   The	  novel	  object	  recognition	  (NOR)	  paradigm	  is	  a	   test	  of	  cognitive	   function	  that	   addresses	   learning	   and	   memory	   and	   preference	   for	   novelty	   (reviewed	   in	  Antunes	  and	  Biala,	  2012).	   	  Briefly,	   the	  test	   involves	  exposing	  mice	  to	  two	  identical	  objects	   for	   a	   brief	   period,	   then	   after	   a	   delay,	   replacing	   one	   of	   the	   familiar	   objects	  with	   a	   novel	   object.	   Mice	   can	   then	   explore	   both	   objects;	   normal	   mice	   typically	  explore	  the	  new	  object,	  as	  they	  have	  learned	  that	  the	  familiar	  object	  does	  not	  offer	  any	   particular	   advantage.	   	   DAT	   Val559	   mice	   display	   a	   small	   but	   non-­‐significant	  increase	  in	  preference	  for	  the	  novel	  object	  (Fig.	  33),	  however,	  WT	  mice	  do	  not	  show	  an	  object	  preference,	  so	  interpretation	  of	  these	  data	  is	  not	  clear.	   	  It	  is	  important	  to	  note	  that	  NOR	  was	  tested	  during	  the	  light	  phase	  of	  the	  light/dark	  cycle,	  so	  the	  lack	  of	  novelty	   preference	  may	   be	   partly	   attributable	   to	   reduced	   activity	   of	   the	   animals.	  	  Performing	  NOR	  during	  the	  dark	  phase	  and/or	  using	  DAT	  Val559	  animals	  that	  have	  been	  backcrossed	  to	  the	  more	  behaviorally	  robust	  C57BL/6J	  background	  strain	  is	  a	  worthwhile	  experiment	  to	  pursue.	  
Prepulse	  Inhibition	  	   Prepulse	  inhibition	  (PPI)	  of	  acoustic	  startle	  is	  a	  dopamine-­‐sensitive	  behavior	  (Koch,	  1999;	  Ralph	  et	  al.,	  2001;	  Powell	  et	  al.,	  2008;	  Wong	  et	  al.,	  2012)	  in	  which	  the	  acoustic	   startle	   response	   is	   reduced	   by	   a	   lower-­‐intensity	   stimulus	   preceding	   the	  startle	   stimulus.	   	   DAT	   Val559	   mice	   show	   no	   PPI	   deficits	   at	   any	   of	   the	   prepulse	  intensities	   tested	   (Fig.	   34),	   suggesting	   that	   startle	   circuitry	   through	   the	   VTA	   is	  intact.	  However,	  AMPH	  is	  known	  to	  disrupt	  PPI	  (Swerdlow	  et	  al.,	  1990).	  	  Since	  DAT	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  Figure	  33.	  DAT	  Val559	  mice	  do	  not	  differ	  from	  WT	  mice	  in	  their	  performance	  on	  the	  novel	  object	   recognition	   task.	   	  NOR	  performance	   is	   indexed	  as	   the	  percent	  of	   trial	  time	  (10	  minutes)	  +/-­‐	  SEM	  spend	  exploring	  the	  novel	  and	  familiar	  objects	  n	  =	  8	  per	  genotype,	  P	  >	  0.05,	  two-­‐way	  ANOVA).	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  Figure	  34.	  DAT	  Val559	  mice	  display	  no	  deficits	   in	  prepulse	  inhibition	  compared	  to	  WT	  controls.	  	  PPI	  is	  displayed	  as	  the	  percentage	  +/-­‐	  SEM	  of	  the	  startle	  response	  that	  can	  be	  inhibited	  by	  the	  presence	  of	  a	  prepulse	  (n	  =	  16	  per	  genotype,	  P	  >	  0.05,	  two-­‐way	  ANOVA).	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Val559	  mice	  show	  significantly	  altered	  response	  to	  AMPH,	  examining	  its	  effects	  on	  PPI	  is	  certainly	  warranted.	  
Home	  Cage	  Monitoring	  	   Although	   we	   did	   not	   observe	   locomotor	   hyperactivity	   during	   open	   field	  testing,	  we	   still	  wanted	   to	   analyze	   the	   behavior	   of	  DAT	  Val559	  mice	   in	   a	   familiar	  environment	  to	  remove	  any	  potential	  caveats	  of	  apparatus	  novelty.	  	  I	  used	  the	  home	  cage	  monitoring	   system	   (HCM)	   to	   record	   and	   annotate	   the	   behavior	   of	   individual	  mice	   over	   a	   period	   of	   three	   days.	   	  Mice	  were	   singly	   housed	   to	   establish	   a	   “home	  cage”,	  then	  recorded	  within	  a	  climate-­‐controlled	  incubator	  to	  limit	  the	  effect	  of	  any	  experimenter	   intervention.	   	   HCM	   returns	   an	   enormous	   volume	   of	   data,	   including	  locomotor	   activity,	   rearing	   behavior,	   hanging	   from	   the	  wire	   cage	   insert,	   sleeping,	  eating,	  drinking,	  and	  grooming.	  Over	  the	  course	  of	  three	  days,	  DAT	  Val559	  mice	  do	  display	   a	   slight	   increase	   in	   total	   locomotor	   behavior	   (Fig.	   35A),	   driven	   largely	   by	  increased	  locomotion	  during	  the	  dark	  (active)	  phase	  (Fig.	  35B).	  	  Locomotor	  activity	  during	  the	  light	  period	  did	  not	  differ	  among	  genotypes	  (Fig.	  35C).	  	   Throughout	   our	   various	   open	   field	   activity	   recordings,	   we	   observed	   a	  significant	   reduction	   in	   rearing	   behavior	   in	   DAT	   Val559	   mice.	   HCM	   recordings	  reveal	  a	  similar	  phenotype	  –	  rearing	  activity	  is	  consistently	  reduced	  in	  DAT	  Val559	  animals,	   regardless	   of	   light/dark	   phase	   (Fig.	   36).	   	   As	   discussed	   in	   Chapter	   4,	  downregulation	   of	   D2	   receptors	   offers	   a	   potential	   mechanism	   for	   this	   behavioral	  finding.	   	   These	   HCM	   findings	   confirm	   a	   reduction	   of	   rearing	   activity	   and	   lend	  support	   to	   the	  notion	   that	  DAT	  Val559	   leads	   to	  desensitization	  of	  D2	   receptors	   in	  the	  brain.	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It	   is	   important	   to	   note	   that	   this	   experiment	   is	   extremely	   underpowered	   –	  only	   three	   homozygous	   animals	   were	   included	   in	   the	   experiment.	   	   Future	  experiments	   must	   first	   focus	   on	   replicating	   the	   current	   findings	   in	   additional	  homozygous	  animals.	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  Figure	  35.	  DAT	  Val559	  mice	  display	  small,	  insignificant	  increases	  in	  locomotor	  behavior	  during	  (A)	  the	  total	  3-­‐day	  recording,	  or	  (B)	  dark	  and	  (C)	  light	  phases.	  Due	  to	  the	  low	  number	  of	  homozygous	  animals,	  differences	  in	  locomotor	  behavior	  are	  not	  statistically	  significant	  (n	  =	  10	  WT,	  11	  het,	  3	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVAs).	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  Figure	  36.	  DAT	  Val559	  mice	  display	  reduced	  rearing	  behavior	  in	  the	  home	  cage	  environment	  during	  (A)	  the	  total	  3-­‐day	  recording	  period,	  or	  (B)	  dark	  and	  (C)	  light	  phases.	  	  Due	  to	  the	  low	  number	  of	  homozygous	  animals,	  the	  difference	  in	  rearing	  behavior	  is	  not	  statistically	  significant	  (n	  =	  10	  WT,	  11	  het,	  3	  homo;	  P	  >	  0.05,	  one-­‐way	  ANOVAs).	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